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Multiple research studies have demonstrated racial, socioeconomic status (SES), and 
neighborhood disparities in first-line treatment of colorectal cancer patients, including 
those with metastatic colorectal cancer.  However, disparities in adjunct monoclonal 
antibody treatment disparities have not been explored.  The purpose of this study was to 
assess racial, SES, and neighborhood disparities in adjunct monoclonal antibody 
treatment of elderly metastatic colorectal cancer patients.  The research was rooted in 3 
theories: the fundamental cause theory, the diffusion of innovations theory, and theory of 
health disparities and medical technology.  Data from the SEER-Medicare database and 
logistic regression were used to assess the relationship between the variables of interest 
and adjunct monoclonal antibody therapy.  In this study, race (p = 0.070), SES (p = 
0.881), and neighborhood characteristics (p = 0.309) did not significantly predict who 
would receive monoclonal antibody therapy.  The results demonstrated a potential 
improvement in historically documented colorectal cancer treatment disparities.  
Specifically, historical treatment disparities may not be relevant to newer therapies 
prescribed to patients with severe disease.  The difference could be related to improved 
access to care or a change in treatment paradigm due to the severity of metastatic 
colorectal cancer.  Future studies aimed at understanding the causes of this social change 
(i.e., reduced treatment disparities) are warranted.  Understanding the root cause of the 
reduced treatment disparities observed in this study could be used to reduce treatment 
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Chapter 1: Introduction to the Study 
Introduction 
In the United States, colorectal cancer survival rates, including survival rates of 
individuals with metastatic colorectal cancer, have been associated with race, 
socioeconomic status (SES), and neighborhood characteristics (degree of urbanization; 
Hines, Markossian, Johnson, Dong, & Bayakly, 2014; Lian et al., 2011; Simpson, Pagán, 
& Chen, 2013).  Specifically, Black Americans, individuals of low SES, and individuals 
residing in rural neighborhoods have been shown to have increased colorectal cancer 
mortality rates (Centers for Disease Control and Prevention [CDC], 2012; Hines et al., 
2014; Lian et al., 2011; Simpson et al., 2013).  Differences in colorectal cancer treatment 
regimen (surgery, radiation, or chemotherapy) have been shown to contribute to these 
survival disparities (Hao et al., 2011; Le, Ziogas, Lipkin, & Zell, 2008; Rane et al., 2014).  
In 2004, the first monoclonal antibody therapy for colorectal cancer was approved for 
treatment of metastatic colorectal cancer when given in adjunct with chemotherapy 
(Scott, Wolchok, & Old, 2012).  A review of Phase II-III clinical trials indicated that 
monoclonal antibody therapy increases survival in metastatic colorectal cancer patient 
populations when added to chemotherapy (Tol & Punt, 2010).  It is possible that 
disparities in monoclonal antibody treatment could contribute to disparities in the 
survival of patients with metastatic colorectal cancer.  However, due to the lack of 
research, it is unknown if there are racial, SES, or neighborhood disparities in 
monoclonal antibody treatment of metastatic colorectal cancer patients.  
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This chapter provides an introduction to the research project including a 
summarization of items that will be described in detail in Chapters 2 and 3.  Specifically, 
I open this chapter with a background section summarizing the literature surrounding the 
topic, present the research gap, and describe the importance of the study.  Following this 
brief background, the problem statement and study purpose are presented.  Afterward an 
overview of the research methodology and the theoretical basis will be provided.  Finally, 
the scope and limitations of the research project are described. 
Background 
In this section, I provide a brief summary of literature related to the topic and the 
research gap, and I describe the importance of the study.  Additional details related to the 
literature search and findings are provided in Chapter 2. 
Literature Related to the Study Topic 
Colorectal cancer survival disparities based on race, SES, and neighborhood 
characteristics have been observed in many different studies.  Specifically, Black 
Americans with colorectal cancer, including metastatic colorectal cancer, have reduced 
survival rates compared to White Americans (Simpson et al., 2013; Sineshaw, Robbins, 
& Jemal, 2014; Wallace et al., 2013; Wassira, Pinheiro, Symanowski, & Hansen, 2013), 
low SES populations have reduced colorectal cancer survival rates compared to higher 
SES populations (Hines et al., 2014; Oliphant et al., 2013b; Wassira et al., 2013), and 
rural populations have reduced colorectal cancer survival rates compared to urban 
populations (Henry, Niu, & Boscoe, 2009; Lian et al., 2011).   
3 
 
In addition, multiple researchers have associated treatment regimen differences 
with these survival disparities, highlighting disparities in both type and aggressiveness of 
colorectal cancer therapies (Bakogeorgos et al., 2013; Obeidat et al., 2010; Serra-Rexach 
et al., 2012).   Le et al. (2008) found significant differences in first-line treatment 
(surgery, radiation, and chemotherapy) comparing Black Americans to White Americans.  
These racial disparity results were supported in subsequent studies by White et al. (2008), 
Hao et al. (2011), and Hines et al. (2012).  In addition, Le et al. found significant 
differences in first-line treatment (surgery, radiation, and chemotherapy) comparing 
higher SES to lower SES areas.  Another potential contributor to colorectal cancer 
treatment disparities are the characteristics of the neighborhood patients reside within.  
Hao et al. (2011) documented urban versus rural disparities in first-line chemotherapy 
treatment in colorectal cancer.  Specifically, populations with urban or suburban zip 
codes were, respectively, 38% and 52% more likely to receive chemotherapy compared 
to populations with rural zip codes (Hao et al., 2011).   
Research Gap 
At highlighted above, multiple studies have provided valuable information on 
colorectal cancer treatment disparities.  However, they were conducted using patient data 
from the 1990s and early 2000, prior to the approval of monoclonal antibodies (Scott et 
al., 2012).  Currently, there are three monoclonal antibodies (bevacizumab, cetuximab, 
and panitumumab) approved for the treatment of metastatic colorectal cancer (Scott et al., 
2012).  Of particular importance to this research study, the literature searches performed 
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did not uncover any studies addressing racial, SES, or neighborhood (degree of 
urbanization) disparities in adjunct monoclonal antibody treatment of colorectal cancer 
patients.  Adjunct monoclonal antibody therapy has been shown to reduce metastatic 
colorectal cancer mortality in multiple populations, including the elderly (Bruera et al., 
2013, Cunningham et al., 2013; Naeim et al., 2013).  Therefore, it is possible that 
disparities in monoclonal antibody treatment are contributing to disparities in metastatic 
colorectal cancer survival.  However, given the lack of research, understanding disparities 
in monoclonal antibody treatment of metastatic colorectal cancer patients is a clear 
research gap. 
Study Importance 
Determining if racial, SES, or neighborhood disparities in monoclonal antibody 
treatment of elderly metastatic colorectal cancer patients exist is a critical first step to 
eliminating these social inequalities.  This study may provide the basis for positive social 
change in one of two ways.  First, if treatment disparities are found, this would illuminate 
the need for policies that improve access to monoclonal antibodies, thereby helping 
reduce social inequalities in colorectal cancer survival.  Alternatively, if treatment 
disparities are not found, an opportunity exists to understand the root cause of the 
reduced treatment disparities, and this knowledge could potentially be used to reduce 




Multiple research studies have demonstrated racial, SES, and neighborhood 
(degree of urbanization) disparities in treatment of colorectal cancer patients with 
surgery, radiation, or chemotherapy (Aarts, Lemmens, Louwman, Kunst, & Coebergh, 
2010; Hao et al., 2011; Le et al., 2008).  These treatment disparities have been associated 
with colorectal cancer survival (Le et al., 2008).  However, due to the lack of research, it 
was unknown if there are racial, SES, or neighborhood disparities in monoclonal 
antibody treatment of elderly metastatic colorectal cancer patients.  
Purpose of the Study 
Disparities in chemotherapy, radiation, and/or surgery have been associated with 
disparities in colorectal cancer survival.  However, information regarding disparities in 
adjunct monoclonal antibody treatment was not found in the literature.  Therefore, my 
aim was to determine whether these historical colorectal cancer treatment disparities have 
persisted into newer monoclonal antibody therapies and the metastatic colorectal cancer 
population.  The expressed purpose of this study was to determine if there are racial, SES, 
or neighborhood (degree of urbanization) disparities in first-line adjunct monoclonal 
antibody treatment of elderly metastatic colorectal cancer patients.   
Study Methodology and Intent 
In this quantitative research study, I used a retrospective cohort study design and 
data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End 




The independent, dependent, and control variables used in this research project 
are described briefly below.  Detailed information on each variable, including operational 
definitions, the location of the data and data codes, can be found in Chapter 3. 
Independent variables.  The first research question addresses racial/ethnic 
disparities in first-line monoclonal antibody treatment.  Therefore, race was the first 
independent variable.  The second research question addresses SES disparities in first-
line monoclonal antibody treatment.  The census tract poverty indicator, located in the 
NCI’s Patient Entitlement and Diagnosis Summary File (PEDSF), was used as a 
surrogate for SES.  The final research question addresses neighborhood characteristic 
(degree of urbanization) differences in first-line monoclonal antibody treatment.  The 
2003 Rural/Urban Continuum Codes from the Economic Research Service (ERS), which 
categories counties on an urban/rural scale based on population size, degree of 
urbanization, and adjacency to a metro or nonmetro area, was used for this purpose (NCI, 
2015c).   
Dependent variable.  The dependent variable for these research questions is 
receipt of first-line adjunct (in combination with chemotherapy) monoclonal antibody 
therapy, “yes” or “no.”   
Covariates.  Four covariates were added to the logistic regression analysis to 
control for confounding.  The first covariate used was gender (male or female).  The 
second covariate used was age at diagnosis.  The third covariate was reason for original 
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Medicare entitlement (age or disability).  Individuals who qualified for Medicare due to 
End Stage Renal Disease were excluded from the study.  The fourth covariate was the 
registry that reported the data.   
Research Questions and Hypotheses 
 The three research questions (RQ1-RQ3) addressed by this research project are 
listed below.  In addition, the null and alternative hypotheses have been stated (H01-H03 
and Ha1-Ha3 respectively).   
RQ1:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there racial 
disparities in first line adjunct monoclonal antibody treatment? 
H01:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody treatment based on race. 
Ha1:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody treatment based on race. 
RQ2:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there 
socioeconomic disparities in first line adjunct monoclonal antibody treatment? 
H02:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
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monoclonal antibody therapy based on area socioeconomic status (as defined by 
the PEDSF census tract poverty indicator). 
Ha2:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on area socioeconomic status (as defined by 
the PEDSF census tract poverty indictor). 
RQ3:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there 
neighborhood characteristic (degree of urbanization) disparities in first line adjunct 
monoclonal antibody treatment? 
H03:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on neighborhood characteristics. 
Ha3:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on neighborhood characteristics. 
Theoretical Framework for the Study 
The theoretical framework used for this project was a combination of theories 
similar to the theoretical framework proposed by Chang and Lauderdale (2009).  The 
overarching theory was the fundamental cause theory.  However, two additional theories 
(the diffusion of innovations theory and the theory of health disparities and medical 
9 
 
technology) were used to extend the fundamental cause theory for the purpose of this 
project.  These theories and their relevance to the research topic are described briefly in 
the following sections.  
Theoretical Propositions 
 The fundamental cause theory was first proposed by Link and Phelan in 1995.  
The theory argues that social states, such as race and SES, contribute to disease 
rates/outcomes.  Since resources are constantly changing, the authors proposed that it is 
the beneficial social connections that serve to protect health regardless of the resource 
mechanism (Phelan et al., 2010).  In support of the fundamental cause theory, two other 
theories were used.  First, the diffusion of innovations theory was first proposed by 
Rogers (1962) but has subsequently been updated with the most recent version of the 
theory published by Rogers in 2010.  The theory presents factors that influence whether 
or not an individual or population will adopt a new innovation (Rogers, 2010).  Second, 
the theory of health disparities and medical technology was developed by Goldman and 
Lakdawalla in 2005.  The theory surrounds the assumption that richer patients 
disproportionately use newer therapies.   
Theoretical Framework Supports the Study Approach 
 In line with the fundamental cause theory, individuals of low SES, minority races, 
or individuals living in rural areas could have systematically less of a given resource due 
to their social connections.  Therefore, it is possible that disparities in monoclonal 
antibody therapy exist due, in part, to disparities in resource acquisition.  Additionally, 
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according to the diffusion of innovation theory (Rogers, 2010), some populations (high 
SES, urban neighborhoods) might be more likely to obtain newer treatments (such as 
monoclonal antibody therapy).  Finally, the theory of health disparities and medical 
technology supports hypothesizes around higher levels of monoclonal antibody use by 
high SES or nonminority populations. 
In summary, these three theories work in concert to provide support for the 
research questions.  The fundamental cause theory attempts to explain disparities based 
on resource acquisition, whereas the diffusion of innovation theory takes a temporal 
approach to explain uptake of new technologies or treatments and the theory of health 
disparities and medical technology proposes that the complexity and quantity of 
treatment influences who will receive treatment.  All three of these theories provide 
rationale for research into disparities in monoclonal antibody treatment of metastatic 
colorectal cancer patients, as it is likely that demographics and social status will 
contribute to disparities in the use of newer, more complex treatments.   
Nature of the Study 
 The specific aim of this quantitative study was to determine if there are racial, 
SES, or neighborhood characteristic (degree of urbanization) disparities in first-line 
adjunct monoclonal antibody treatment of elderly metastatic colorectal cancer patients.  
In this section, I briefly describe the design selected to address this question including the 




 Quantitative research was the most appropriate research design to answer the 
research questions.  The most complete dataset available to answer these questions was 
archival data from the NCI’s SEER-Medicare database.  Therefore, since archival data 
were used, this quantitative study is strictly observational and no interventions were be 
performed.   
Data for all the variables were obtained from five data sources within the SEER-
Medicare database: the PEDSF file (Patient Entitlement and Diagnosis Summary File) 
and four Medicare claims files, the DME file (Durable Medical Equipment File), the 
Medicare Part D Event (PDE) file, the Medicare Outpatient Claims file, and the Medicare 
Carrier Claims file.  The PEDSF dataset was available through 2011, while all the claims 
datasets were available through 2012 with the first full year of PDE data in 2007.  
Therefore, this project was limited to individuals diagnosed with metastatic colorectal 
cancer from January 2007 to December 2011.  This allowed for assessment of 
chemotherapy and monoclonal antibody treatment into the 2012 claims datasets for 
individuals diagnosed in the second half of 2011.  
Methodology 
Population. The specific population used for this study was elderly (65+) 
Medicare enrolled individuals diagnosed with metastatic colorectal cancer between 
January 2007 and December 2011 and treated with first-line chemotherapy within 6 
months of diagnosis as in Meyerhardt, Sanoff, Carpenter, and Schrag (2012).  This 
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population was carefully selected for appropriateness in regards to the research question 
and to control for confounding.   
Sampling. This population was sampled using the NCI’s SEER-Medicare 
database.  The SEER-Medicare database is a unique research-oriented database resulting 
from the linkage of the SEER cancer registries database and the Medicare enrollment and 
claims data files (NCI, 2013a; Warren, Klabunde, Schrag, Bach, & Riley, 2002).   
Patient data for the study variables (independent, dependent, covariate/control, 
and selection variables) from 2007 to 2012 were compiled for all individuals meeting the 
inclusion and exclusion criteria using MySQL, Python and SPSS.   
Analysis. Logistic regression in SPSS was used to model the dichotomous 
dependent variable based on the independent variables as in Burns and Burns (2008).  
Specifically, the output of logistic regression predicted which dependent variable group 
(monoclonal antibody, “yes” or “no”) a sample should reside in based on the independent 
variables (race, SES, neighborhood characteristics; Burns & Burns, 2008).  Additional 
models were planned to control for potential confounding variables.   
Definitions 
Study Variables 
 Concise definitions of the independent variables, dependent variable, and control 
variables/covariates are provided in the following sections.   
 Independent variables.  There are three research questions and three total 
independent variables included in this research project.  Data for all of the independent 
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variables were available from the PEDSF (NCI, 2015c).  The three independent variables 
included in this research project are defined below: 
Neighborhood characteristics (degree of urbanization).  Neighborhood was 
defined using the 2003 Rural/Urban Continuum Codes from the ERS, which categories 
counties on an urban/rural scale based on population size, degree of urbanization, and 
adjacency to a metro or nonmetro area (NCI, 2015c).  This variable categorizes 
neighborhoods as Big Metro, Metro, Urban, Less Urban, Rural, or Unknown (NCI, 
2015c).   
Race.  Race used the SEER recode of the patient’s self-reported race to allow for 
analysis of Latino individuals.  The SEER recode reports race as one of the 11 selections: 
Caucasian, Black, American Indian/Alaska Native, Chinese, Japanese, Filipino, 
Hawaiian, Other Asian or Pacific Islander, Unknown, Caucasian, Spanish origin or 
surname, Other unspecified (NCI, 2015c).  Given the low representation of some of the 
races in the cohort, American Indian/Alaska Native persons were excluded from the race 
analysis and Chinese, Japanese, Filipino, Hawaiian and Other Asian or Pacific Islander 
groups were pooled into a single group entitled Asian or Pacific Islander.  
Socioeconomic status (SES).  As in an article by Schlichting, Soliman, Schairer, 
Schottenfeld and Merajver (2012), the Census Tract Poverty Indicator variable was used 
as a surrogate measure of SES.  This variable uses information from the American 
Community Survey that measures and reports census tract poverty levels (Kentucky 
Cancer Registry, n.d.). 
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 Dependent variable.  The dependent variable for all three research questions was 
receipt of first-line adjunct (in combination with chemotherapy) monoclonal antibody 
therapy.  As in Meyerhardt et al. (2012), first-line adjunct monoclonal antibody treatment 
was defined as at least one claim for a monoclonal antibody (bevacizumab, cetuximab, or 
panitumumab) within 1 month of chemotherapy (which must occur within 6 months of 
diagnosis).  For the purpose of this research project, the dependent variable (first-line 
monoclonal antibody treatment) was recorded dichotomized as “yes” or “no.”  
 Covariates.  Four covariates were added to the logistic regression analysis to 
control for confounding.  These covariates are defined below. 
Age at diagnosis.  As documented by Medicare. 
Gender.  Gender was self-reported and defined as male or female.   
 Reason for original Medicare entitlement.  Reason for original Medicare 
entitlement; age, disability, End Stage Renal Disease (ESRD), or disability and ESRD.  
Age and disability were the only options for this covariate as individuals with ESRD 
were excluded from the study. 
SEER Registry that reported the data.  Which geographically based SEER-
Registry reported the data.   
Study Terms 
Operational definitions for the independent, dependent, and control/covariate 
variables are documented in the study variable section above.  In this section, I provide 
two additional definitions required for sample selection and study execution. 
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First-line chemotherapy.  Given chemotherapy within 6 months of cancer 
diagnosis as in Meyerhardt et al. (2012).   
Socioeconomic status (SES).  SES is a representation of the social and economic 
state of an individual or population.   
Assumptions 
There is one large assumption necessary to justify this research project: 
specifically that monoclonal antibodies improve survival of elderly metastatic colorectal 
cancer patients.  Clinical studies have shown a survival benefit in elderly metastatic 
colorectal cancer patients treated with adjunct monoclonal antibody therapy 
(Cunningham et al., 2013).  However, real world evidence of improved survival of 
elderly metastatic colorectal cancer patients associated with monoclonal antibody therapy 
has not been shown using the SEER-Medicare population.  
Scope and Delimitations 
Scope 
The focus of this study is on identifying disparities in first-line adjunct 
monoclonal antibody treatment of elderly metastatic colorectal cancer patients.  The 
natural next question is whether or not any observed monoclonal antibody treatment 
disparities correlate with disparities in survival.  A robust analysis of survival would 
require assessment and controlling for multiple comorbidities both pre- and post-
diagnosis.  This type of analysis is large, complex, and out of scope for this study.  
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However, if disparities in adjunct monoclonal antibody therapy are found, a future study 
could address the impact of these findings on colorectal cancer survival. 
Delimitations 
This study was limited to U.S. elderly (65+ years) Medicare Part B and Part D 
enrolled (but with no HMO coverage), SEER registry colorectal cancer patients whose 
cancer had metastasized at diagnosis and who received first-line chemotherapy.  This 
very specific population was selected to reduce validity threats and bias in the study.  
However, as a result, it is unclear how these results will generalize to other populations 
(e.g., elderly population with different health insurance, individuals in a different region 
of the United States, younger individuals, and individuals who are diagnosed with an 
earlier stage cancer, and progress to metastatic cancer). 
Limitations and Methods to Address Limitations 
Design/Methodology Weaknesses  
Study design weaknesses.  In this study, I employed a retrospective cohort 
observational study design.  Given the sample selection criteria, loss to follow-up (the 
main concern in cohort studies) should be small.  Specifically, assessment of monoclonal 
antibody therapy (the dependent variable) occurs within 1 month of chemotherapy.  
Given that receipt of chemotherapy is a selection criterion, the loss to follow-up time was 
only 1 month long, limiting the impact of this concern. 
Data source weaknesses.  I used archival data from the SEER-Medicare database 
to address the research questions.  Therefore, the study quality is limited by the validity, 
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reliability and completeness of the SEER-Medicare database.  Given that hospitals, 
clinicians, and pathologists are responsible for accurate reporting and coding of SEER 
data, there is the potential for missing or inaccurate data.  However, there are published 
studies that have documented good reliability, validity, and completeness of different 
subsets of the SEER-Medicare data (Du et al., 2008; Mahnken et al., 2008). 
As a result of the database used for this study, concerns regarding extrapolation of 
the study results do exist.  This SEER database includes data from approximately 28% of 
the U.S. cancer population.  However, this sample comes from specific SEER funded 
cancer registries.  These registries are geographically dispersed, located in 13 different 
states.  However, it is unclear whether the data within the SEER database is a true 
representation of the greater U.S. cancer population.  This threat cannot be avoided and 
will be noted in the limitations section of Chapter 5. 
Threats to validity. Study validity could be threatened by confounding variables.  
Therefore, the logistic regression analysis plans included covariates to test for 
independent associations between the independent and dependent variables.  However, 
the possibility still exists that other variables, not cited in the literature as associating 
treatment and thus not included in the models, could confound the analysis.   
To increase statistical conclusion validity, great effort was employed to ensure the 
study was powered appropriately and that the statistical tests did not violate any 
assumptions.  In addition, the statistical analysis plan was explicitly laid out and further, 
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undocumented analyses were not performed.  This effort attempts to limit the type I error 
rate.   
Biases 
Given that this is a cohort study, there is the potential for bias in the outcome 
assessment.  For example, it is possible that hospitals that treat primarily black patients 
are less likely to record treatments compared to hospitals that treat primarily white 
patients.  However, Mahnken et al. (2008) found that the completeness of the SEER-
Medicare data did vary nonsignificantly by race and ethnicity.  Therefore, if the dataset is 
relatively complete (all treatments reported regardless of race, SES, or neighborhood 
characteristics), bias in the outcome assessment should be reduced. 
Other potential biases include selection bias.  In the case of this study, all SEER-
Medicare colorectal cancer patients were included in the cohort if they met the sample 
selection criteria (there was no random selection from the SEER dataset).  This reduced 
selection bias.  Additionally, the SEER sample is large (represents 28% of U.S. cancer 
cases), also reducing issues associated with selection.   
Significance 
 In this section, I describe the potential significance of the study results.  
Specifically, how the results could advance knowledge of the discipline, impact 
practice/policy, and promote positive social change. 
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Advance Knowledge of the Discipline 
Given the survival benefit associated with adjunct monoclonal antibody therapy 
(Tol & Punt, 2010), it is possible that disparities in adjunct monoclonal antibody therapy 
are contributing to disparities in metastatic colorectal cancer survival.  Increased 
understanding of colorectal cancer treatment disparities could advance the knowledge of 
the discipline and provide a new hypothesis to explain why colorectal cancer survival 
disparities are persisting.  If racial, SES, or neighborhood (degree of urbanization) 
disparities are found, future studies could determine if these disparities contribute to 
disparities in metastatic colorectal cancer survival.    
Additionally, given that the elderly have the highest colorectal cancer burden (risk 
and survival) of any age group, focusing on this group could potentially increase the 
impact of the study results.  Additionally, limiting this study to elderly colorectal cancer 
patients will also allow this research to build on treatment disparity research already 
generated using this population (Le et al., 2008; White et al., 2010).   
Potential Practice/Policy Contributions 
If racial, SES, or neighborhood (degree of urbanization) disparities are found, 
research into why these disparities exist could commence.  Understanding of the 
reasoning behind treatment disparities could have a direct influence on practice or policy.  
For example, it is possible that newer treatment options are less well known to 
practitioners at rural hospitals compared to urban hospitals, making them less likely to 
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prescribe adjunct monoclonal antibody therapy.  If this was determined, policies could be 
put in place to educate rural doctors regarding new efficacious treatments.   
Potential for Positive Social Change 
Determining if racial, SES, or neighborhood disparities in monoclonal antibody 
treatment of elderly metastatic colorectal cancer patients exist is a critical first step to 
eliminating these social inequalities.  This study may provide the basis for positive social 
change in one of two ways.  First, if treatment disparities are found, this would illuminate 
the need for policies that improve access to monoclonal antibodies, thereby helping 
reduce social inequalities in colorectal cancer survival.  Alternatively, if treatment 
disparities are not found, an opportunity exists to understand the root cause of the 
reduced treatment disparities, and this knowledge could potentially be used to reduce 
treatment disparities in other cancer populations. 
Summary 
 Colorectal cancer survival disparities based on race, SES, and neighborhood 
characteristics have been observed in many different studies.  Specifically, Black 
Americans have reduced colorectal cancer survival rates compared to White Americans 
(Simpson et al., 2013; Sineshaw et al., 2014; Wallace et al., 2013; Wassira et al., 2013), 
low SES populations have reduced colorectal cancer survival rates compared to higher 
SES populations (Hines et al., 2014; Oliphant et al., 2013b; Wassira et al., 2013), and 
rural populations have reduced colorectal cancer survival rates compared to urban 
populations (Henry et al., 2009; Lian et al., 2011).   
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In order to address these survival disparities, it is important to understand the 
potential underlying causes of these disparities.  Multiple articles have highlighted 
disparities in both type and aggressiveness of colorectal cancer therapies (surgery, 
radiation, and chemotherapy; Bakogeorgos et al., 2013; Obeidat et al., 2010; Serra-
Rexach et al., 2012).  However, this project is unique as it is unknown if these historical 
colorectal cancer treatment disparities have extended to the newer monoclonal antibody 
therapies and individuals with metastatic colorectal cancer.  Therefore, the purpose of this 
study was to determine if there are racial, SES, or neighborhood (degree of urbanization) 
disparities in first-line adjunct monoclonal antibody treatment of elderly metastatic 
colorectal cancer patients.   
I used archived colorectal cancer patient data available from the NCI’s (NCI) 
SEER-Medicare database.  Specifically, a retrospective cohort study was performed, 
using the SEER-Medicare database, on patients diagnosed with colorectal cancer from 
January 2007 to December 2011.  The data were analyzed using logistic regression with 
defined covariates.   
Determining if racial, SES, or neighborhood disparities in monoclonal antibody 
treatment of elderly metastatic colorectal cancer patients exist is a critical first step to 
eliminating these social inequalities.  This study may provide the basis for positive social 
change either through illuminating the need for policies that improve access to 
monoclonal antibodies (if disparities are found) or providing rationale to further 
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understand the root cause of the reduced treatment disparities (if disparities are not 
found). 
In this chapter, I provided an introduction to the research project including 
summarization of items that will be described in detail in Chapters 2 and 3.  In the 
following chapter, I describe, in detail, the literature review performed as a basis for this 
research study.  Within the literature review, the literature gap described briefly in 
Chapter 1 will be clearly illuminated.  Additionally, the theoretical foundation for the 




Chapter 2: Literature Review 
Introduction 
In the United States, colorectal cancer accounts for 8.6% of all new cancer cases 
and 8.8% of all cancer deaths (NCI, n.d.a).  Colorectal cancer risk and mortality rate 
increases with age, with the elderly being most affected by the disease (CDC, 2013).  In 
the United States, elderly individuals (65 years+) account for 60% of all new colorectal 
cancer cases and 70.9% of all colorectal cancer deaths (NCI, n.d.a).  Colorectal cancer 
survival rates in the United States have been shown to be associated with race, SES, and 
neighborhood characteristics (degree of urbanization; CDC, 2012; Hao et al., 2011; 
Naishadham, Lansdorp-Vogelaar, Siegel, Cokkinides, & Jemal, 2011; White, Vernon, 
Franzini, & Du, 2010).  Specifically, Black Americans, individuals of low SES, and 
individuals residing in rural areas have been shown to have increased colorectal cancer 
mortality (CDC, 2012; Naishadham et al., 2011; White et al., 2010).  White et al. (2010) 
also showed that racial disparities in colorectal cancer survival persisted when the 
population was limited to the elderly (65 years+).  
Colorectal cancer survival has been shown to be influenced by treatment received.  
For example, using a population of elderly colorectal cancer patients, Le et al. (2008) 
found significant differences in first-line treatment (surgery, radiation, and 
chemotherapy) comparing Black Americans to White Americans and higher SES to 
lower SES.  Hao et al. (2011) also described disparities in first-line chemotherapy 
treatment in colorectal cancer.  Specifically, populations with urban or suburban zip 
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codes were, respectively, 38% and 52% more likely to receive chemotherapy compared 
to populations with rural zip codes (Hao et al., 2011).  Additionally, urban Black 
American colorectal cancer patients had 24% reduced rates of chemotherapy compared 
urban White American colorectal cancer patients (Hao et al., 2011).  In a meta-analysis of 
studies published from 1995 to 2009, Aarts et al. (2010) found that colorectal cancer 
patients of low SES received less aggressive therapies and less adjunct therapies.   
Although these studies have provided valuable information on colorectal cancer 
treatment disparities, including disparities in elderly populations, they were conducted 
using patient data from the 1990s and early 2000.  The colorectal therapies employed 
during this period included surgery, radiation and chemotherapy.  Beginning in 2004, 
monoclonal antibody therapies specifically for metastatic colorectal cancer came onto the 
market (Scott et al., 2012).  Currently, there are three monoclonal antibodies 
(bevacizumab, cetuximab, and panitumumab) approved for the treatment of metastatic 
colorectal cancer (Scott et al., 2012).  A review of clinical trials and observational 
studies, included in this chapter, indicated that monoclonal antibodies increased 
progression-free survival and overall survival in elderly metastatic colorectal cancer 
patients when added to chemotherapy.  Therefore, as with chemotherapy, it is possible 
that disparities in monoclonal antibody treatment could contribute to disparities in 
colorectal cancer survival.   
However, due to the lack of research, it is unknown if there are racial, SES, or 
neighborhood disparities in monoclonal antibody treatment of elderly metastatic 
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colorectal cancer patients. Therefore, the purpose of this study was to determine if there 
are racial, SES, or neighborhood disparities in first-line adjunct monoclonal antibody 
treatment of U.S. elderly colorectal cancer patients.   
This chapter includes three major sections.  First, the literature search strategy 
will be reviewed in detail, including the rationale behind each combination of search 
terms.  This section also includes tables highlighting the relevant articles identified by 
each combination of search terms.  Second, I describe the theoretical foundation 
supporting the research question will be outlined.  Specifically, one overarching theory 
and two supporting theories provide rationale for potential disparities in colorectal cancer 
treatment.  Third, an in depth review of the literature identified by the literature search 
will be provided.  This section includes multiple subsections reviewing disparities in 
colorectal cancer survival, underlying causes of the disparities, and the utility of 
monoclonal antibodies in elderly colorectal cancer patients.  Each subsection also 
contains rationale for inclusion in this document as well as the relationship to the research 
questions. Additionally, in the literature review section, key variables are outlined and 
justified.  I conclude the chapter with an evaluation of the literature review and a 
description of how this study will address the gap and extend knowledge of colorectal 
cancer treatment disparities research. 
Literature Search Strategy 
In this section of the literature review, I discuss databases and search terms used.  
Literature searches were conducted to locate articles surrounding colorectal cancer, the 
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elderly, drug treatments, and disparities in treatments or care. Search terms and articles 
located are provided in table form in this section, and key articles will be reviewed in 
Literature Review.  As will be described, the reviewed literature informed the design of 
the study and methodology discussed in Chapter 3.  
Databases and Search Terms 
Two databases were searched for literature related to colorectal cancer, the 
elderly, drug treatment, and disparities: PubMed and Science Direct. PubMed is a 
biomedical literature database developed and maintained by the National Center for 
Biotechnology Information.  Science Direct is a database with content primarily focused 
on medicine, nursing and allied health.  These two databases were selected for their 
relevance to the research topic.  Specifically, they were chosen for their utility in locating 
journal articles surrounding colorectal cancer epidemiology, drug treatments, and 
disparities in cancer care. Monoclonal antibody therapies for colorectal cancer, the focal 
point of the research question, came onto the market in 2004 (Scott et al., 2012).  
Therefore, the literature searches were restricted from 2004 to 2015.  Only peer-reviewed 
primary literature articles were included in the tables below.  However, review articles 
were read and bibliographies of these sources were also reviewed to ensure the database 
searches did not miss any important articles.   
Colorectal cancer epidemiology searches.  PubMed and Science Direct were 
queried using a combination of the following terms to locate articles regarding colorectal 
cancer survival disparities in the elderly: colorectal cancer, survival, epidemiology, 
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elderly, and disparities. The specific searches are outlined in Table 1.  These searches 
were restricted from 2004 to 2015 and only peer-reviewed primary journal articles were 
included.  However, bibliographies of secondary source articles were reviewed to ensure 
all important primary articles were captured.  Many of these searches produced a 
significant number of articles.  All articles produced in the queries were reviewed; 
however, only potentially relevant articles are listed in Table 1.  Potentially relevant 
articles met at least one of the following four criteria: 
• Provided U.S. colorectal cancer survival data from after 2004. 
• Discussed treatment or care of elderly colorectal cancer patients. 
• Discussed disparities in colorectal cancer survival, treatment, or care based on 
race, socioeconomic status, or geography. 
• Discussed any disparity in colorectal cancer within the population of elderly U.S. 





Colorectal Cancer Epidemiology Primary Literature From PubMed and Science Direct 




Ahmed, Howel & Debrah (2014); Tong et al. (2014); Sineshaw, 
Robbins & Jemal (2014); Simpson et al. (2013); Allemani et al. 
(2013); Oliphant et al. (2013a); Mitry et al. (2013); Oliphant et 
al. (2013b); Wassira, Pinheiro, Symanowski & Hansen (2013); 
Chien, Schootman & Pruitt (2013); Wallace et al. (2013); Lam, 
Lu, Kouzminova & Lin (2013); Jafri, Gould, El-Serag, Duan & 
Davila (2013); Wan, Zhan, Lu & Tiefenbacher (2012); 
Lansdorp et al. (2012); Renouf et al. (2011); Lian et al. (2011); 
Cueto, Szeja, Wertheim, Ong & Tsikitis (2011); Tsai et al. 
(2011); Osterlund et al. (2011); White, Vernon, Franzini & Du 
(2010); Lejeune et al. (2010); Koroukian et al. (2010); Henry, 
Niu & Boscoe (2009); Ran et al. (2009); Lang et al. (2009); 
Kelsall et al. (2009); Le, Ziogas, Lipkin & Zell (2008) 
"Colorectal Cancer"b and 
Elderlyb 
Naeim et al. (2013); Bruera et al. (2013); Fu, Tsai, Marshall & 
Potosky (2013); Bakogeorgos et al. (2013); Cunningham et al. 
(2013); Serra-Rexach et al. (2012); Singal, Lin, Kuo, Riall & 
Goodwin (2013); Abdelwahab, Azmy, Abdel-Aziz, Salim & 
Mahmoud (2012); Jehn, Boning, Kroning, Possinger & Luftner 
(2012); Price et al. (2012); Wildes et al. (2010); Vrdolijak, 
Omrcen, Boban & Hrabar (2011); Kozloff et al. (2010); White 
et al. (2008); Wright, Barlow, Green, Baldwin & Taplin (2007) 
"Colorectal Cancer"b, Survivalb 
and Disparitiesb 
Sineshaw et al. (2014); Wassira et al. (2013); Wallace et al. 
(2013); Lansdorp et al. (2012); Wan, Zhan, Lu & Tiefenbacher 
(2012); Cueto et al. (2011); White et al. (2010); Lejeune et al. 
(2010); Henry et al. (2009); Le et al. (2008)  
Note. a Text Word Search; b Title Search 
 
Colorectal cancer disparities search.  Additional database queries were 
performed to specifically locate any additional articles regarding colorectal cancer 
disparities and to exclude any bias searches that could have resulted from including either 
“survival” or “elderly” in the previous search.  For this purpose, PubMed and Science 
Direct were queried using a combination of the following terms: colorectal cancer, 
disparities and one of the following: treatment, race or racial, state, rural, geographical 
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or geography, or socioeconomic status.  Given the importance of treatment disparities to 
the research question, the search query that included the terms colorectal cancer, 
treatment, and disparities was queried three times, each time moving one of the three 
search terms to a text word query instead of a title query.  Additionally, given that only 
one article was identified with the search colorectal cancer, socioeconomic status, and 
disparities, an additional search was performed after eliminating the search term 





Colorectal Cancer Disparities Primary Literature From PubMed and Science Direct 
Search terms Primary research articles 
"Colorectal Cancer"b, 
Treatmentb and Disparitiesb 
Simpson et al. (2013); Wan et al. (2012); Cueto et al. (2011); 
Haas et al. (2011); White et al. (2010); Lejeune et al. (2010); 
White et al. (2008); Le et al. (2008) 
"Colorectal Cancer"b, 
Treatmenta and Disparitiesb 
Zullig et al. (2013); Wassira et al. (2013); Wallace et al. (2013); 
Cueto et al. (2011); Haas et al. (2011); Crawford, Jones & 
Richardson (2010); Obeidat et al. (2010); White et al. (2010); 
Lejeune et al. (2010); Hao et al. (2011); White et al. (2008); Le 
et al. (2008); McKibbin et al. (2008); Demissie et al. (2004) 
"Colorectal Cancer"b, 
Treatmentb and Disparitiesa 
Hines & Markossian (2012); Cueto et al. (2011); Haas et al. 
(2011); White et al. (2010); Lejeune et al. (2010); White et al. 
(2008); Le et al. (2008); Hassan, Arthurs, Sohn & Steele (2009) 
"Colorectal Cancer"b, "Race or 
Racial"b and Disparitiesb 
Sineshaw et al. (2014); Wassira et al. (2013); Wallace et al. 
(2013); Lansdorp-Vogelaar (2012); Stimpson, Pagan & Chen 
(2012); Wilkins et al. (2012); Murphy et al. (2011); Laiyemo et 
al. (2010); Hao et al. (2011); Robbins, Siegel & Jemal (2012); 
White et al. (2010); White et al. (2008) 
"Colorectal Cancer"b, Stateb 
and Disparitiesb 
Rane et al. (2014); Naishadham, Lansdorp-Vogelaar, Siegel, 
Cokkinides & Jemal (2011) 
"Colorectal Cancer"b, Ruralb 
and Disparitiesb 
Rane et al. (2014); Wilkins et al. (2012); Beyer, Comstock, 
Seagren & Rushton (2011); Cole, Jackson & Doescher (2012) 
"Colorectal 
Cancer"b,"Geographical or 
Geography"b and Disparitiesb 
None 
"Colorectal Cancer"b, 
"Socioeconomic status"b and 
Disparitiesb 
Le et al. (2008) 
"Colorectal Cancer"b and 
"Socioeconomic status"b 
Hines, Markossian, Johnson, Dong & Bayakly (2014); Saldana-
Ruiz, Rubin, Colen & Link (2013); Steinbrecher et al. (2012); 
Kelsall et al. (2009); Le et al. (2008); Gomez, O'Malley, 
Stroup, Shema & Satariano (2007) 




Colorectal cancer monoclonal antibody treatment disparities search.  A final 
database query was performed to specifically locate any articles regarding colorectal 
cancer disparities and monoclonal antibody therapies.  For this purpose, PubMed and 
Science Direct were queried using a combination of the following terms: colorectal 
cancer, disparities and one of the following: antibody, bevacizumab, cetuximab or 
panitumumab.  Given that very little research has been performed surrounding disparities 
in monoclonal antibody treatment of colorectal cancer patients, the search terms were 
relaxed.  The term colorectal cancer was queried as a title search term; however, the 
other two search terms in each case were only listed as text search terms. The exact 
search terms are described in detail in Table 3.   
Table 3 
Colorectal Cancer Monoclonal Antibody Treatment Disparities Primary Literature From 
PubMed and Science Direct 
Search terms Primary research articles 
"Colorectal Cancer"b, 
Antibodya and Disparitiesa 
McKibbin et al. (2008); Wallace et al. (2013) 
"Colorectal Cancer"b, 
Bevacizumaba and Disparitiesa 
McKibbin et al. (2008); Wallace et al. (2013) 
"Colorectal Cancer"b, 
Cetuximaba and Disparitiesa 
Wallace et al. (2013) 
"Colorectal Cancer"b, 
Panitumumaba and Disparitiesa 
None 
Note. a Text Word Search; b Title Search 
 
It is apparent from this search that very little research has been done surrounding 
disparities in monoclonal antibody treatment of colorectal cancer patients.  Of the two 
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relevant articles located with this search, neither addressed racial, socioeconomic, or 
geographical disparities in monoclonal antibody treatment of colorectal cancer patients.   
Literature Search Strategy: Summary 
The literature search revealed a significant amount of literature surrounding 
colorectal cancer survival disparities.  The search uncovered disparities in survival in 
many populations including the elderly, blacks, Hispanics, Native Americans, 
populations with low SES, populations living in rural counties as well as state-to-state 
geographical disparities.  Additionally, the literature search addressed potential 
underlying causes of these disparities including differences in screening, access to care, 
and treatment.  Of particular relevance to the research topic, the literature search 
uncovered documented disparities in colorectal cancer treatment.  However, the treatment 
disparities explored in these articles are differences in older therapies (chemotherapy and 
surgery).  The searches did not uncover any articles addressing racial, socioeconomic, or 
neighborhood disparities in monoclonal antibody treatment of colorectal cancer patients.  
Given that monoclonal antibody treatment has been shown to improve survival in the 
elderly, understanding disparities in monoclonal antibody treatment could help explain 
the persistence of colorectal cancer survival disparities. 
Theoretical Foundation 
The theoretical framework for this project is a combination of theories similar to 
the theoretical framework proposed by Chang and Lauderdale (2009).  The overarching 
theory is the fundamental cause theory.  However, two additional theories (the diffusion 
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of innovations theory and the theory of health disparities and medical technology) are 
used to extend the fundamental cause theory for the purpose of this project.  I describe 
these theories and their relevance to the research topic in detail in the sections below. 
Fundamental Cause Theory 
The overarching theory for the research questions is the fundamental cause 
theory.  This theory was originally developed to explain why the association between 
SES and mortality persists across multiple diseases and risk factors (Link & Phelan, 
1995).  This theory proposes that beneficial social connections protect health and reduce 
mortality (Link & Phelan, 1995).   
Origin and definition of the theory.  Link and Phelan (1995) first proposed the 
fundamental cause theory in 1995.  Link and Phelan (1995) argue that social states, such 
as race and SES, contribute to disease rates for two major reasons.  First, social states 
impact resources available to combat diseases (Link & Phelan, 1995).  Second, social 
state is tied to multiple other disease risk factors (Link & Phelan).  An important 
assumption of this theory is that the relationship between social state and disease persists 
over time (Phelan et al., 2010).  Since resources are constantly changing, it is the 
beneficial social connections that serve to protect health regardless of the resource 
mechanism (Phelan et al.). 
Utilization of the theory.  The fundamental cause theory has been used primarily 
to address differences in disease and disease mortality rates based on SES.  The theory is 
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especially useful when attempting to explain SES disparities that persist over time and 
across varying resources.   
Of particular importance to the research questions, in 2005, Phelan and Link 
expanded the theory to help explain why breakthroughs in disease detection or treatment 
do not often reduce social disparities.  The authors argue that social and economic 
inequalities contribute to resource acquisition (Phelan & Link, 2005).  Therefore, as new 
methods of treating or preventing disease become available, these resources are not 
distributed equally (Phelan & Link).  Instead they are distributed based on “knowledge, 
money, power, prestige, and beneficial social connections” (Phelan & Link, 2005, p. 
227).  Therefore, even as the ability to combat disease incidence or mortality improves 
(as with the introduction of monoclonal antibodies for colorectal cancer) the acquisition 
of these new resources is not equal and therefore disparities persist. 
These arguments were further supported in an article by Chang and Lauderdale 
(2009).  In this work the authors address disparities in cholesterol levels in the era of 
nongeneric statins (Chang & Lauderdale, 2009).  The authors found that in the years 
before statin therapy, high SES populations had cholesterol levels higher than low SES 
populations (Chang & Lauderdale).  However, looking at cholesterol levels through the 
statin era, this gradually reversed with the high SES population having lower cholesterol 
levels compared to the low SES population (Chang & Lauderdale).  The authors propose 
that high SES populations had greater access to statins compared to the lower SES 
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populations (Chang & Lauderdale).  This distribution of resources disparity contributed 
to the reversal of cholesterol situation comparing the SES groups. 
 Relationship to the research questions.  Although in recent years (2004-2009) 
new colorectal cancer treatments and technologies appear to be contributing to increasing 
survival rates in all races, racial disparities in colorectal cancer survival, specifically 
comparing Black Americans and White Americans, are increasing (Sineshaw et al., 
2014).  Sineshaw et al. (2014) propose that minority populations have not benefited as 
greatly from newer treatments or these treatments have not be disseminated into these 
populations as greatly (Sineshaw et al.).  This hypothesis is supported by Simpson et al. 
(2013).  In the Simpson et al. (2013) study, black patients with metastatic colorectal 
cancer were less likely to receive multimodality therapy compared to White Americans.   
In this research project I address disparities in monoclonal antibody treatment of 
elderly metastatic colorectal cancer patients.  Adjunct monoclonal antibody therapy has 
been shown to be highly efficacious in increasing colorectal cancer survival (Bruera et 
al., 2013, Cunningham et al., 2013; Naeim et al., 2013).  However, monoclonal antibody 
therapy is new and expensive.  Thus, in accordance with the fundamental cause theory, it 
is possible that minority populations or populations of low SES will be less likely to 
receive this new resource.  These resource acquisition differences could contribute to the 
persisting disparities in colorectal cancer survival. 
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Diffusion of Innovations Theory 
As an extension of the fundamental cause theory, the diffusion of innovation 
theory (Rogers, 1962) will be used to help explain why some populations (high SES, 
certain geographies) might be more likely to obtain newer treatments.  This model is 
much older and more widely used compared to the fundamental cause theory.  The model 
states that widening disparities are influenced by the nature of the new technology and 
the uptake/diffusion of the technology (Rogers, 1962).   
Origin and definition of the theory.  The diffusion of innovations theory was 
first proposed by Rogers in1962.  The theory has subsequently been updated with the 
most recent version of the theory published by Rogers in 2010.  The theory proposes five 
innovation adopter categories based on how long post availability the innovation is 
expected be adopted (Rogers, 2010).  The categories use a normal distribution with 
innovators (~2.5% of the population) adopting the innovation quickly following 
availability, followed by early adopters (13.5%), early majority (34%), late majority 
(34%), and 16% laggards (Rogers, 2010).  Of particular importance to the model and the 
research questions, there are several factors that influence whether or not an individual or 
population will adopt a new innovation, and thus which adopter category that individual 
or population will reside within (Rogers, 2010).  These factors include relative advantage, 
compatibility, complexity, triability (ability to “try it out” before committing to adoption) 
and observability (observed results) (Rogers, 2010).  The requirements needed to meet 
each of these factors can differ from one population to another.  Therefore, Rogers (2010) 
37 
 
notes that it is critical to understand the target population and specific social factors that 
can contribute to innovation adoption (Rogers, 2010). 
Utilization of the theory.  Relevant to the research questions, the diffusion of 
innovations theory has been used as a model to explain multiple findings including drug 
prescribing differences and the uptake of new diagnostic tests.  For example, Armstrong, 
Weiner, Weber, and Asch (2003) used the diffusion of innovations theory to help 
understand early uptake the BRCA1/2 test for breast cancer susceptibility.  The authors 
found that early adopters of the test were proactive in inquiring about the test and had 
heard about the test from sources in addition to their doctor or genetic counselor 
(Armstrong et al., 2003).  These adoption characteristics, including access to outside 
knowledge of the test, could differ based on the social characteristics or demographics of 
a population.   
Additionally, Makowsky, Guirguis, Hughes, Sadowski, and Yuksel (2013) used 
the diffusion of innovations theory to understand the adoption of pharmacist prescribing 
behaviors in Alberta, Canada.  The authors found that prescribing behaviors varied 
greatly and was dependent on the innovation, the adopter, readiness of the system, and 
communication/influence (Makowsky et al., 2013).  The authors found that patient 
focused pharmacists were more likely to prescribe medications compared to disease 
focused pharmacists (Makowsky et al.).  Additionally, pharmacists commented that 
physician relationships influenced their decision to prescribe (Makowsky et al.).  Of 
importance to this research study, access to patient-centered health care and a 
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collaborative healthcare system could influence drug prescribing decisions and uptake of 
new innovations (such as monoclonal antibodies).   
 Relationship to the research questions.  In concert with the fundamental cause 
theory, the diffusion of innovations theory helps provide support for the research 
questions.  As noted in the section above, racial disparities in colorectal cancer survival, 
specifically comparing Black Americans and White Americans, are increasing (Sineshaw 
et al., 2014).  Many studies have documented the efficacy of bevacizumab (monoclonal 
antibody) in metastatic colorectal cancer.  However, the uptake of monoclonal antibody 
therapy has not been immediate or complete.  According to Renouf et al. (2011), 5.9% of 
patients diagnosed with colorectal cancer in 2004 were given bevacizumab compared to 
30.6% of colorectal cancer patients diagnosed in 2006.  In concert with the diffusion of 
innovations theory, it is conceivable that different populations could reside in different 
adopter categories based on social factors such as race and SES.  Thus, it is possible that 
a greater percentage of high SES, nonminority populations fall into innovator or early 
adopter categories. This could contribute to the widening colorectal cancer survival 
disparities and supports the research questions aimed at addressing disparities in 
monoclonal antibody treatment. 
Theory of Health Disparities and Medical Technology 
As additional support for the fundamental cause theory and the diffusion of 
innovations theory, the theory of health disparities and medical technology is used 
(Goldman & Lakdawalla, 2005).  This theory states that medical advances are linked to 
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widening disparities due to disparities in health care utilization (Goldman & Lakdawalla, 
2005).   
Origin and definition of the theory.  The theory of health disparities and 
medical technology is a relatively new theory developed by Goldman and Lakdawalla in 
2005.  The theory itself is very similar to the fundamental cause theory, but focuses on 
the quantity and complexity of newly introduced therapies (Goldman & Lakdawalla, 
2005).  The theory was originally developed to help explain why better-educated people 
are healthier (Goldman & Lakdawalla).  The authors rooted their theory in basic 
consumer theory and argue that new medical technologies disproportionately benefit the 
heaviest health care users; richer patients (Goldman & Lakdawalla).  They claim that 
richer more well-educated patients tend to be the heaviest health care users and use more 
complex treatment regimens (Goldman & Lakdawalla).  Therefore, richer patients 
disproportionately use newer therapies. 
Utilization of the theory.  Goldman and Lakdawalla (2005) used the theory of 
health disparities and medical technology to help explain why the introduction of a 
complicated anti-retroviral therapy for HIV patients benefited rich well-educated patients 
disproportionately.  The authors found that richer patients were more likely to likely to 
invest effort into obtaining and adhering to the complex treatment regimen (Goldman & 
Lakdawalla, 2005).   
Additionally, as noted above, the theory relies on the assumption that the heaviest 
healthcare users benefit most from newer, more complex technologies and treatments 
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(Goldman & Lakdawalla, 2005).  Therefore, Goldman and Lakdawalla (2005) assessed 
disparities in survival of chronically ill populations and found the largest survival 
disparity was based on education.  Specifically, more educated populations had higher 
survival rates compared to lower education populations (Goldman & Lakdawalla).  This 
highly educated population, they argue, is the population expected to be the heaviest 
health care utilizers, supporting their theory. 
 Relationship to the research questions.  Treatment for metastatic colorectal 
cancer can be multifaceted including surgery (if possible), chemotherapy and monoclonal 
antibody therapy.  Given that the research questions address disparities in adjunct 
monoclonal antibody therapy, a relatively complex treatment regimen, this theory is 
appropriate and compliments the other two theories previously presented.  Utilizing this 
theory, it is possible that richer patients use more health care resources compared to 
poorer individuals and are thus more likely to obtain adjunct monoclonal antibody 
therapy.  This could contribute to disparities in monoclonal antibody treatment based on 
social status or demographics. 
Theoretical Foundation Summary 
 Utilization of the three theories noted above in drug uptake and disease outcome 
research was first proposed by Chang and Lauderdale (2009).  The overarching theory for 
this research project is the fundamental cause theory.  As commented above, this theory 
focuses on disparities in resource distribution and can help explain why breakthroughs in 
disease treatment (such as monoclonal antibody therapy) do not reduce social disparities 
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in survival.  Specifically, as new methods of treating disease become available, these 
resources are not distributed equally (Phelan & Link, 2005).  Instead they are distributed 
based on “knowledge, money, power, prestige, and beneficial social connections” (Phelan 
& Link, 2005, p. 227).  This theory proposes that beneficial social connections protect 
health and reduce mortality (Link & Phelan, 1995).  In line with the fundamental cause 
theory, it is possible that disparities in monoclonal antibody therapy exist due to 
disparities in resource acquisition.   
Two additional theories are used to extend the fundamental cause theory for the 
purpose of this research project.  First, the diffusion of innovation theory (Rogers, 2010) 
is used to help explain why some populations (high SES, certain geographies) might be 
more likely to obtain newer treatments.  This model states that widening disparities are 
influenced by the nature of the new technology and the uptake/diffusion of the 
technology (Rogers).  For monoclonal antibody therapy, this model is supported by 
Renouf et al. (2011).  The authors found that uptake of monoclonal antibodies for 
colorectal cancer treatment was not immediate or complete (Renouf et al.).  Early 
adopters of monoclonal antibody therapy could have innovator-like characteristics such 
as pro-active inquiry into treatment regimens that might contribute to treatment 
disparities based on social characteristics or demographics. Second, the theory of health 
disparities and medical technology is used (Goldman & Lakdawalla, 2005).  This theory 
states that medical advances are linked to widening disparities because new medical 
technologies disproportionately benefit the heaviest health care users; richer patients 
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(Goldman & Lakdawalla).  Given that richer more well-educated patients tend to be the 
heaviest health care users and use more complex treatment regimens, richer patients 
disproportionately use newer therapies (Goldman & Lakdawalla).  This could contribute 
to higher monoclonal antibody use by high SES or nonminority populations. 
In summary, these three theories work in concert to provide support for the 
research questions.  The fundamental cause theory attempts to explain disparities based 
on resource acquisition; whereas the diffusion of innovation theory takes a temporal 
approach to explain uptake of new technologies or treatments; and the theory of health 
disparities and medical technology proposes that the complexity and quantity of 
treatment influences who will receive treatment.  All three of these theories provide 
rationale for research into disparities in monoclonal antibody treatment of colorectal 
cancer patients, as it is likely that demographics and social status will contribute to 
disparities in utilization of newer, more complex treatments.    
Literature Review 
 In this literature review I have provided an overview of colorectal cancer 
epidemiology, reviews studies related to disparities in colorectal cancer survival, and 
examines the potential underlying causes of colorectal cancer survival disparities.  I have 
also addressed studies related to the safety and efficacy of monoclonal antibodies in 
elderly colorectal cancer patients.  In addition, I’ve described strengths and weaknesses 
of previous approaches and, on this basis, variables and concepts chosen for the study 
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were justified.  Finally, I provided a review and synthesis of the studies related directly to 
the research questions. 
Colorectal Cancer Epidemiology 
In the United States, colorectal cancer accounts for 8.6% of all new cancer cases 
and 8.8% of all cancer deaths (NCI, n.d.b).  Colorectal cancer risk and mortality rate 
increases with age, with the elderly being most affected by the disease (CDC, 2013).  In 
the U.S., elderly individuals (65 years+) account for 60% of all new colorectal cancer 
cases and 70.9% of all colorectal cancer deaths (NCI, n.d.a).  As identified in the 
literature search section above, many studies have uncovered disparities in colorectal 
cancer survival based on demographics such as race, SES, or neighborhood 
characteristics (degree if urbanization).  However, the underlying causes of these 
disparities, especially in patients with metastatic colorectal cancer, have been only 
minimally addressed in the literature.   
Review of Studies Related to Constructs and Methods  
 This research study aims to address disparities in adjunct monoclonal therapy of 
elderly metastatic colorectal cancer patients.  This topic is important due to previously 
observed survival disparities within this population.  Therefore, this section will provide 
an in-depth review of what is known about survival disparities in colorectal cancer and 
will provide the rationale for further research into treatment disparities. 
Disparities in colorectal cancer survival.  The research topic for the study 
addressed disparities in monoclonal antibody therapy based on several demographic 
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predictors.  This topic is important as it could help explain previously observed and, in 
some cases, widening disparities in colorectal cancer survival.  Many studies have 
addressed disparities in colorectal cancer survival.  These studies have uncovered 
disparities based on age, race, socioeconomic status, and neighborhood characteristics 
(degree of urbanization).  These studies also provide the rationale for the research topic 
and are described in detail in the sections below. 
Disparities in the elderly.  Colorectal cancer survival disparities have been 
documented in the elderly population.  Using data from the SEER-Medicare linked 
database, White et al. (2010) found significant survival disparities comparing elderly 
black patients to elderly white patients (adjusted Hazard Ratio: 1.24; 95% CI: 1.14-1.35).  
Similar results were obtained by Gomez et al. (2007), also using the SEER-Medicare 
linked database.  Contrarily, Wallace et al. (2013) observed only modest survival 
disparities comparing elderly black to elderly white colorectal cancer patients.  However, 
the population in the Wallace et al. (2013) differed from the other two studies.  Namely, 
as opposed to using national-level data, Wallace et al. (2013) limited the population 
studied to residents of South Carolina and expanded the definition of elderly to include 
patients over 50 years of age.  The White et al. (2010) and Gomez et al. (2007) studies 
defined elderly as over 65 years of age.  The source population differences could explain 
the discrepancy in results obtained in these studies.   
Additionally, Chien et al. (2013) identified spatial disparities in colorectal cancer 
survival of elderly patients residing in Atlanta and Detroit.  Specifically, their research 
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identified geographical areas with excessive risk of colorectal cancer death (Chien et al., 
2013).  However, the authors comment that additional research is needed to understand 
the moderating pathways driving these disparities (Chien et al., 2013).   
Finally, disparities in colorectal cancer mortality based on age were identified in a 
study by Ahmed et al. (2014).  Specifically, elderly patients over 80 years of age had 
higher cancer-specific mortality rates compared to patients 60-80 years of age (Ahmed et 
al., 2014).  Relevant to the research topic, Ahmed et al. (2014) also identified treatment 
disparities associated with advancing age that were correlated with mortality rates.  
Similarly, Serra-Rexach et al. (2012) found that a population of colorectal cancer patients 
younger than 75 years of age had a better cancer-specific survival rate compared to the 
75+ years of age group.  These results are documented in detail in Table 4. 
The survival disparities observed within the population of elderly colorectal 
cancer patients provide some of the rationale for using this population in this research 
study.  Additionally, many of the key referenced survival disparities studies used data 
from the SEER-Medicare database (Chien et al., 2013; Lang et al., 2009; White et al., 
2010).  This is the data source used for this research project.  Therefore, this research 





Advanced Age-Related Colorectal Cancer Survival Disparities 




















areas with excess risk of 
colorectal cancer death.  
Spatial patterns varied by 
cancer type and stage. 














Elderly patients (50+ 
years) showed only 
modest racial disparities 
in survival (less than 50 
years) (Hazard Ratio: 
1.16; 95 % CI 1.01-1.32). 












Black patients had worse 
survival compared to 
white patients (adjusted 
Hazard Ratio: 1.24; 95% 
CI: 1.14-1.35).  Asian 
patients had better 
survival compared to both 
black and white patients 
(adjusted Hazard Ratio: 
0.80; 95% CI: 0.70-0.92).   





















and 2001 and 
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Two or more geriatric 
syndromes were 
associated with increased 
disease-specific mortality 
(Hazard Ratio: 2.71; 95% 
CI: 1.80-4.07). 
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through 2005. 5-year survival 
5-year survival improved 
temporally, with survival 
improving from 43% to 
46.3% in colon cancer and 
from 39.4% to 42.2% in 
rectal cancer from 1992-
2000.   

















The younger than 75 years 
of age group had a better 
cancer-specific survival 
rate compared to the 75+ 
years of age group (36.41 
months vs. 26.05 months; 
hazard ratio: 0.66). 












through 1999. Mortality rate 
Unadjusted colorectal 
cancer mortality rates 
were higher in Black 
Americans and Hispanic 
compared to White 
Americans and lower in 
Japanese compared to 
White Americans.  
Adjustments for stage 
eliminated the difference 
between White Americans 
and Hispanics and White 
Americans and Japanese.  
However, comparing 
blacks to White 
Americans, cancer stage 
and SES only accounted 
for half of the observed 
mortality difference. 
Ahmed et al. (2014) 
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30-day and 6-month 
mortality was the highest 
in patients 80+ years.  
Association of age with 
mortality at 6-months was 
the highest in patients 
receiving curative surgery 
(OR: 3.8, 95% CI: 2.8-
5.2) compared to those 
receiving palliative 





Socioeconomic disparities.  Socioeconomic disparities in colorectal cancer 
survival have been documented in the literature.  Specifically, populations with lower 
SES often have higher colorectal cancer mortality rates.  Oliphant et al. (2013b) found 
that both post-operative death and 5-year survival rates were independently predicted by 
low SES.  Similarly, Lian et al. (2011) and Lejeune et al. (2010) found that lower SES 
areas had higher colorectal cancer-specific mortality rates.  Interestingly, in several 
studies, survival disparities based on race (Le et al., 2008;Wassira et al., 2013; White et 
al., 2010; Yan et al., 2009) or urban versus rural geography (Henry et al., 2009; Hines et 
al., 2014) were somewhat attenuated when the authors controlled for SES.  Therefore, 
SES appears to associate with colorectal cancer survival and might even account for 
some of the observed racial and geographical disparities in survival.  Since this research 
study attempts to uncover treatment differences that could contribute to observed 
colorectal cancer survival disparities, it is critically important to include SES as a 
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Low SES was independently 
associated with increased 
postoperative death (Adjusted 
Odds Ratio: 2.26; 95% CI: 
1.45-3.53) and lower 5-year 
survival rates (Adjusted 
Relative Excess Risk: 1.25; 
95% CI: 1.03-1.51).  However, 
when postoperative deaths were 
excluded, the relative survival 














Black Americans had a 20.1% 
higher risk of colorectal cancer 
death compared to White 
Americans.  This increased risk 
persisted when adjusted for 
tumor stage, sex, diagnosis 
period, tumor sub-location, 
marital status, and SES. 












year time period 
5-year 
mortality 
5-year survival rate in this 
urban underserved population 
was worse than the national rate 
(52.9% vs. 64.3%).  Colorectal 
cancer screening was associated 
with improved survival.  
Advanced age and later stage 
cancer was associated with 
reduced survival.  However, 
insurance status of the patients 
was not associated with 
survival. 


















Lower SES neighborhoods had 
higher colorectal cancer-
specific mortality (Hazard 
Ratio: 1.2; 95% CI: 1.1-1.5).   



















socioeconomic status were 
associated with a reduction in 
the survival difference between 
both blacks and White 
Americans and Black 
























Patients from lower SES areas 
had poorer overall survival and 
were also less likely to receive 
treatment within 6 months of 
diagnosis.  When limited to 
patients receiving treatment 
within 1 month of diagnosis, no 
survival disparity existed based 
















There were geographical areas 
of the state with both higher and 
lower survival rates.  When 
race/ethnicity and area SES 
were controlled, the risk of 
death was attenuated in several 
areas.  However, in some areas, 
survival disparities persisted. 








1992. Survival rate 
Black Americans had 
significantly higher rates of late 
stage disease and were more 
likely to reside in lower SES 
census tracts.  After adjusting 
for age, marital status, sex, SES 
group, cancer stage, and 
treatment, race was no longer a 

















colorectal cancer Survival rate 
Even with universal health care, 
area-level SES was associated 
with reduced survival rates 
(Hazard Ratio: 0.73; 95% CI: 
0.53-1.00) from colorectal 
cancer (after adjustment for age, 
sex, tumor stage and treatment). 
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After adjustment for age, sex, 
histology, tumor site, and stage, 
Black Americans had increased 
cancer-specific death rates 
compared to White Americans 
(Hazard Ratio: 1.19; 95% CI: 
1.14-1.25).  However, when 
adjusted for area-level SES and 
treatment, the disparity was 
reduced (Hazard Ratio: 1.08; 
















2007) Survival rate 
Rural residents had a 14% 
increased risk of death (Hazard 
Ratio: 1.14, 95% CI: 1.07-1.22).  
However, when adjusted for 
SES level, no differences in 
survival between rural and 
urban tracts were noted. 
Steinbrech


















SES and colorectal cancer 
incidence were positively 
associated in Hispanics, but 
negatively associated in Black 
Americans and White 
Americans.  In White 
Americans, as SES increased, 
colorectal cancer mortality 
declined.  However, this was 
















Unadjusted colorectal cancer 
mortality rates were higher in 
Black Americans and Hispanic 
compared to White Americans 
and lower in Japanese compared 
to White Americans.  
Adjustments for stage 
eliminated the difference 
between White Americans and 
Hispanics and White Americans 
and Japanese.  Comparing 
Black Americans to White 
Americans, cancer stage and 
SES only accounted for half of 




 Racial disparities.  Many key studies have reported significant racial disparities in 
colorectal cancer survival (Hassan et al., 2009; Hines et al., 2012; Le et al., 2008; 
Wallace et al., 2013; Wassira et al., 2013; White et al., 2010) .  For example, a study by 
Wassira et al. (2013) showed that Black Americans had reduced colorectal cancer 
survival compared to White Americans.  This difference persisted even after adjustment 
for tumor stage, sex, age, diagnosis period, tumor sub-location, marital status and SES 
(Wassira et al., 2013).  However, the role of race has been debated.  A study by Yan et al. 
(2009) found that after adjusting for age, marital status, sex, SES group, cancer stage, and 
treatment, race was no longer a significant predictor of overall survival.  Therefore, the 
data is somewhat mixed as to whether race or other factors associated with race predict 
colorectal cancer survival.  However, it is well documented that Black Americans have 
higher colorectal cancer mortality rates compared to White Americans.  Although the 
data sources are minimal, colorectal cancer survival disparities have also been noted in 
other minority races including Native Americans (Cuerto et al., 2011) and Hispanics 
(Jafri et al., 2013; Wan et al., 2012).  Authors from several documented studies comment 
that treatment related data are needed to advance the understanding of racial disparities in 
colorectal cancer (Wassira et al., 2013; Wallace et al., 2013).  This might help explain the 
difference in results comparing the Wassira et al. (2013) study to the Yan et al. (2009) 
study; as Yan et al. (2009) controlled for treatment regimen.  This point is of particular 
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importance to this study as disparities in treatment could help explain some of the racial 
disparities in colorectal cancer survival. 
In recent years (2004-2009), new treatments and technologies appear to be 
contributing to increasing survival rates in all races (Sineshaw et al., 2014).  However, 
these survival increases are greater in White Americans compared to Black Americans 
(Sineshaw et al., 2014).  Therefore, racial disparities in colorectal cancer survival, 
specifically comparing Black Americans and White Americans, are increasing (Sineshaw 
et al., 2014).  Similar widening disparities were observed in a study by Robbins et al. 
(2012).  Sineshaw et al. (2014) propose that minority populations have not benefited as 
greatly from newer treatments or these treatments have not be disseminated into these 
populations as robustly (Sineshaw et al., 2014).  This hypothesis is supported by Simpson 
et al. (2013).  In the Simpson et al. (2013) study, black metastatic colorectal cancer 
patients were less likely to receive multimodality therapy compared to White Americans.  
When adjusted for differences in treatment, the increased risk of death seen in black 
versus white patients disappeared (Simpson et al., 2013).   
 Given that race has been associated with colorectal cancer survival and the 
presence of studies linking racial disparities to treatment disparities, it is critically 
important to include race as a variable in this study.  It is possible that newer technologies 
(monoclonal antibody therapies) are driving the recent widening disparities in colorectal 
cancer based on race.  Studies describing racial disparities in colorectal cancer survival 
























Comparing 1992-1997 to 2004-2009, 
the 5-year  
survival rate increased in all races 
except nonHispanic Black Americans 
(nonHispanic White Americans = 
11.4% to 17.7%; nonHispanic Black 















Black race was associated with a 
higher mortality rate (Hazard Ratio: 
1.15, 95% CI: 1.08-1.22).  When the 
data were adjusted for patient, tumor, 
and demographic factors, the Hazard 
Ratio reduced marginally, but was still 
significant.  When the data were 
adjusted for treatment, there was no 
longer a significant different in 















Black Americans had a 20.1% higher 
risk of colorectal cancer death 
compared to White Americans.  This 
increased risk persisted when adjusted 
for tumor stage, sex, diagnosis period, 



















Disparities in survival comparing 
Black Americans to White Americans 
increased over the time period.  
Comparing age groups, younger 
patients (less than 50 years) showed 
the greatest racial disparities in 
survival (Hazard Ratio: 1.34, 95% CI: 
1.06-1.71).  Elderly male patients (50+ 
years) showed only modest racial 
disparities in survival (Hazard Ratio: 
1.16, 95% CI: 1.01-1.32).  No racial 
disparity was observed in elderly 
female patients. 
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Comparing 1993-1997 to 2003-2007, 
there were no significant 
improvements in 5-year survival for 
Hispanics.  There was a modest 
increase in 1-year survival for young 

















Screening accounted for 19% of the 
survival disparity between Black 
Americans and White Americans.  
36% of the survival disparity was 













Survival rates from colon cancer were 
worse for Native Americans (Hazard 
Ratio: 1.20; 95% CI: 1.08-1.34), 
however no difference was found in 

















Black patients had worse survival 
compared to white patients (adjusted 
Hazard Ratio: 1.24; 95% CI: 1.14-
1.35).  Asian patients had better 
survival compared to black and white 
patients (adjusted Hazard Ratio: 0.80; 



















There were geographical areas of the 
state with both higher and lower 
survival rates.  When race/ethnicity 
and area SES were controlled, the risk 
of death was attenuated in several 
areas.  However, in some areas, 
survival disparities persisted. 












After adjusting for age, marital status, 
sex, SES group, cancer stage, and 
treatment, race was no longer a 
significant predictor of overall 
survival. 





















After adjustment for age, sex, 
histology, tumor site, and stage, Black 
Americans had increased cancer-
specific death rates compared to White 
Americans (Hazard Ratio: 1.19; 95% 
CI: 1.14-1.25).  However, when 
adjusted for area-level SES and 
treatment, the disparity was reduced 
(Hazard Ratio: 1.08; 95% CI: 1.03-
1.13). 














Death rate from Colorectal Cancer was 
highest in Hispanics and nonHispanic 
Black Americans and in several 
geographical regions.  Spatial access to 
oncologists was significantly 
associated with survival in nonurban 
areas only.  Access to care did not 























Black Americans had slightly higher 
death rates from both colon and rectal 
cancer (Hazard Ratio for colon cancer: 
1.11, 95% CI: 1.00-1.24; Hazard Ratio 
for rectal cancer: 1.24, 95% CI: 1.14-



















NonWhite Americans were diagnosed 
younger and with a greater proportion 
of stage III tumors.   Age and tumor 
stage at diagnosis were the only 
predictors of lower survival. 



















Over the time period (1985-2008) 
mortality rates decreased in both Black 
Americans and White Americans.  
However, the decreases were smaller 
for Black Americans.  As a result, 
black to white mortality ratios 
increased from 1.17 to 1.41 for 
localized disease, from 1.03 to 1.30 for 
regional disease, and from 1.21 to 1.72 

















Unadjusted colorectal cancer mortality 
rates were higher in Black Americans 
and Hispanic compared to White 
Americans and lower in Japanese 
compared to White Americans.  
Adjustments for stage eliminated the 
difference between White Americans 
and Hispanics and White Americans 
and Japanese.  However, comparing 
Black Americans to White Americans, 
cancer stage and SES only accounted 
for half of the observed mortality 
difference. 
 
Neighborhood disparities.  The presence of neighborhood level disparities 
(degree of urbanization) in colorectal cancer survival is controversial.  Several studies 
have shown that controlling for SES attenuated rural versus urban difference in colorectal 
cancer survival.  For example, Hines et al. (2014) reported that rural residents in Georgia 
had 14% higher risk of colorectal cancer mortality compared to urban residents.  
However, when the authors adjusted for SES level, the disparity was attenuated (Hines et 
al., 2014).  Additionally, Henry et al. (2009) found geographical areas in New Jersey with 
higher rates of colorectal cancer death.  As in Hines et al. (2014), when the authors 
controlled for SES, the increased risk of death was attenuated in many areas (Henry et al., 
2009).   
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Lian et al. (2011) took a different approach to the question and directly assessed 
neighborhood socioeconomic deprivation as a predictor of colorectal cancer mortality 
rates using national-level data.  Contrary to the previously listed studies, in the Lian et al. 
(2011) article, SES did not explain all the observed geographical variation in mortality.  
Therefore, although neighborhood SES appears to contribute to colorectal cancer 
mortality, other neighborhood characteristics might also contribute to colorectal cancer 
mortality rates.  In this study, neighborhood characteristic (degree of urbanization) 
disparities in monoclonal antibody treatment will be addressed to assess the possibility 
that rural residents have reduced levels of treatment compared to urban residents.  Studies 
describing neighborhood characteristic disparities in colorectal cancer survival are 




Neighborhood Characteristics Related to Colorectal Cancer Survival Disparities 





















 Rural residents had a 14% 
increased risk of death (Hazard 
Ratio: 1.14, 95% CI: 1.07-1.22).  
However, when adjusted for SES 
level, no difference in survival 
















Death rate from Colorectal 
Cancer was higher than the state 
average in several geographical 
regions.  Spatial access to 
oncologists was significantly 
associated with survival in 
nonurban areas only.  Access to 


















There were geographical areas of 
the state with both higher and 
lower survival rates.  When 
race/ethnicity and area SES were 
controlled, the risk of death was 
attenuated in several areas.  















Identified geographic areas with 
excess risk of colorectal cancer 
death.  Spatial patterns varied by 




















There was significant 
geographical variation in 
colorectal cancer-specific 
mortality.  Lower SES 
neighborhoods had higher 
colorectal cancer-specific 
mortality (Hazard Ratio: 1.2; 95% 
CI: 1.1-1.5).  .  However, 
neighborhood SES did not 
account for geographical variation 




 Underlying causes of colorectal cancer survival disparities.  As documented in 
detail in the sections above, there are a multitude of studies describing disparities in 
colorectal cancer survival based on many different factors including age, race, SES and 
neighborhood characteristics (degree of urbanization).  However, in order to reduce these 
disparities, it is important to understand the underlying causes of these disparities.  This 
area of research is less well developed, however the three main areas of exploration 
include observed disparities in access to care, screening and treatment.   
Access to care disparities.  One potential underlying cause of the colorectal 
cancer survival disparities are disparities in access to care.  Oliphant et al. (2013a) found 
that access and utilization of a colorectal cancer specialist for surgery as opposed to a 
nonspecialist was associated with a reduced risk of postoperative death and an increased 
5-year survival rate.  Likewise, Zullig et al. (2013) found that older age was associated 
with reduced rate of colorectal cancer specialist referral.  Therefore, it is possible that 
access to a specialist contributes to the colorectal cancer survival disparity seen in the 
elderly.  Additionally, Laiyemo et al. (2010) found racial disparities in follow-up to 
abnormal colorectal cancer screening results; with Black Americans less likely than 
White Americans to obtain follow-up within 1 year of abnormal result.  Access to care 
was proposed as a reason for this disparity (Laiyemo et al., 2010)  However, if access to 
care is gauged by healthcare spending, Wright et al. (2007) found that the total cost for 
colorectal cancer care was slightly higher in Black Americans compared to White 
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Americans.  Therefore, the role that access to care disparities play in overall colorectal 
cancer survival is still unclear. 
Screening disparities.    Another potential underlying cause of colorectal cancer 
survival disparities are disparities in early detection or screening.  Multiple papers have 
highlighted racial differences in colorectal cancer screening.  For example, Crawford et 
al. (2010), Stimpson et al. (2012), and Wilkins et al. (2012) all found that Black 
Americans had lower colorectal cancer screening rates compared to White Americans.  
The relevance of these results to survival was addressed by Lansdorp-Vogelaar et al. 
(2012).  In this article, the authors found that 19% of the difference in survival between 
elderly Black Americans and White Americans with colorectal cancer could be explained 
by differences in screening (Lansdorp-Vogelaar et al., 2012).  Therefore, disparities in 
early detection via screening do appear to contribute to disparities in colorectal cancer 
survival.  However, according to Lansdorp-Vogelaar et al. (2012) there are additional 
factors contributing to the differences in survival, including potential disparities in 
treatment, which need further research.  Interestingly, when Stimpson et al. (2012) 
adjusted their analysis for SES, no racial screening disparities were found.   
Cole et al. (2012) found a modest difference in colorectal screening comparing 
rural to urban zip codes.  Specifically, after adjustment for demographics and health 
characteristics, rural residents had lower screening rates compared to urban residents 
(48% vs. 54%, respectively) (Cole et al., 2012).  These screening rate disparities could be 
reflecting access to care disparities given the geographical nature of the disparity.  
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However, this was not address by Cole et al. (2012). Finally, Lang et al. (2009) 
performed a temporal study to correlate colorectal cancer screening rates and survival 
rates.  Across the time period (1992-2005), earlier detection did not appear to impact 
survival (Lang et al., 2009).  However, the authors did find that technological 
improvements (new technologies/treatments or better use of current treatments) and 
demographics were responsible for the largest share of the temporal 5-year survival 
improvement (Lang et al., 2009). 
Treatment disparities.  A final potential underlying cause of colorectal cancer 
survival disparities are disparities in treatment.  This area of disparity research has been 
researched to a greater extent compared to access to care or screening disparities.  
Multiple papers have found that different demographic variables including age, rural 
versus urban geography, SES, and race are associated with different treatment regimens.  
For example, although targeted treatments (such as chemotherapy) have been shown to 
increase survival rates, Mitry et al. (2013) found that only 10% of elderly received 
targeted treatments, compared to 40% of younger populations.  These results are 
supported in the literature as age-related disparities in colorectal cancer treatment 
(surgery, chemotherapy, radiation) have been observed in multiple different studies 
including Bakogeorgos et al. (2013), Obeidat et al. (2010) and Serra-Rexach et al. (2012).  
Of importance for this study, this age-related treatment disparity has persisted into newer 
colorectal cancer therapies. Fu et al. (2013) and Kozloff et al. (2010) observed reduced 
adjunct bevacizumab treatment with increasing patient age.  Therefore, the literature 
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supports an age-related colorectal cancer treatment disparity, where the elderly are less 
likely to receive newer treatments. 
In addition to age disparities, many articles have addressed racial and SES 
disparities in colorectal cancer treatments.  Le et al. (2008) found significant differences 
in first-line treatment (surgery, radiation, and chemotherapy) comparing Black 
Americans to White Americans.  These racial disparity results were supported in 
subsequent studies by Hao et al. (2011), Hines et al. (2012), and White et al. (2008).  
Interestingly, Zullig et al. (2013) found no racial disparities in treatment when the 
population was limited to Veteran Affairs (VA) hospitals.  In their article, Zullig et al. 
(2013) proposed that the racial disparities in treatment observed in the aforementioned 
studies could be related to insurance status or access to care differences.   
Compared to higher SES areas, Lejeune et al. (2010) found that patients from 
lower SES areas were less likely to receive treatment within 6 months of colorectal 
cancer diagnosis.  Additionally, Le et al. (2008) found significant differences in first-line 
treatment (surgery, radiation, and chemotherapy) comparing higher SES to lower SES 
areas.  Hao et al. (2011) described urban versus rural disparities in first-line 
chemotherapy treatment in colorectal cancer.  Specifically, populations with urban or 
suburban zip codes were, respectively, 38% and 52% more likely to receive 
chemotherapy compared to populations with rural zip codes (Hao et al., 2011).   
Of particular importance to this study, my literature searches did not uncover any 
studies addressing racial, SES, or neighborhood disparities in monoclonal antibody 
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treatment of colorectal cancer.  Adjunct monoclonal antibody therapy has been shown to 
reduce colorectal cancer mortality in multiple populations, including the elderly (as 
discussed in the next section).  It is possible that disparities in monoclonal antibody 
treatment are contributing to disparities in colorectal cancer survival.  However, given the 
lack of research, disparities in monoclonal antibody treatments are a clear literature gap.  
Studies describing access to care, screening and treatment disparities in colorectal 





Access to Care, Screening and Treatment Disparities 
Access to care disparities 

















Patients with a primary care 
physician (PCP) were more likely 
to be screened for colorectal 
cancer (OR: 2.05; 95% CI: 2.03-
2.07).  Ethnic disparities in 
screening were almost eliminated 
after accounting for PCP. 
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Black Americans were more 
likely to report colorectal cancer 
screening barriers.  Having a 
physician recommend screening 
was associated with the highest 
screening rates regardless of race. 

















Older age at diagnosis was 
associated with reduced odds of 
medical oncology referral and 
surveillance colonoscopy. 


























Black Americans were less likely 
than White Americans to obtain 
follow-up colonoscopy within 1 
year of abnormal FSG result 
(62.6% vs. 72.4% respectively).   








stage II-III rectal 








The total colorectal cancer cost 
for Black Americans was higher 
than White Americans ($44,199 
vs. $38,588).  However, after 
adjusting for covariates, this 
difference was insignificant.   
    table continues 
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Both postoperative mortality rates 
and 5-year survival rates were 
improved in patients who 
received surgery from a specialist.   
Screening disparities 
















year time period 
5-year 
mortality 
Colorectal cancer screening was 
associated with improved survival 
in this urban underserved 
population.  Insurance status of 















Screening accounted for 19% of 
the survival disparity between 
Black Americans and White 
Americans.   
















White Americans were more 
likely than Black Americans or 
Hispanics to have received either 
type of colorectal cancer 
screening (fecal occult blood 
testing or endoscopy).  Persons 
without insurance or a usual 
source of care were less likely to 
obtain screening. 





Study and the 
linked Area 
Resource File 
Subjects with a 
personal history 
of cancer, 
subjects over 50 
years old, or 
subjects over 40 
years old with a 





White Americans were more 
likely to report a colorectal 
endoscopy exam (44%), followed 
by Black Americans (36%) and 
Hispanics (28%).  The difference 
in screening rates between White 
Americans and Black Americans 
was eliminated when adjusted for 
area socioeconomic status. 
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Black respondents had lower 
screening rates compared to 
White Americans (50.4% and 
63.4% respectively).   
    table continues 
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Although the rates in both rural 
and urban communities increased 
over time, after adjustment for 
demographics and health 
characteristics, rural residents had 
lower screening rates compared to 
urban residents (48% vs. 54% 
respectively).   













Comparing the time periods, 
earlier detection did not appear to 
impact survival.  Technological 
improvements (new 
technologies/treatments or better 
use of current treatments) and 
demographics were responsible 
for the largest share of the 
temporal 5-year survival 
improvement. 
Treatment disparities 

























Compared to the national 
colorectal cancer sample, 
individuals diagnosed in West 
Virginia were diagnosed in early 
stages, but had poorer survival 
rates.  The West Virginia cohort 
had lower treatment rates. 














Comparing the 1997-2004 time-
period to the earlier time period, 
patients receiving chemotherapy 
increased from 19% to 57%.  
However, from 2005-2009, less 
than 10% of the elderly received 
targeted treatments, compared to 
40% for younger patients. 












Native Americans and White 
Americans had similar surgery 
recommendation rates.  Native 
Americans were more likely to 
receive radiation, but less likely to 
receive sphincter-preserving 
surgery.   




























Patients from lower SES areas 
were less likely to receive 
treatment within 6 months of 
diagnosis.  When limited to 
patients receiving treatment 
within 1 month of diagnosis, no 
survival disparity existed based on 
area SES. 



















57% of newly diagnosed patients 
received bevacizumab, compared 
to 44% of patients with 
progressive disease.  Patients aged 
80+ were less likely than younger 
elderly patients (65-69) to receive 
adjunct bevacizumab (OR: 0.64; 
CI: 0.57-0.73).   














Use of bevacizumab as a first-line 
adjunct therapy decreased with 
age.  Comparing elderly (65+ 
years) receiving bevacizumab to 
elderly not receiving 
bevacizumab, there was a 
significant increase in median 
survival with bevacizumab 

















Within this group, advancing age 
was associated with a reduction 
chemotherapy treatment.  
Receiving chemotherapy was 
associated with lower risk of 
death for all stratified elderly age 
groups. 













Elderly individuals (65+ years) 
were less likely to receive first-
line doublet chemotherapy 
compared to younger (under 65 
years) patients (54% vs. 84%).  
The use of each of the medicines 
studied (irinotecan, oxaliplatin 
and bevacizumab) were all lower 















Elderly patients (70+ years) were 
more likely to receive only single 
agent chemotherapy, fewer cycles 
(6.2 cycles compared to 8.3 for 
younger patients), and lower 
doses (42.8% of planned dose 
compared to 78.4% for younger 
patients).   





















The younger than 75 years of age 
group was more likely to receive 
surgery, radiation, and 
chemotherapy and less likely to 
receive palliative care compared 
to the older group (75+).   



















based on race 
or age 
Black Americans were less likely 
to be treated with the newer 
chemotherapy option (Irinotecan) 
compared to White Americans 
(OR: 0.641; 95% CI: .453-0.907).  
Older elderly patients (71+ years) 
were less likely to receive 
Irinotecan compared to younger 
elderly patients (66-70 years). 














Receipt of standard of care (stage 
specific and defined by the 
Physician Data Query guidelines) 
increased in both race groups over 
time.  However, Black Americans 
were overall 16% less likely to 
receive standard of care compared 
to White Americans (OR: 0.85; 
95% CI: 0.78-0.90). 














Black Americans and Hispanics 
were less likely than White 
Americans to undergo surgery 
(OD: 0.57, 95% CI: 0.52-0.63 and 
OR: 0.82, 95% CI: 0.70-0.95 
respectively).  Similar disparities 
were seen for receipt of adjunct 
chemotherapy.  Adjustment for 
area sociodemographics, surgeon 
capacity, and medical oncologist 
capacity reduced the observed 
disparities.  






Black and white 
persons 
diagnosed with 
stage III colon or 





Urban and suburban patients were 
more likely than rural patients to 
receive chemotherapy (38% and 
53% more likely respectively).  
Urban black patients were 24% 
less likely to receive 
chemotherapy compared to urban 
white patients.  There were no 
racial differences within suburban 
and rural areas of residence. 
    table continues 
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2007. Surgery rates 
Black Americans had lower rates 
of surgery (50% decreased odds 
for colon cancer; 67% decreased 
odds for rectal cancer).   

















NonWhite Americans were 
diagnosed younger and with a 
greater proportion of stage III 
tumors.  No disparities in 
treatment (surgery, adjunct 
therapy, disease recurrence) were 
found comparing nonWhite 
Americans to White Americans.   


















Lower SES census tracts had 
lower colon cancer surgery rates.  
Rural and lower-SES census tracts 
also had reduced rates of 
chemotherapy.   




Black and white 
persons 
diagnosed with 





Black Americans were less likely 
than White Americans to receive 
standard of care.  Black 
Americans were also more likely 
to refuse recommended treatment. 

















Black Americans and White 
Americans were equally likely to 
receive National Comprehensive 
Cancer Network guideline-
concordant colorectal cancer care 
through the VA system.    


















and 2001 and 
admitted to home 
health care 30 




Functional limitation and geriatric 
syndromes were associated with 
lower likelihood of treatment 
(surgery-only or surgery + 




Safety and efficacy of adjunct monoclonal antibody treatment in elderly 
colorectal cancer patients.  In this study, I aim to understand a potential underlying 
disparity in colorectal cancer survival, namely disparities in adjunct monoclonal antibody 
treatment.  Therefore, for the validity of the hypothesis, it’s critically important that 
monoclonal antibodies extend survival and are safe to use in the study population.   
Multiple studies determined that adjunct monoclonal antibody treatment with 
either bevacizumab or cetuximab was safe in elderly patients with either manageable side 
effects or side effects equivalent to the younger populations of patients (Abdelwahab et 
al., 2012; Bruera et al., 2013, Cunningham et al., 2013; Naeim et al., 2013).  
Additionally, multiple clinical studies showed improved survival in elderly colorectal 
cancer patients treated with adjunct monoclonal antibody therapy.  For example, in a 
large Phase III study, Cunningham et al. (2013) found that elderly patients that received 
bevacizumab plus chemotherapy had a median progression-free survival time of 9.1 
months compared to 5.1 months in patients treated with chemotherapy only.  Progression-
free survival improvement was also seen with adjunct bevacizumab in a smaller Phase II 
study by Vrdoljak et al. (2011).  Similar results were obtained with adjunct cetuximab 
therapy.  Specifically, elderly colorectal cancer patients treated with cetuximab plus 
chemotherapy had a progression-free survival time of 8.8 months, compared to 5.8 
months for chemotherapy only (Price et al., 2012).  
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Several recent population-based observational studies have supported these 
clinical findings.  Kozloff et al. (2010) and Renouf et al. (2011) both found that adjunct 
bevacizumab therapy increased median survival time in elderly colorectal cancer patients.  
Additionally, Jehn et al. (2012) found that the efficacy and side effect profile of adjunct 
cetuximab therapy was similar comparing elderly patients to younger patients.   
Table 9 includes both clinical and observational studies citing the efficacy and/or 





Monoclonal Antibody Treatment of Elderly Colorectal Cancer Patients 
Clinical Studies with Adjunct Monoclonal Antibody Therapy 










Phase II study 
in elderly 
colorectal 




Median overall survival was 
12.7 months with manageable 
side-effects and no new safety 



















Drug activity, efficacy, and 
safety of triple chemotherapy + 
bevacizumab were equivalent to 
the overall colorectal cancer 
population.   
Cunningha















Elderly patients had improved 
progression-free survival with 
the addition of adjunct 
bevacizumab to their 
chemotherapy (median survival 
9.1 months vs. 5.1 months; 
hazard ratio: 0.53, 95% CI: 
0.41-0.69).  Adverse events 
were slightly higher in the 
combination group, but overall 
the combination was tolerated 







Phase II trial 









Median progression-free was 
11.5 months and overall 
survival was 21.2 months.  
Side-effects were similar to 
those reported in earlier studies 
with younger age groups. 





Price et al. 
(2012) 
















The addition of bevacizumab to 
capecitabine to the elderly (75+ 
years) population increased 
progression free survival (5.8 
months vs. 8.8 months; Hazard 
ratio: 0.65).  Compared to the 
younger age groups, there were 
no major toxicity differences. 
Abdelwaha








(65 years +) 
who 
progressed 






Median survival time was 7 
months and median 
progression-free survival was 4 
months for irinotecen 
(chemotherapy) + cetuximab 
(anti-EGFR monoclonal 
antibody).  Side effects were 
tolerable. 
Observational Studies with Adjunct Monoclonal Antibody Therapy 
























Side-effects and efficacy 
(progression-free survival) of 
cetuximab + irinotecan were 
similar comparing the greater 
than 65 age group to the less 





















Comparing elderly (65+ years) 
receiving bevacizumab to 
elderly not receiving 
bevacizumab, there was a 
significant increase in median 




















In the 2003/2004 cohort, 5.9% 
received bevacizumab; whereas 
in the 2006 cohort 30.6% 
received bevacizumab.  Overall 
survival was improved in the 
2006 cohort compared to the 
2003/2004 cohort (13.8 months 




Evaluation of Strengths and Weaknesses of Previous Approaches 
The vast majority of literature cited in the sections above utilized secondary data 
sources (such as the SEER-Medicare database) to address their research questions.  In a 
broad sense, this has multiple benefits.  First, the data is already collected, organized, and 
available for use saving both time and cost.  Second, using secondary data sources results 
in assess a larger or more geographically broad sample.  Third, since the data is already 
collected, it is possible to retrospectively use several years of collected data; something 
that might not have been possible if primary data collection were performed.  
Alternatively, data for some of the literature cited above was collected or compiled 
specifically for the study in question.  These included the utilization of hospital records, 
telephone surveys, or clinical trials.  The benefit of these approaches is the researchers 
were able to address very specific questions; which may not have been answered using 
published database sources.  However, these approaches can be time consuming and 
expensive.  Therefore, researchers using these approaches often had smaller sample sizes 
or addressed a limited sample (either temporally or geographically).  Table 10 describes 






Strengths and Weaknesses of Previous Data Collection Methods Related to the Study 
Previous Data  
Collection Method Strengths Weaknesses 
Telephone Surveys 
Ability to address a very specific 
question in a very specific 
geographical region.  Wilkins et al. 
(2012) were able to address the 
impact of physician colorectal cancer 
screening recommendation on 
screening rates and also identify 
specific screening barriers. 
Telephone surveys are time 
consuming and limited the scope 
in Wilkins et al. (2012).  This type 
of approach is not feasible for 
national-level assessments or large 
sample sizes.  Research is often 






If present in medical records, this 
approach would allow the researchers 
to address a specific question.  
Hassan et al. (2009) had specific 
questions about diagnosis and 
survival at a single VA center, 
therefore, this approach was 
appropriate.  This approach also 
allows the researcher to address 
differences over time. 
This approach also limits the 
study scope.  Hospital record 
research is likely only feasible if 
performed at a few hospitals.  This 
would not be feasible on a large 
scale and could be time 
consuming. 
Clinical Trials 
Clinical trials allow the researcher to  
prospectively address questions such 
as drug efficacy (Naeim et al., 2013; 
Bruera et al., 2013; Cunningham et 
al., 2013).  These studies are very 
well controlled. 
This approach is very expensive 
and time consuming.  It is also not 
feasible for some types of 









Researchers used these databases to 
ask a multitude of research questions 
including the impact of demographics 
on colorectal cancer survival and 
treatment without performing any 
primary data collection (Naishadham 
et al., 2011; White et al., 2010; 
Simpson et al., 2013).  This method 
can save time in data collection and 
allows for large, broad data sets.  
Using secondary databases can 
limit the questions that can be 
asked.  The data in these sources 
can be difficult to access and use 
if not coded uniformly.  The 
multitude of data often requires 





Given the research questions address disparities in monoclonal antibody treatment 
based on demographic variables at a national level, some of these approaches are more 
feasible than others.  For example, telephone surveys are not feasible for this study.  It 
would be difficult to randomly call enough metastatic colorectal cancer patients to 
adequately assess the use of monoclonal antibody therapy.  Additionally, clinical trials 
would not be feasible due to cost, time, and ethics of the questions asked.  Therefore, 
since the SEER-Medicare linked database contains all the variables needed to address the 
research question in the study, the secondary data collection method using published 
databases is appropriate.   
The SEER-Medicare database is a large population-based database that contains 
matched medical records and demographic information for Medicare beneficiaries who 
have been diagnosed with cancer (NCI, 2015a).  For this research project, several SEER-
Medicare datasets containing data from colorectal cancer patients 65+ years in age were 
requested and obtained.  The first file obtained was the SEER PEDSF; a file containing 
demographics and information related to the patient’s cancer diagnosis (i.e. information 
on cancer stage, diagnosis date, previous primary tumors) (NCI, 2015b).  In addition to 
the SEER file, four matched Medicare claims files were obtained.  These included the 
Part D Event (PDE) dataset, the Outpatient Claims dataset, the Durable Medical 
Equipment (DME) dataset and the Carrier Claims dataset from 2007 to 2012.  The PDE 
dataset includes all drugs prescribed under Medicare Part D; data available only 2007 to 
2012 (NCI, 2015b).  The remaining datasets contain all Part B claims including diagnosis 
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and procedure codes (NCI, 2015b).  These five patient matched SEER-Medicare datasets 
contain information on all the variables required to answer the research questions. 
Justification of Chosen Variables 
The independent variables (race, SES, neighborhood characteristics) selected for 
the research study were chosen due to their relationship with colorectal cancer survival 
(either overall survival or survival specific to the metastatic colorectal cancer population).  
This is critical as this study aims to understand disparities in an underlying factor that 
could contribute to differences in colorectal cancer survival.  The dependent variable, 
adjunct monoclonal antibody therapy is a new therapy shown to increase survival in 
metastatic colorectal cancer patients.  Disparities in treatment of colorectal cancer 
patients have been documented, but the findings have not been extended to monoclonal 
antibody therapy.  If racial, SES, or neighborhood disparities in adjunct monoclonal 
antibody treatment are found, future studies could determine if these disparities 
contribute to the previously observed disparities in survival.   
Review and Synthesis of Studies Related to the Research Questions 
The study evaluates racial, SES, and neighborhood (degree of urbanization) 
disparities in adjunct monoclonal antibody treatment of elderly colorectal cancer patients. 
As outlined in the literature review sections above, there are documented disparities in 
colorectal cancer survival based on race, SES, and neighborhood characteristics.  The 
underlying cause(s) of these disparities is not well researched; although many papers 
have suggested treatment disparities as a needed follow-up study.  For example, 
79 
 
Sineshaw et al. (2014) propose that minority populations have not benefited as greatly 
from newer treatments or these treatments have not be disseminated into these 
populations as greatly (Sineshaw et al., 2014).  However, research has not been 
performed to determine if disparities in newer colorectal cancer therapies (such as 
monoclonal antibodies) exist.  Given the documented efficacy of monoclonal antibody 
therapy, this study evaluated adjunct monoclonal antibody treatment to determine if any 
of the groups exhibiting survival disparities (minority race, low SES, rural neighborhood) 
also have disparities in monoclonal antibody treatment. 
The dependent variable in the study is rate of adjunct monoclonal antibody 
treatment.  A review of clinical trials and post-marketing observational studies indicate 
that all three available antibodies increase progression-free survival or overall survival 
when added to chemotherapy (Bruera et al., 2013, Cunningham et al., 2013; Naeim et al., 
2013).  Therefore, as with chemotherapy, it is possible that disparities in monoclonal 
antibody treatment could contribute to disparities in colorectal cancer survival.   
There are three independent variables in this study.  Each independent variable 
was selected due to its association with colorectal cancer survival. The first independent 
variable is race.  There are many key studies that have associated race with increased risk 
of colorectal cancer death (Simpson et al., 2013; Sineshaw et al., 2014; Wallace et al., 
2013; Wassira et al., 2013).  The second independent variable is SES.  As with race, 
many studies have associated low SES with increased risk of colorectal cancer death 
(Hines et al., 2014; Oliphant et al., 2013b; Wassira et al., 2013).  The third independent 
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variable is neighborhood characteristics.  Although less well researched, two studies have 
identified rural neighborhood as a risk factor for reduced colorectal cancer survival 
(Henry et al., 2009; Lian et al., 2011).   
Summary and Conclusion 
As outlined in the literature review above, colorectal cancer survival disparities 
based on race, SES, and neighborhood characteristics have been observed in many 
different studies.  Specifically, Black Americans have reduced colorectal cancer survival 
rates compared to White Americans (Simpson et al., 2013; Sineshaw et al., 2014; 
Wallace et al., 2013; Wassira et al., 2013), low SES populations have reduced colorectal 
cancer survival rates compared to higher SES populations (Hines et al., 2014; Oliphant et 
al., 2013b; Wassira et al., 2013), and rural populations have reduced colorectal cancer 
survival rates compared to urban populations (Henry et al., 2009; Lian et al., 2011).   
In order to address these colorectal cancer survival disparities, it is important to 
address the potential underlying causes of these disparities.  Historical research into the 
underlying causes of colorectal cancer survival disparities can be lumped into three main 
categories; access to care disparities, screening disparities, and treatment disparities.  This 
study aims to fill a gap and expand on potential treatment disparities in colorectal cancer.  
Multiple articles have highlighted disparities in both type and aggressiveness of 
colorectal cancer therapies (surgery, radiation, and chemotherapy) (Bakogeorgos et al., 
2013; Obeidat et al., 2010; Serra-Rexach et al., 2012).  Although these studies have 
provided valuable information on colorectal cancer treatment disparities, including 
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disparities in elderly populations, they were conducted using patient data from the 1990s 
and early 2000.  The colorectal therapies employed during this period included surgery, 
radiation and chemotherapy.  Beginning in 2004, monoclonal antibody therapies for 
colorectal cancer came onto the market (Scott et al., 2012).  Prior to this research project, 
it was unknown if these historical treatment disparities had extended to the newer 
monoclonal antibody therapies.   
Determining if disparities in monoclonal antibody treatment of elderly metastatic 
colorectal cancer patients exist is a critical first step to eliminating these social 
inequalities.  If racial, SES, or neighborhood disparities are found, future studies could 
determine if these disparities contribute to any observed disparities in survival.  
Additionally, if treatment disparities are found, this would illuminate the need for policies 
that improve access to monoclonal antibodies, thereby helping reduce social inequalities 
in colorectal cancer survival.  Alternatively, if treatment disparities are not found, an 
opportunity exists to understand the root cause of the reduced treatment disparities, and 
this knowledge could potentially be used to reduce treatment disparities in other cancer 
populations. 
The next chapter outlines the specific study design aimed at addressing the 
literature gap described above.  The study methodology and statistical analysis plans will 
also be described in detail. 
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Chapter 3: Research Method 
Introduction 
In this chapter I describe, in detail, the methodology for this research project.  
This includes information regarding the design and the rationale behind the chosen 
design. Additionally, the archived dataset (SEER-Medicare) that was used is described 
and justified.  All variables (independent, dependent, and covariate/control) are identified 
and operationalized.  Detailed information about the coding and location of these 
variables is also provided.  I also describe the study population and the sample selection 
protocol that was used (including inclusion and exclusion criteria and power analysis).  
Additionally, within this chapter, the analysis procedure used is outlined.  This includes 
justification of the software analysis chosen (SPSS) and details on the descriptive and 
inferential statistical methods.  Finally, information regarding internal, external, 
construct, and statistical validity, in addition to ethical practices, is presented.   
Research Design and Rationale 
 In this section, I outline, in detail, the study research design and rationale.  This 
includes the selected independent, dependent, and control variables and the time/resource 
constraints.   
Research Design 
Study variables.  The independent, dependent, and control variables used in this 
research project are described in detail below.  For each variable, the location of the data 
and data codes are listed. 
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Independent variables.  There were three research questions and three total 
independent variables included in this research project.  All of the independent variables 
are available from the PEDSF (NCI, 2015c).  The PEDSF is linked by a 10 digit patient 
ID (column #1 in the PEDSF document; patient_id) to the four Medicare claims files 
used in this research project. 
The first research question addressed racial/ethnic disparities in first-line 
monoclonal antibody treatment.  Therefore, race was the first independent variable.  For 
this research project, race was identified using the SEER race recode as listed in column 
#101 of the PEDSF (rac_recb); 1 = Caucasian, 2 = Black, 3 = American Indian/Alaska 
Native, 4 = Chinese, 5 = Japanese, 6 = Filipino, 7 = Hawaiian, 8 = Other Asian or Pac. 
Islander, 9 = Unknown, 11 = Caucasian, Spanish origin or surname, 12 = Other 
unspecified (NCI, 2015c).  Given the low representation of some of the races in the 
cohort, American Indian/Alaska Native persons were excluded from the race analysis, 
and Chinese, Japanese, Filipino, Hawaiian and Other Asian or Pacific Islander groups 
were pooled into a single group entitled Asian or Pacific Islander. 
The second research question addressed SES disparities in first-line monoclonal 
antibody treatment.  As in an article by Schlichting et al. (2012), the census tract poverty 
level was used to estimate of SES.  This variable is located in column #146 
(census_pov_ind) in the PEDSF document and lists census track poverty as 1 = 0% to < 
5% poverty, 2 = 5% to < 10% poverty, 3 = 10% to < 20% poverty, 4 = 20% to 100% 
poverty, 9 = unknown (NCI, 2015c). 
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The final research question addressed neighborhood (degree of urbanization) 
differences in first-line monoclonal antibody treatment.  The PEDSF document includes 
the 2003 Rural/Urban Continuum Codes from the ERS, which categories counties on an 
urban/rural scale based on population size, degree of urbanization, and adjacency to a 
metro or nonmetro area (NCI, 2015c).  The PEDSF recode of these values was used for 
this research project.  This is column #97 (urbrur) in the PEDSF document and identifies 
county of residence as 1 = Big Metro, 2 = Metro, 3 = Urban, 4 = Less Urban, 5 = Rural, 
and 9 = Unknown (NCI, 2015c).   
Dependent variable.  There were several research questions built into this 
research project.  However, each research question addressed the independent variable’s 
association with the percentage of elderly (65 years+) metastatic colorectal cancer 
patients who receive first-line adjunct monoclonal antibody therapy.  Therefore, the 
dependent variable for these research questions was receipt of first-line adjunct (in 
combination with chemotherapy) monoclonal antibody therapy, “yes” or “no.”    
There are three monoclonal antibodies (bevacizumab, cetuximab, and 
panitumumab) currently approved for first-line treatment of patients with metastatic 
colorectal cancer when given in combination with chemotherapy (Amgen, 2014; Bristol-
Myers Squibb & Eli Lilly and Company, 2013; Genentech, 2013).  These monoclonal 
antibodies can be covered by Medicare Part B (if administered at an outpatient clinic or a 
physician’s office) or Medicare Part D (if administered as a prescription drug from a 
specialty pharmacy).  Therefore, this information was obtained from the Medicare PDE 
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dataset, the Medicare Outpatient Claims dataset, and the Medicare Carrier Claims dataset.  
The DME dataset was not used for this variable as data for these three drugs is not 
present within this dataset.   
In the PDE dataset, the brand name for each monoclonal antibody (Avastin, 
Erbitux, or Vectibix) is listed in column #90 (BN).  In addition the following NDC codes 
for the administered drug will be present in column #35 (PROD_SRVC_ID) of the PDE 
dataset (NCI, 2015b): 
• Bevacizumab (Avastin): 50242006001 or 50242006101 (293 patients from 
2007-2012) 
• Cetuximab (Erbitux): 66733094823 or 66733095823 (59 patients from 2007-
2012) 
• Panitumumab (Vectibix): 55513095401 or 55513095601 (23 patients from 
2007-2012) 
In the Carrier Claims and Outpatient Claims dataset, receipt of one of the 
monoclonal antibodies is listed as a “J” HCPCS code (columns #93 in the Carrier Claims 
data set or columns #241 in the Outpatient Claims data set; NCI, 2015b): 
• Bevacizumab:  J9035 (25,825 patients from 2007-2012) 
• Cetuximab:  J9055 (7,004 patients from 2007-2012) 
• Panitumumab: J9303 (2,026 patients from 2007-2012) 
First-line adjunct monoclonal antibody treatment was defined as at least one claim 
for a monoclonal antibody (bevacizumab, cetuximab, or panitumumab) in one of the 
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three files above within 1 month of first postdiagnosis chemotherapy claim (which must 
have occurred within 6 months of diagnosis) as in Meyerhardt et al. (2012).  Given the 
need to compare claim dates to determine if monoclonal antibody was received within 1 
month of chemotherapy, the drug dispense date for each monoclonal antibody claim was 
also used.  This is listed an MMDDYYYY in PDE dataset column #27 (srvc_mon, 
srvc_day, srvc_yr) and in column #32 (from_dtm, from_dtd, from_dty) of the Outpatient 
Claims and Carrier Claims datasets.  For the purpose of this research project, the 
dependent variable (first-line monoclonal antibody treatment) was recorded dichotomized 
as “yes” or “no.”   
Control variables.  Multiple covariates were assessed to control for confounding.  
The first covariate assessed was gender.  This is column #41 (m_sex) in the PEDSF file: 
1 = male, 2 = female.  The second covariate was age at diagnosis.  This is column #1881 
in the PEDSF file.  The third covariate was reason for original Medicare entitlement.  
This is column #43 in the PEDSF file: 0 = Age, 1 = Disability (individuals with 2 = End 
Stage Renal Disease or 3 = Disability/End Stage Renal Disease were excluded from the 
study).  The final covariate was which registry reported the data.  This is indicated by the 
first two digits in the patient ID (PEDSF column #1).   
Research design.  The specific aim of this study was to determine if there are 
racial, SES, or neighborhood (degree of urbanization) disparities in first-line adjunct 
monoclonal antibody treatment of elderly, Medicare-enrolled, metastatic colorectal 
cancer patients.  As monoclonal antibody therapy has been shown clinically to improve 
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survival, it would be unethical to perform an intervention study to address these 
questions.  Therefore, the method used was strictly observational, using a retrospective 
cohort quantitative research design.  Specifically, individuals meeting the selection 
criteria were selected from the SEER-Medicare colorectal cancer population as outlined 
in the sample selection section of this document.  Disparities in monoclonal antibody 
treatment were then assessed across different populations (different SES levels, races, 
and neighborhood characteristics) using logistic regression.   
Rationale.  All the research questions can be addressed using numerical values 
and/or discrete categories for all variables.   Therefore, quantitative research was the most 
appropriate research design.  Given the utility of the achieved SEER-Medicare database 
to answer the research questions, I used only secondary data.   
Time and resource constraints. I used data from the NCI’s SEER-Medicare 
database.  The SEER-Medicare database is a large population-based database that 
contains matched medical claim records and demographic information for Medicare 
beneficiaries who have been diagnosed with cancer (NCI, 2015a).  Data from five files 
within this database for years 2007 to 2012 (PEDSF 2007-2011 only) was accessed for a 
reasonable fee ($1600).  Data access required completion of a dissertation proposal, 
International Review Board (IRB) approval, approval of an application by SEER-
Medicare oversight committee, and dissertation chair approval/completion of a data use 
agreement (NCI, 2015e; E. Yanisko, personal communication, February 5, 2013).   
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Use of a retrospective research design and archival data reduced the time 
constraints associated with data collection.  However, time constraints still existed.  Upon 
completion of a final data application (which required several iterations), approval by the 
SEER-Medicare oversight committee took 4 weeks, and data acquisition took an 
additional 3 weeks (E. Yanisko, personal communication, February 5, 2013).  In all, it 
took 4 months from submission of the first draft application to receipt of the final data 
set.  All the data obtained from SEER-Medicare were received uniformly coded and there 
were training courses and support staff available to help with the extraction/compilation 
process (E. Yanisko, personal communication, February 5, 2013). 
Methodology 
In this section, I describe the population used for this study and the procedures 
used to sample that population.  Since archival data were used and no new data were 
collected on study subjects, this section does not contain procedures for new data 
collection.   
Population 
The research questions addressed disparities in monoclonal antibody therapy of 
elderly metastatic colorectal cancer patients.  The specific population used for this study 
was elderly (65+) individuals diagnosed with metastatic colorectal cancer between 
January 2007 and December 2011, treated with first-line chemotherapy within 6 months 
of diagnosis.  Individuals with a previous cancer history and individuals with end stage 
renal disease were excluded.  Since monoclonal antibodies can be prescribed under 
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Medicare Part B or D, to limit the impact of insurance coverage differences, the 
population was limited to individuals with evidence of enrollment in Part B and D 
Medicare.  This population is about 65% of the Medicare population (MedPac, 2013).  
Additionally, given that claims billed to Medicare HMOs (Medicare Part C; Medicare 
Advantage) would not be included in the SEER-Medicare database, the study cohort was 
limited to patient without HMO coverage.  Given that metastatic colorectal cancer 
patients have high mortality rates and the time from cohort selection (which required a 
chemotherapy claim) to assessment of the dependent variable was only 1 month, to limit 
unnecessary patient exclusion, continuous Medicare Part B and D enrollment was not 
required.   
Tumor resection (if possible) followed by chemotherapy (5-Fluorouracil, 
Oxaliplatin, or Irinotecan) is the standard of care for metastatic colorectal cancer (NCI, 
2015f).  Monoclonal antibody therapy is indicated for first-line metastatic colorectal 
cancer as an adjunct to chemotherapy.  Given this, only individuals who received first-
line chemotherapy, as indicated by a chemotherapy claim within 6 months of cancer 
diagnosis, as in Meyerhardt et al. (2012), were included in the study population.  Finally, 
as previously stated, given that adjunct monoclonal antibody therapy is only approved for 
metastatic colorectal cancer, the population of interest included only patients with 
metastatic colorectal cancer.   
In the United States, colorectal cancer accounts for 8.6% of all new cancer cases 
and 8.8% of all cancer deaths (NCI, n.d.a).  In 2010, 131,607 people in the United States 
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were diagnosed with colorectal cancer (CDC, 2013).  Colorectal cancer risk and mortality 
rate increases with age, with the elderly being most affected by the disease (CDC, 2013).  
In the United States, elderly individuals (65 years+) account for 60% of all new 
colorectal cancer cases and 70.9% of all colorectal cancer deaths (NCI, n.d.a).  In 2010, 
approximately 79 thousand elderly (65+) individuals were diagnosed with colorectal 
cancer (CDC, 2013).  At diagnosis, the tumor in approximately 20% of patients has 
already metastasized (Roswell Park Cancer Institute, n.d.a).  Therefore, the population of 
elderly persons diagnosed per year with metastatic colorectal cancer is approximately 
15.8 thousand.   
In terms of prevalence, there are approximately 1.16 million people living with 
colorectal cancer in the United States (NCI, n.d.a).  Of all individuals diagnosed and 
being treated for colorectal cancer, it is estimated that 55% of these individuals have 
metastasized tumors (Roswell Park Cancer Institute, n.d.).  Therefore, the population of 
individuals living with metastasized colorectal cancer is approximately 638,000, with the 
majority of these individuals over the age of 65.   
Sampling and Sampling Procedures 
The sampling strategy was carefully designed to eliminate as many confounding 
variables as possible.  The detailed sampling procedures are described in the following 
section. 
Sampling procedures.  SEER-Medicare datasets for colon and rectal cancer 
patients from 2007 to 2011 (PEDSF) and 2007 to 2012 (Outpatient Claims file, DME file, 
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Carrier Claims File and PDE file) were received from the NCI.  These datasets included 
clinical and demographic data from all SEER district reported colorectal cancer cases 
(NCI, 2015c).  In order to be included in the study, an individual must have met the 
following inclusion and exclusion criteria: 
• First colorectal cancer diagnosis at or after 65 years of age (PEDSF column 
#1881; Age at Diagnosis).   
• First diagnosis of colorectal cancer occurred between January 2007 and 
December 2011 (PEDSF column #1888; Year of Diagnosis).   
• Cancer sequence number (number of primary tumors the individual had been 
diagnosed with up to and including their colorectal cancer diagnosis) of 00 or 
01 indicating that the colorectal cancer tumor was their first primary tumor 
(PEDSF column #1884). 
• Covered by Medicare Part B for at least 1 month during the year of diagnosis 
(PEDSF columns #548).  Value >/= 1 for diagnosis year.  Presence of a 
chemotherapy claim in one of the Part B files (DME, Carrier Claims or 
Outpatient Claims) was also required for inclusion and demonstrates 
coverage. 
• Covered by Medicare Part D for at least 1 month during the year of diagnosis 
(PEDSF column #221).  Value >/= 1 for diagnosis year.   
o Monoclonal antibody therapy can be covered under Medicare Part B or 
Medicare Part D.  Therefore, this selection criterion is included to help 
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ensure complete medical records for all study participants and limit the 
impact of insurance coverage on the disparity measures.  
• Not Enrolled in a Medicare managed care plan during the year of diagnosis 
(Medicare Part C) (PEDSF column #550; HMO Months).  Any number other 
than 00 for both the year of diagnosis and the year of treatment will result in 
exclusion. 
o Managed care plans enrollees have their claims processed by the 
managed care entities, not Medicare.  Thus, these claims will not be in 
the SEER-Medicare data.   
• Colorectal cancer had undergone metastasis at diagnosis (PEDSF column 
#1953; CS Mets at Dx).  Specifically, individuals with codes 00 (none/no 
distant metastasis) or 99 (unknown/distant metastasis not stated) will be 
excluded. 
o Monoclonal antibodies are only approved for use in metastatic 
colorectal cancer patients. 
• Patients that qualified for Medicare due to End Stage Renal Disease were 
excluded (PEDSF column #43; rsncd1).  Individuals with codes of 2 or 3 were 
excluded. 
• Given chemotherapy up to 31 days before or 6 months after of diagnosis as 
determined by comparing diagnosis date (PEDSF column #1886 = Month of 
Diagnosis; PEDSF column #1888; Year of Diagnosis) to the first 
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chemotherapy claim date.  Given that no day of the month is listed for 
diagnosis, the diagnosis day was set to the last day of the diagnosis month to 
ensure all within 6 months of diagnosis chemotherapy claims were captured.  
Chemotherapy receipt was defined as receiving any of the following as single 
agents or in combination.  The “J” HCPCS codes are listed in columns #93 in 
the Carrier Claims data set, column #93 in the DME dataset, or columns #241 
in the Outpatient Claims data set (NCI, 2015b).  The NDC codes are located 
in column #409 in the DME dataset (NCI, 2015b).  Date of receipt was 
defined using the Claim From Date located in column #32 of all three datasets 
(NCI, 2015b).  Only the earliest chemotherapy claim and claim date for each 
individual was recorded. 
o 5-fluorouracil (5-FU): 
 HCPCS = J9190 
 NDC Codes = 00703301513, 00703301812, 00703301912, 
10139006301, 10139006310, 10139006311, 10139006312, 
10139006320, 10139006350, 63323011710, 63323011720, 
63323011751, 63323011761, 66758004401, 66758004403 
o capecitabine: 
 HCPCS = J8520, J8521 
 NDC Codes = 00004110020, 54868414300, 54868414301, 
54868414302, 00004110150, 00004110175, 54868526000, 
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54868526001, 54868526002, 54868526003, 54868526004, 
54868526005, 54868526006, 54868526007, 54868526008, 
54868526009 
o leucovorin: 
 HCPCS = J0640 
 NDC Codes = 00703279301, 00703279701, 00703514001, 
00703514501, 00703514591, 00904231560, 25021081310, 
25021081430, 25021081530, 25021081567, 25021081630, 
25021081667, 55390000901, 55390005110, 55390005210, 
55390005301, 55390005401, 55390081810, 55390082401, 
55390082501, 55390082601, 62701090030, 62701090099, 
62701090125, 63323071050, 63323071100 
o floxuridine:  
 HCPCS = J9200 
 NDC Codes = 55390013501, 63323014507 
o oxaliplatin:  
 HCPCS = J9263 
 NDC Codes = 00024059010, 00024059120, 00024059240, 
00069006701, 00069007001, 00069007401, 00069101001, 
00703398501, 00703398601, 25021021120, 25021021250, 
41616017640, 41616017840, 47335017640, 47335017840, 
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61703036318, 61703036322, 63323017530, 63323017650, 
63323065010, 63323065017, 63323065020, 63323065027 
o irinotecan  
 HCPCS = J9206 
 NDC Codes = 00009111101, 00009111102, 00009752901, 
00009752902, 00009752903, 00009752904, 00009752905, 
00143970101, 00143970201, 00703443211, 00703443411, 
10019093401, 10019093402, 10019093417, 10019093479, 
10518010310, 18111000202, 18111000203, 23155017931, 
23155017932, 25021020002, 25021020005, 25021021402, 
25021021405, 55390029501, 55390029601, 59762752902, 
61703034909, 61703034916, 61703034936, 63323019302, 
63323019305, 66758004801, 66758004802 
Power Analysis 
This section describes the G*Power analysis used to estimate sample size required 
for each of the three research questions.  This section also provides justification for the 
effect sizes, alpha level, and power level chosen.   
Alpha level.  I used an alpha level 0.05 for this study.  In social sciences, an alpha 
level of 0.05 is often employed (Web Center for Social Research Methods, 2006).  This is 
because an alpha level of 0.05 represents a compromise between Type I and Type II 
error.  This alpha level allows for a 5% chance that the null hypothesis will be rejected 
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when it is true (i.e. there is no difference between groups; Type I error) (Web Center for 
Social Research Methods, 2006).  Additionally, being conservative and not setting the 
alpha level too low reduces the risk of Type II error or failing to reject the null hypothesis 
when it is false (Web Center for Social Research Methods, 2006).  Finally, given that the 
research questions ask if there is a difference between groups and do not specify 
directionality, a two tailed analysis was used. 
Effect size and power level.  In G*Power version 3.1.9.2 (Faul, Erdfelder, 
Buchner, & Lang, 2009) the effect size is represented as an odds ratio, the average 
probability of “yes” to the dependent variable (in this case monoclonal antibody 
treatment), and a specified power level.  Although it’s never been researched, it is 
reasonable to hypothesize that the racial, SES, and neighborhood (degree of urbanization) 
differences in monoclonal antibody treatment will mimic historical differences in other 
colorectal cancer treatments.  This hypothesis is in line with the Fundamental Cause 
Theory which states that even with changing resources, it is the beneficial social 
connections that serve to protect health regardless of the resource mechanism (Phelan et 
al., 2010).  In other words, groups that showed chemotherapy, radiation, or surgery 
treatment disparities might show similar monoclonal antibody treatment disparities.   
For SES odds ratio estimation, Lejeune et al. (2010) cites the difference in 
adjusted treatment rates (surgery, radiation, or chemotherapy) between high and low SES 
districts as 1.15.  However, in Hines et al. (2014), the difference in chemotherapy rates 
comparing high to low SES districts was greater (OR = 0.83).  Given that the degree of 
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disparity differs between the two studies, to be conservative, 1.15 was used as the odds 
ratio estimate for SES differences.  In terms of racial disparities, Obeidat et al. (2010) 
determined that Black Americans were less likely than White Americans to receive newer 
chemotherapy options (OR = 0.641).  However, White (2008) found more modest 
differences between Black Americans and White Americans in terms of chemotherapy 
receipt (OR = 0.85).  Therefore, for this power analysis, a conservative OR of 0.85 was 
used.  For urban/rural disparity estimation, the Hines et al. (2014) article found that 
chemotherapy rates differed comparing urban to rural districts (OR = 0.84).  Therefore, 
an odds ratio of 0.84 was used for this final power analysis. 
In addition to the odds ratios, G*Power also requires the average probability of 
receiving treatment.  In an observational study conducted using 2006 treatment data, 
Renouf et al. (2011) found that 30.6% of metastatic colorectal cancer patients received 
adjunct bevacizumab.  Therefore, given that this study is assessing 2007 to 2012 
treatment data, a conservative probability of 0.306 was used.   
Finally, adjunct monoclonal antibody treatment of colorectal patients is 
hypothesized to vary by race, SES and neighborhood (degree of urbanization).  However, 
it is unlikely that any of these variables fully explain differences in treatment.  When the 
magnitude of the expected outcome is unknown, Cohen (1988) suggests selecting a 
medium power level of 0.5.  This medium power level (0.5) means that 6% of the 
variance in treatment is explained by the independent variable (Cohen, 1988).  This 
power level was used for the research questions. 
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Independent variable association with control variables.  For all three research 
questions, there are four control variables planned into the logistic model.  An R2 for the 
relationship between the primary independent variable and the control variables must be 
defined for the power analysis.  A literature search did not return data on the correlation 
between the independent variables (race, SES, neighborhood characteristics) and the 
control variables (gender, age at diagnosis, reason for original Medicare entitlement, and 
reporting registry) in this elderly metastatic colorectal cancer population.  Therefore, for 
the purpose of this analysis, a value representing (by convention) a medium correlation 
(R = 0.3) was selected.  Thus, the R2 value for the relationship between the independent 
variable in each research question and the control variables was set at (0.3)2 = 0.09. 
Power analysis.  This research study has three different research questions and 
three different independent variables, all tested as a predictors of a binary outcome 
variable (monoclonal antibody treatment; yes or no) using logistic regression.  Each 
independent variable has a different expected odds ratio.  Therefore, three different power 
analyses were performed. 
Utilizing the information above regarding available alpha level, effect size, power 
level and association with control variables, the software program G*Power was used to 
estimate required sample size for this logistic regression analysis (Faul, et al., 2009).  The 
inputs and outputs of this analysis are represented in Appendix C. 
Estimated available sample size.  According to the NCI (2015d), the number of 
newly diagnosed colorectal cancer patients in the SEER dataset was 12,062, 11,489, and 
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10,564 in 2007 to 2009 respectively.  This is an average of 11,372 new cases per year.  In 
order to be included in this count the patients had to be enrolled in both Medicare Part A 
and Medicare Part B (NCI, 2015d).  Since this research study is limited to patients 
enrolled in Medicare Part B and D (approximately 65% of the Medicare population), the 
number of patients meeting the study selection criteria is approximately 7,392 patients 
per year.  This study cohort included individuals diagnosed over five years (2007-2011).  
Therefore, within the SEER dataset (2007-2011), an estimated 36,960 will be colorectal 
cancer patients enrolled in Medicare Part B and D.  Approximately 20% of these patients 
were expected to be excluded due to enrollment in Medicare managed care/HMO, 
leaving approximately 29,568 patients. This sample is further reduced as this study only 
addresses treatment in patients diagnosed with metastatic colorectal cancer.  If an 
estimated 20% of these patients were diagnosed with metastatic colorectal cancer, the 
expected available sample size for this study over the years 2007 to 2011 is 5,914.  The 
sample size will be limited once more by the number of patients receiving first-line 
chemotherapy.  If an estimated 50% receive first-line chemotherapy, this would result in 
a sample size of 2,957.   
The actual final sample size was 2,241, slightly lower than estimated.  However, 
the sample size is still significantly above the size required for all three research 
questions (1029, 764, and 666 respectively) with a power of 0.5. 
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Procedures for Recruitment, Participation, and Data Collection 
As stated above, since archival data were used and no new data were collected on 
study subjects, this section does not contain procedures new data collection.  However, 
this section provides detailed information on the SEER-Medicare database and how the 
data were accessed. 
Data access.  This study used data from the NCI’s SEER-Medicare database.  
The SEER-Medicare database is a large population-based database that contains matched 
medical claim records and demographic information for Medicare beneficiaries who have 
been diagnosed with cancer (NCI, 2015a).  The process for requesting the data is outlined 
in detail on the SEER Medicare website (NCI, 2015g).  Specifically, for this project, an 
application form (Appendix A), a SEER-Medicare data use agreement (Appendix B), and 
proof of Institutional Review Board (IRB) approval were submitted (NCI, 2015g).  Upon 
application approval, the data needed for these research questions for years 2007 to 2012 
was accessed for a reasonable fee ($1600).  The five data files obtained were the Part D 
Event (PDE) dataset, the Durable Medical Equipment (DME) dataset, the Carrier Claims 
dataset, the Patient Entitlement and Diagnosis Summary File (PEDSF) and the Outpatient 
Claims dataset.  All colorectal cancer patient data within these five files from 2007 to 
2012 (PEDSF 2007-2011 only) was obtained.   
SEER-Medicare sample information.  The SEER-Medicare database is a unique 
research-oriented database resulting from the linkage of the Surveillance, Epidemiology, 
and End Results (SEER) cancer registries database and the Medicare enrollment and 
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claims data files (NCI, 2015a; Warren et al., 2002).  The cancer diagnosis and 
demographic information within the SEER-Medicare database comes from the SEER 
program.  The SEER program includes NCI contracted registries in Connecticut, Iowa, 
New Mexico, Utah, Hawaii, Georgia, Louisiana, New Jersey, Puerto Rico, Kentucky and 
California (NCI, n.d.a).  These registries represent approximately 28% of the U.S. cancer 
population (NCI, 2013).  When the SEER database is linked to the Medicare claims 
databases, such as in the SEER-Medicare dataset, researchers have access to data that 
includes incidence, cancer site, stage, histology, demographics, medical procedures, 
initial treatments, and vital status (NCI, n.d.a).  Starting in 2007, SEER began linking the 
Medicare Part D (PDE) file which allows researchers to perform prescription drug 
research (NCI, 2013).  In total, there are 1.6 million persons with cancer included in the 
dataset and over 900 publications using the dataset (NCI, 2013).   
Instrumentation.  Given that archived data were used, no instrumentation was 
used for the current study.  All the data within the SEER-Medicare linked database comes 
from either cancer registry documents or Medicare claim forms.  In the case of the SEER 
program (cancer registry documents), data collection is both passive and active.  After 
hospitals, clinicians and pathologists collect the data, SEER registry personnel actively 
perform follow-ups to collect data or passively collect data through state databases (NCI, 
2011).  Once data is compiled by the registries, they incorporate mortality data from the 
National Center of Health Statistics, Medicare claims records, and information from the 
U.S. Census Bureau (NCI, 2011).  Subsequently quality checks are implemented to 
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ensure all the data has been linked appropriately and the data is then de-identified (NCI, 
2011).   
Given that hospitals, clinicians, and pathologists are responsible for accurate 
reporting and coding of SEER data, there is the potential for missing or inaccurate data.  
There are multiple published studies that have assessed the reliability and the validity of 
different subsets of the SEER-Medicare data.  Du et al. (2008) assessed the validity and 
reliability of the SEER report on breast cancer chemotherapy.  In this assessment, the 
authors reviewed medical charts from 1228 women diagnosed with breast cancer and 
compared these results to the SEER-Medicare reports (Du et al., 2008).  For patients who 
did not receive chemotherapy, the SEER-Medicare data agreed with the chart review over 
99% of the time (Du et al., 2008).  For the women listed as receiving chemotherapy in the 
SEER-Medicare dataset, the authors were able to find strong evidence for chemotherapy 
in the chart review for 97% of the cases, indicating strong validity (Du et al., 2008).  In a 
separate analysis, Du et al. (2008) list the overall reliability (kappa) of the SEER-
Medicare breast cancer chemotherapy data as 0.69 (95% confidence interval = 0.63-
0.76).   
Mahnken et al. (2008) assessed the completeness of the SEER-Medicare database 
for Oral and Pharyngeal Cancer.  When comparing to the SEER limited-use dataset, the 
authors found that 6.4% of the incident cases were missing from the larger SEER-
Medicare linked database (Mahnken et al., 2008).  The completeness of the data did vary 
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nonsignificantly by race and ethnicity and could be partly explained by differences in 
Medicare coverage (Mahnken et al., 2008).   
Operationalization of constructs.  All of the variables used in this research 
project are available within the PEDSF (Patient Entitlement and Diagnosis Summary 
File), the Outpatient Claims dataset, the DME (Durable Medical Equipment) dataset, the 
Carrier Claims dataset or the Part D Event (PDE) dataset (NCI, 2015c).  The independent 
and dependent variables are operationalized below.  The control/covariate and selection 
variables have been described in detail in the previous sections. 
• Race:  Identified as listed in column #101 of the PEDSF (rac_recb); 
1=Caucasian, 2=Black, 3=American Indian/Alaska Native, 4=Chinese, 
5=Japanese, 6=Filipino, 7=Hawaiian, 8=Other Asian or Pac. Islander, 
9=Unknown, 11=Caucasian, Spanish origin or surname, 12=Other unspecified 
(NCI, 2015c).   
• Socioeconomic Status: The PEDSF Census Tract Poverty Indicator will be 
used as an estimation of SES.  This is column #146 (census_pov_ind) in the 
PEDSF document and uses data from the 2010 Census (NCI, 2015c).   
• Neighborhood characteristics (degree of urbanization):  This will be defined 
using the 2003 Rural/Urban Continuum Codes from the Economic Research 
Service (ERS), which categories counties on an urban/rural scale based on 
population size, degree of urbanization and adjacency to a metro or nonmetro 
area (NCI, 2015c).  The PEDSF re-code of these values will be used for this 
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research project.  This is column #91 (urbrur) and identifies county of 
residence as 1=Big Metro, 2=Metro, 3=Urban, 4=Less Urban, 5=Rural, 
9=Unknown (NCI, 2015c).   
• Monoclonal antibody therapy (yes/no):  Receipt of bevacizumab, cetuximab 
or panitumumab (as identified by a claim in the PDE, Carrier Claims, or 
Outpatient dataset) within 1 month of first post-diagnosis chemotherapy 
claim.  Location and codes for each file are described below. 
o PDE dataset:  The brand names for the three monoclonal antibodies 
(Avastin, Erbitux, Vectibix) will be listed in column #90 (BN).  In 
addition, the following NDC codes for the administered drug will be 
present in column #35 (PROD_SRVC_ID): bevacizumab 
(50242006001 or 50242006101), cetuximab (66733094823 or 
66733095823), panitumumab (55513095401 or 55513095601).  
o Outpatient Claims dataset:  Receipt of one of the monoclonal 
antibodies will be listed as a “J” HCPCS code in column #241 (hcpcs): 
bevacizumab (J9035), cetuximab (J9055), panitumumab (J9303).   
o Carrier Claims dataset:  Receipt of one of the monoclonal antibodies 
will be listed as an HCPCS code (above) in column #93.   
105 
 
Research Questions and Hypothesizes 
RQ1:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there racial 
disparities in first line adjunct monoclonal antibody treatment? 
H01:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody treatment based on race. 
Ha1:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody treatment based on race. 
RQ2:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there 
socioeconomic disparities in first line adjunct monoclonal antibody treatment? 
H02:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on area socioeconomic status (as defined by 
the PEDSF census tract poverty indicator). 
Ha2:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on area socioeconomic status (as defined by 
the PEDSF census tract poverty indictor). 
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RQ3:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there 
neighborhood characteristic (degree of urbanization) disparities in first line adjunct 
monoclonal antibody treatment? 
H03:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on neighborhood characteristics. 
Ha3:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on neighborhood characteristics. 
Data Analysis Plan 
In this section, I describe, in detail, the analysis plan used for this research project.  
This includes the software packages that were used for data compilation, management 
and analysis, how sample selection occurred, and the statistical methods that were 
employed. 
Hardware 
The SEER-Medicare datasets and all raw analysis files were stored on a server 
leased from Hivelocity and accessed remotely over a secure firewall using VPN.  The 
Hivelocity server had a 2 x 1000GB Hard Drive with 2 x 2.26GHz Quad-Core L5520 





 Python 2.7.5, MySQL 5.6.24 Community Server, MySQL Workbench 6.3.3.0 and 
BASH (BourneAgain SHell) were employed to create a database to allow access to the 
data, compile needed variables into tables and select the study cohort based on the listed 
inclusion and exclusion variables.  Data for the selected cohort was then imported into 
IBM SPSS Statistics 21 and SPSS was used for subsequent descriptive and inferential 
statistical analyses (IBM, n.d.).  For this research project, it was necessary to compile, 
sort and select data from ~100,000 total cases.  Therefore, a high capacity, effective data 
management program such as MySQL and Python with the ability to query, select and 
split datasets was critical.  Additionally, SPSS was capable of performing logistic 
regression analyses (IBM, n.d.), as was required by this project.   
Data Preparation 
Prior to analysis, the data needed to be organized and the cohort needed to be 
selected.  A pictorial representation of the methods followed during the cohort selection 
process can be found in Figure 1 and the step by step details can be found in Appendix D.  





Figure 1.  Pictorial representation of the software used and files generated during the 





After the data were compiled and the preliminary cohort was selected using the 
steps outlined above, the all variables needed for the selected cohort will be imported into 
SPSS.  The variables transferred to SPSS, including several computed variables are 
documented in Appendix E. 
At this point, the cohort in SPSS had already been selected on the following 
variables:  
1. Cases with diagnosis dates from January 2007 to December 2011. 
2. Cases with an age at diagnosis of 65 or over. 
3. Cases with a sequence number of 00 or 01 (first primary tumor). 
4. Cases with cancer metastasis at diagnosis. 
5. Evidence (at least 1 month in the diagnosis year) of Medicare Part B and 
Medicare Part D enrollment. 
6. No HMO coverage in the year of diagnosis. 
7. Chemotherapy received within 6 months of diagnosis. 
Once the data were in SPSS, individuals with Medicare entitlement due to End 
Stage Renal disease (Reason for original Medicare entitlement codes 2 or 3) were 
excluded.  Additionally, any patient with a chemotherapy claim more than 31 days before 
diagnosis were excluded.  Using the computed column “days” (6a in Appendix D – 
indicates days from first post diagnosis chemotherapy claim to first monoclonal antibody 
claim), individuals with a monoclonal antibody within 1 month (31 days) of their 
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chemotherapy claim date were coded as “yes” in the “Monoclonal antibody” column, all 
others were coded as “no”.   
As a final step in data preparation, codes for each variable were defined (e.g., 1 = 
male, 2 = female) in the variable view section of SPSS.  In addition variable type 
(categorical or continuous) was defined in the variable view.  Once all variables were 
defined, data analysis (descriptive and inferential) began. 
Statistical Tests 
This section will describe, in detail, the statistical tests that employed to answer 
the research questions.  Statistical assumptions and interpretation of outputs will also be 
discussed. 
Descriptive statistics.  Descriptive statistics in SPSS were used to understand 
sample distribution.  Specifically tables and/or figures were generated to document 
distribution of the sample in terms of race, gender, age at diagnosis, SES, neighborhood 
characteristics (degree of urbanization), reporting registry, and reason for original 
Medicare entitlement over the study period (2007-2011) and by diagnosis year.  
Additionally, also using SPSS, frequency tables were generated to relate the 
independent/control variables to the dependent variable as outlined below: 
• Frequency of monoclonal antibody therapy by gender. 
• Frequency of monoclonal antibody therapy stratified by reporting registry. 
• Frequency of monoclonal antibody stratified by reason for original Medicare 
entitlement (age or disability). 
111 
 
• Frequency of monoclonal antibody therapy stratified by age at diagnosis. 
• Frequency of monoclonal antibody therapy by year of diagnosis. 
• Frequency of monoclonal antibody therapy by race. 
• Frequency of monoclonal antibody therapy across SES ranges (as defined 
using the Census Tract Poverty Indicator) 
• Frequency of monoclonal antibody therapy stratified on neighborhood 
characteristics (degree of urbanization as defined using the 2003 Rural/Urban 
Continuum code) 
Inferential statistics.  Logistic regression is used to model a dichotomous 
outcome variable (in this case receipt of monoclonal antibody, “yes” or “no”) based on 
other predictor variable(s) (Burns & Burns, 2008).  The output of logistic regression 
predicts which dependent variable group a sample should reside in based on the 
independent variable(s) (Burns & Burns, 2008).  For example, in this study, using a 
simple ANOVA, it is possible that race would predict (to a certain extent) the chance of 
monoclonal antibody receipt.  However, in this example, in order to determine if the 
independent variable (race) is independently associated with the dependent variable 
(monoclonal antibody receipt), the model will need to control for differences in these 
covariates.  In other words, is the association between the independent and dependent 
variable still significant after adding the covariates to the model?  Logistic regression 
methods will allow this to be accomplished.   
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There are two main assumptions that must be met in order use logistic regression.  
First, the dependent variable must be dichotomous (Burns & Burns, 2008).  The 
dependent variable (monoclonal antibody therapy) is dichotomous, meeting this 
assumption.  Second, the categories must be mutually exclusive and exhaustive, because 
a sample must only be in one group and every sample must be assigned to a group (Burns 
& Burns, 2008).  This assumption is also met with this data set.  For all independent, 
dependent and control variables every sample will fall within one (and only one) of the 
categories.  Burns and Burns (2008) also note that larger samples are often needed for 
logistic regression and recommend at least 50 cases per predictor.  For the analyses 
described in Table 12, the maximum number of predictor variables will be seven.  As 
noted in the power section above, the sample size (2,241) exceeds this minimum number.   
Logistic regression does not assume linear relationships between dependent and 
independent variables, nor does it assume equal variance within groups or normal 
distribution (Burns & Burns, 2008).  Therefore, these conditions do not need to be tested 
prior to analysis. 
There are multiple logistic regression analyses performed on the study data given 
the different research questions.  All logistic regression analyses performed described in 
Table 11.  Covariate analyses to test for independent associations (analyses 4, 5 and 6 in 
Table 11) were planned to be performed only if a significant association was found 
between the independent variable and the dependent variable for that research question.  
For example, if race is found to not associate with monoclonal antibody treatment in 
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analysis 1, analyses 4 will not be performed as there will be no need to test for variables 
confounding the relationship (as a relationship does not exist).  For analysis 7, a final 
logistic regression models was generated with any variable (independent or covariate) 
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Covariates and Confounding Variables 
Any control variable found to significantly associate with monoclonal antibody 
treatment during covariate analysis in Chapter 4 was added to the logistic regression 
analyses to control for confounding.  There are four control variables/covariates being 
controlled for in this research project.  The first control variable was gender.  Oliver et al. 
(2013) cites weak correlations between receipt of chemotherapy or surgery and gender.  
Specifically, women were slightly more likely than men to receive surgery (95.5% vs. 
92.2%) and men were slightly more likely than women to receive chemotherapy (38.6% 
vs. 45.2%) (Oliver et al., 2013).  These treatment differences might extend to monoclonal 
antibody therapy and it is therefore important to control for gender in the statistical 
model.   
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The second control variable was age at diagnosis.  This study was limited to 
individuals over 65 years of age.  However, even in the over 65 age group, increasing age 
has been correlated with treatment disparities.  Fu et al. (2013) and Kozloff et al. (2010) 
observed reduced adjunct bevacizumab treatment with increasing patient age.  Therefore, 
it was important to control for age at diagnosis in the model.   
The third control variable was reason for original Medicare entitlement (age or 
disability).  Individuals with End Stage Renal Disease (ESRD) or disability + End Stage 
Renal Disease were excluded.  However, underlying disability has the potential to impact 
treatment prescribed/received and needed to be included in the model. 
The final control variable was which registry reported the data.  Naishadham et al. 
(2011) found state to state differences in progress toward reducing colorectal cancer 
mortality from 1990-2007.  Specifically, the southern states showed little to no 
improvement, whereas the north-eastern states showed improvement often in excess of a 
33% reduction in mortality (Naishadham et al., 2011).  Therefore, it is possible that 
geographic region (as indicated by reporting district) could impact treatment received. 
Results Interpretation 
Descriptive statistics.  The planned descriptive statistical analyses were 
presented in the statistical tests section of this chapter and are reported in frequency 
tables in Chapter 4.  These frequency tables stratify the cohort by each 




Inferential statistics.  The outputs of the logistic regression analyses described in 
the statistical tests section of this chapter are log odds (b coefficients – slope values), 
odds ratio (Exp(B)) and p-values.  These values are located in the “Variables in the 
Equation” table in the logistic regression SPSS output (Burns & Burns, 2008).  The log 
odds values (“b”) ranges from 0 to infinity and estimates the likelihood of the 
membership in the target group (monoclonal antibody receipt = yes) versus the other 
group (monoclonal antibody receipt = no) (Burns & Burns, 2008).  For example, if “b” 
was 0.04 for the independent variable SES (% below poverty level), then for every one 
unit increase (percentage point) increase in SES, the increase in log odds of receipt of 
monoclonal antibody receipt increases by 0.04.  Negative log odds values mean the 
relationship is negative (reduces likelihood of monoclonal antibody receipt) instead of 
positive.  Additionally, the Exp(b) has been reported.  These are the odds ratios for the 
predictors (independent variables).  The odds ratios indicate the increased (or reduced) 
chance of monoclonal antibody receipt based on the model of independent 
variables/covariates.  95% confidence intervals for the odds ratios have also be generated 
in SPSS.  Odds ratios for each research question (race, SES, neighborhood 
characteristics) were compared with and without covariate inclusion (if necessary) to 
determine if the independent variable is independently associated with the dependent 
variable (monoclonal antibody receipt). 
A p-value (Sig.) for each logistic regression model has also been reported (Burns 
& Burns, 2008).  This value informs whether or not the model was significant for the 
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independent variable and dependent variable in question.  A p-value of less than 0.05 has 
been considered significant.   
Finally, two pseudo R Square values (Cox & Snell and Nagelkerke) have been 
reported for each model.  These variables are measures of model fit (values close to 0.0 
are a poor fit; values close to 1.0 are a good fit). 
Threats to Validity 
Threats to External Validity 
The external validity of this study could be threatened by population validity or 
the ability to extrapolate the data to the larger U.S. elderly population.  The SEER 
database includes data from approximately 28% of the U.S. cancer population.  However, 
this sample comes from specific SEER funded cancer registries.  These registries are 
geographically dispersed, located in 13 different states.  However, it is possible that the 
ability to extrapolate the data obtained will be limited.  It is unclear whether the data 
within the SEER database is a true representation of the greater U.S. cancer population.  
This threat cannot be avoided and will be noted in the limitations section of Chapter 5. 
Given that this research is observation (nonexperimental) and used nonsubjective 
medical record data, many of the other threats to external validity are avoided.  For 
example, ecological validity issues, interaction effect of testing issues, interaction effects 
of selection biases and the experiment treatment, and reactive effects of experimental 
arrangements are avoided due to the study design. 
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Threats to Internal Validity 
Internal validity could be threatened by confounding variables.  To address this 
potential issue, research into potential alternative causes of treatment disparities was 
performed.  Historical treatment associations with gender, age at diagnosis, and 
geographical region (i.e. reporting registry) were found in the literature review.  
Therefore, the logistic regression analysis included these three variables as covariates to 
test for independent associations between the independent and dependent variables.  In 
addition, other health issues such as serious disability could influence treatment.  
Therefore, in addition, the original reason for Medicare entitlement (age or disability) 
was included as a covariate in the logistic regression model.  Individuals who qualified 
for Medicare due to end stage renal disease (ESRD) and individuals with a previous 
cancer history were excluded from the study.   
The internal validity of this study could also be threatened by maturation.  
Maturation occurs when changes in the dependent variable occur over time.  This study 
used data over five years of cancer diagnoses and treatments.  Therefore, it is possible 
that the year of diagnosis could impact prescribed treatment.  In other words, if fewer 
individuals diagnosed in 2007 were prescribed a monoclonal antibody compared to 
diagnosed in 2011, there could be higher levels of disparity in 2007 compared to 2011 (in 
line with the Diffusions of Innovations Theory).  To address this, monoclonal antibody 
treatment rates have been analyzed by diagnosis year in Chapter 4.  If a significant 
difference exists, Chapter 5 will document a potential for maturation issues in the cohort.  
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An additional threat to internal validity is sample selection.  In the case of this 
study, all SEER-Medicare colorectal cancer patients were included if they met the sample 
selection criteria (there was no random selection from the SEER dataset).  This reduces 
selection bias threats.  Additionally, the SEER sample is large (represents 28% of U.S. 
cancer cases) also reducing issues associated with selection.   
Experimental mortality is another potential threat to internal validity.  This is 
reduced through sample selection.  Since treatment information is reported through the 
Medicare claims datasets, only samples with evidence of Medicare Part B and Part D 
enrollment in the year of diagnosis (as indicated by at least 1 month of coverage) were 
included in the sample.  In addition, individuals with any evidence of HMO plan 
enrollment in the year of diagnosis were excluded as these individuals could have claims 
not reported in the Medicare data files.  Finally, presence of a chemotherapy claim was 
also required for cohort selection, demonstrating coverage.  This should reduce the 
incidence of missing treatment data after diagnosis.  Additionally, the timeframe from 
cohort selection to measurement of the dependent variable (monoclonal antibody 
treatment) was only 1 month.  This short timeframe should also reduce experimental 
mortality concerns.   
Threats to Construct or Statistical Conclusion Validity 
All of the variables used in this research study were explicitly operationalized to 
reduce threats to construct validity.  Many of the other threats to construct validity are 
reduced due to the observational nature of this study.  For example, there should be no 
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interaction of different treatments, interaction of testing and treatment, evaluation 
apprehension, or experimenter expectancy issues.   
To increase statistical conclusion validity, great effort has been employed to 
ensure the study was powered appropriately and that the statistical tests have not violated 
any assumptions.  In addition, the statistical analysis plan was explicitly laid out and 
further analyses were not performed.  This will ensure that the type I error rate is not 
unnecessarily inflated.   
Ethical Procedures 
Given that this research utilized anonymized medical records and demographic 
data, human and data ethnic concerns are minimized.  However, the efforts to further 
minimize human and data ethic concerns are described in the following sections. 
Ethical treatment of humans.  The ethical concerns surrounding this research 
study are substantially minimized due to the use of anonymized archival data.  No new 
data collections were performed.  Therefore, there are no ethical concerns surrounding 
recruitment materials, data collection, or intervention activities.  In addition, zip codes 
were not requested, minimizing the chance that any data could be accidently unblinded.  
All of the SEER-Medicare patient files received from the NCI were anonymized and no 
attempt was made to de-anonymize the data.  Finally, an approved IRB application was 
completed prior to requesting the data.  
Ethical treatment of data.  All data received from the SEER-Medicare database 
was pre-anonymized.  The raw data were not shared with anyone not associated with this 
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project (chair, co-chair, statistic support, etc.) and all researchers ensured that attempts to 
de-anonymize data did not occur.  The data were stored securely on a leased Hivelocity 
server and accessed through a VPN firewall.  All the data reported within this dissertation 
document were aggregate data only; no individual or raw data has been shared publically.  
There are no conflicts of interest associated with this study. 
Agreements to gain access to data.  In order to gain access to the SEER-
Medicare database, a proposal consisting of a data application, a data use agreement 
(submitted documents in Appendix A and B) and proof of IRB approval was submitted to 
the SEER-Medicare liaisons.  The Walden University IRB approval (approval #12-11-14-
0086341) was utilized to satisfy the IRB requirement.  The data use agreement (DUA) 
was required to be signed by the PhD scientist overseeing the research; in this case, Dr. 
Raymond Panas (chair).  This data application package was approved by the SEER-
Medicare (NCI) committee (Appendix F). 
Summary 
As outlined in the methodology plan above, this study was observational and used 
archived colorectal cancer patient data available from the NCI’s (NCI) SEER-Medicare 
database.  This data within this database contains all information needed to answer the 
three research questions regarding disparities in monoclonal antibody treatment.   
A retrospective cohort study was performed using individuals diagnosed with 
metastatic colorectal cancer between January 2007 and December 2011.  The data were 
compiled using MySql, Python and SPSS.  The outlined sampling procedure limited the 
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sample to elderly patients eligible for first-line adjunct monoclonal antibody therapy 
(individuals with metastatic colorectal cancer given first line chemotherapy).  
Additionally, the sampling procedure aimed to reduce the impact of insurance coverage 
on claim availability in the dataset by excluding patient covered by managed care 
organizations/HMOs (as their claims would not be billed through Medicare and would 
not be represented in the SEER-Medicare dataset).   
I present the results in Chapter 4 using descriptive statistics, frequency tables, and 
logistic regression.  Logistic regression is the appropriate inferential statistic due to the 
dichotomous nature of the dependent variable (monoclonal antibody therapy, “yes” or 
“no”).  Covariate analyses were employed when necessary to determine whether or not 
the independent variables are independently associated with the dependent variable. 
Finally, validity and ethical concerns have been explicitly addressed.  
Specifically, threats to internal, external, construct, and statistical validity have been 
addressed and efforts have been taken to minimize threats and maximize the impact of 
the data.  Additionally, human and data ethical concerns have been discussed.  The use of 
archived, anonymized data reduces ethical concerns.  However, steps were still taken to 
protect the data and ensure the anonymized data remains anonymized and secure. 
In the following chapter, I describe selection of the study cohort including 
attrition at each inclusion/exclusion variable.  Additionally, I present demographics of the 
cohort, and descriptive statistics of the independent, control and dependent variables.  
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Finally, logistic regression modeling is used to test the three research questions 
surrounding disparities in adjunct monoclonal antibody treatment. 
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Chapter 4: Results 
Introduction 
The purpose of this research study is to assess disparities (based on race, SES, and 
neighborhood characteristics) in adjunct monoclonal antibody treatment of elderly 
metastatic colorectal cancer patients.  In this chapter, I will first outline the selection of 
the study cohort, present the demographics of the study cohort, and use descriptive 
statistics to relate the independent variables and the covariates to the dependent variable 
(monoclonal antibody treatment).  Subsequently, using the selected cohort and logistic 
regression, the three research questions will be tested.  The research questions along with 
null and alternative hypotheses are outlined below: 
RQ1:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there racial 
disparities in first line adjunct monoclonal antibody treatment? 
H01:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody treatment based on race. 
Ha1:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody treatment based on race. 
126 
 
RQ2:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there 
socioeconomic disparities in first line adjunct monoclonal antibody treatment? 
H02:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on area socioeconomic status (as defined by 
the PEDSF census tract poverty indicator). 
Ha2:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on area socioeconomic status (as defined by 
the PEDSF census tract poverty indictor). 
RQ3:  Within the population of elderly (65 years+) individuals diagnosed with 
metastatic colorectal cancer from January 2007 to December 2011, are there 
neighborhood characteristic (degree of urbanization) disparities in first line adjunct 
monoclonal antibody treatment? 
H03:  There is no significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on neighborhood characteristics. 
Ha3:  There is a significant association between the percentage of elderly (65 
years+) metastatic colorectal cancer patients who receive first line adjunct 
monoclonal antibody therapy based on neighborhood characteristics. 
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Data Collection  
In this research, I used secondary data from the NCI’s SEER-Medicare database 
and thus was strictly retrospective and observational.  Therefore, no treatments or 
interventions were administered and no adverse events were identified.  Additionally, all 
of the data remained anonymized and no attempt was made to identify patients.  As 
requested by the NCI, to conserve anonymity, all data cells with less than 11 counts have 
been masked. 
The SEER-Medicare database is a large population-based database that contains 
matched medical records and demographic information for Medicare beneficiaries who 
have been diagnosed with cancer (NCI, 2015a).  For this research project, a request was 
made for five linked SEER-Medicare datasets containing data from colorectal cancer 
patients for the years 2007 to 2012 (with the exception of the PEDSF with years 2007-
2011 only).  The first dataset, the PEDSF, is the primary SEER file and contains 
demographics and information related to the patient’s cancer diagnosis (i.e., information 
on cancer stage, diagnosis date, previous primary tumors; NCI, 2015b).  The other four 
datasets are all Medicare claims datasets.  This included the PDE dataset, the Outpatient 
Claims dataset, the DME dataset, and the Carrier Claims dataset.  The PDE dataset 
includes all drugs prescribed under Medicare Part D and the other three datasets 
(Outpatient Claims dataset, the DME and the Carrier Claims dataset) contain all Part B 
claims including diagnosis and procedure codes (NCI, 2015b).  These five patients 
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matched SEER-Medicare datasets contain information on all the variables required to 
answer the research questions described above. 
The data request/application process began in December, 2014 and required 
several revisions and reviews.  The specific concern from the NCI was in regard to data 
security and storage.  The original proposed plan (storage on a home server) and the 
secondary plan (storage on the Walden server with access via sFTP) were unacceptable to 
the protocol reviewers.  The final approved application included plans to lease a secure 
server at Hivelocity and access the data via VPN.  The raw data files and the analysis 
files were stored securely on a Hivelocity server throughout the data compilation/analysis 
process.  Only the final summary tables enclosed in this chapter were saved and shared 
outside the secure server.  The entire application process took 4.5 months and data were 
received and uploaded to the server in April, 2015.  Copies of the application and data 
use agreement can be found in Appendix A and B.   
Given that secondary data were used, there were no discrepancies in data 
collection.  However, during the application process, several study design 
recommendations were received from the NCI.  Specifically, the NCI recommended the 
addition of NDC codes to the DME dataset query, the exclusion of patients with HMO 
coverage, the exclusion of individuals with a history of other primary tumors, and the 
exclusion of individuals with end stage renal disease.  These changes were all made to the 




The study cohort was selected from a pool of 119,712 patients in the SEER-
Medicare database diagnosed with colorectal cancer from January 2007 to December 
2012 using MySQL, Python, and SPSS.  The methods for this process can be found in 
Appendix D.  A pictorial representation of cohort selection, including the number of 
eliminated patients at each step in the selection process, is described in Figure 2.  All 





Figure 2.  Flow chart showing the selection of the study cohort based on multiple 
different inclusion and exclusion criteria.  The number of individuals excluded at each 
step in the process is listed. 
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Demographics of the Study Cohort 
 The study cohort, as outlined in the cohort selection figure above, includes elderly 
(65+) patients diagnosed with metastatic colorectal cancer between January 2007 and 
December 2011 and given chemotherapy within 6 months of diagnosis (as evident by a 
Medicare claim).  Individuals included in the cohort had to have evidence of Part B 
Medicare coverage (at least 1 month in the year of diagnosis), evidence of Part D 
Medicare coverage (at least 1 month in the year of diagnosis), but no HMO coverage in 
diagnosis year.  Additionally, they could have no history of a previous primary tumor and 
could not have been entitled to receive Medicare due to ESRD.  The demographics of this 
cohort are described in detail in Tables 14 through 20. 
As described in Table 12, the cohort is 72% white with an additional 8.7% white 
with Spanish origin or surname.  The next most prevalent race is black, which makes up 
10.7% of the cohort.  For the purpose of this research question, due to low patient 
numbers in some groups, all Asian and Pacific Islander races (Chinese, Japanese, 
Hawaiian, Filipino and Other Pacific Islander) were combined into the group called 
Asian or Pacific Islander.  Three other SEER reported race categories, American 
Indian/Alaska Native, Unknown, and Other Unclassified were excluded from the table 
and subsequent analyses due to having a total of 11 patients or less over the years 2007 to 
2011.  Looking at the cohort over diagnosis years 2007 to 2011, the percentage of White 
Americans and White Americans with Spanish origin or surname remains fairly 
consistent; however, the percentage of Black Americans in the cohort almost doubles 
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(from 7.4% to 13.8%) over the timeframe.  The incidence of colorectal cancer in Black 
Americans is known to be slightly higher than in White Americans and Black Americans 
make up 13.5% of the United States population (NCI, n.d.b).  Therefore, the percent of 
Black Americans in the cohort could be low.  However, given that the chemotherapy 
rates in Black Americans in the general population over the years 2007 to 2011 is 
unknown and chemotherapy is a selection variable for the cohort, it is difficult to estimate 
if this racial breakdown is representative of the larger population. 
Table 12 
Demographics of the Study Cohort by Year - Race 




Study cohort (n) 407 450 439 488 457 2241 
Race (n/%)       




































     White (Spanish origin 














The cohort is distributed equally by gender (48.3% male and 51.7% female) as 
described in Table 13.  Additionally, the gender distribution is fairly constant over the 





Demographics of the Study Cohort by Year - Gender 
 2007 2008 2009 2010 2011 All Years 
(2007-
2011) 
Study cohort (n) 407 450 439 488 457 2241 
Gender (n/%)       

























As described in Table 14, the average age of diagnosis of the cohort is 74.09 (+/- 
6.51) years.  This is consistent over the study time frame with the lowest age at diagnosis 
of 73.53 (+/- 6.07 years) in 2007 and the highest age at diagnosis of 74.48 (+/- 6.61) in 
2009.  This average age at diagnosis in this cohort is consistent with the average 
diagnosis age in the general colorectal cancer population given that this study only 
includes individuals 65 years and older (NCI, n.d.b). 
Table 14 
Demographics of the Study Cohort by Year – Age at Diagnosis 
 2007 2008 2009 2010 2011 All Years 
(2007-
2011) 
Age at diagnosis 














The study cohort is also fairly evenly distributed across the four SES levels as 
described in Table 15.  The highest percentage (28.7%) of individuals in the cohort 
resided in a census tract with 10% to less than 20% poverty, while the lowest percentage 
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(21.3%) of individuals in the cohort resided in a census tract with 0% to less than 5% 
poverty.  The distribution is fairly consistent over the 2007 to 2011 timeframe with a 
slight reduction (25.8% in 2007 to 21.4% in 2011) in the number of individuals residing 
in the lowest SES areas (20% to 100% poverty).   
Table 15 
Demographics of the Study Cohort by Year – Socioeconomic Status 




Study cohort (n) 407 450 439 488 457 2241 
Census tract poverty 
indicator (SES) (n/%) 
      
     0% - <5% poverty  









































     20% - 100% poverty  

















Note. *Less than 11 patients in group.  Value masked for privacy purposes. 
The breakdown of reporting registry for the patients in the cohort is described in 
Table 16.  The highest percentage of individuals in the cohort (34.3%) had data reported 
from California.  This is followed by 13.5% in New Jersey and 11.1% in Georgia with 
the lowest percentage being reported from Utah (1.5%).  Frequency of patients within the 
other reporting registries is described in detail in Table 16.  Distribution of the cohort 
across reporting registry is fairly consistent across the timeframe 2007 to 2011.  Given 
that the SEER-Medicare database relies on data from 13 registries in district geographies, 
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this geographical breakdown is not representative of the larger U.S. metastatic colorectal 
cancer population. 
Table 16 
Demographics of the Study Cohort by Year – Reporting Registry 














Study cohort (n) 407 450 439 488 457 2241 
Reporting registry 
(n/%) 
      
     Hawaii * * * * * 35 (1.6%) 
     Iowa 33 (8.1%) 39 (8.7%) 29 (6.6%) 39 (8.0%) 30 (6.6%) 170 
(7.6%) 
     New Mexico * * 12 (2.7%) * 11 (2.4%) 49 (2.2%) 
     Seattle 20 (4.9%) 27 (6.0%) 15 (3.4%) 23 (4.7%) 21 (4.6%) 106 
(4.7%) 
     Utah * * * * * 34 (1.5%) 
     Kentucky 31 (7.6%) 37 (8.2%) 38 (8.7%) 28 (5.7%) 27 (5.9%) 161 
(7.2%) 
     Louisiana 18 (4.4%) 22 (4.9%) 28 (6.4%) 42 (8.6%) 43 (9.4%) 153 
(6.8%) 


































Note. *Less than 11 patients in group.  Value masked for privacy purposes. 
 
Neighborhood characteristics (degree of urbanization) for patients within the 
study cohort are described in Table 17.  The cohort is primarily from Big Metro areas 
(52.7%) with the least number of patients from Rural areas (2.5%).  This is fairly 





Demographics of the Study Cohort by Year – Neighborhood Characteristics 




Study Cohort (n) 407 450 439 487 457 2240a 
Neighborhood 
Characteristics (n/%) 
      
























































Note.*Less than 11 patients in group.  Value masked for privacy purposes. 
aOne missing value 
 
Table 18 describes the cohort based on the reason for original Medicare 
entitlement (why they first gained access to Medicare).  As described in the cohort 
selection section, individuals who gained Medicare entitlement due to ESRD were 
excluded from this study.  Therefore, individuals in the cohort were only entitled due to 
Age or Disability.  Individuals in the cohort were primarily entitled due to age (90.6%).  
This is fairly consistent over the time frame with slightly fewer (7.1%) begin entitled due 







Demographics of the Study Cohort by Year – Reason for Original Medicare Entitlement 




Study Cohort (n) 407 450 439 488 457 2241 
Reason for Original 
Medicare Entitlementa 
      
























aEntitlement due to End Stage Renal Disease Excluded from Cohort 
 
Analysis of Covariates 
Four covariates were assessed to determine if they need to be added to the logistic 
regression model to control for confounding.  The first covariate assessed was gender 
(male or female).  The second covariate was age at diagnosis.  The third covariate was 
reason for original Medicare entitlement (Age or Disability only; Individuals that 
qualified for Medicare due to End Stage Renal Disease were excluded from the study 
cohort).  The fourth covariate was reporting registry.   
Distribution of these covariates is described in the following tables and figures.  
In addition, univariate analysis describing the association of each of the covariates with 
the dependent variable (monoclonal antibody treatment) is presented.  Covariates with 
significant association with the dependent variable will be carried into the logistic 
regression model to test for independent association of the dependent and independent 




The first covariate to be analyzed for association with monoclonal antibody 
treatment rate is gender.  Table 19 describes the frequency of the adjunct monoclonal 
antibody receipt based on gender in the cohort.  The frequency is fairly equivalent with 
slightly fewer women (percentage-wise) receiving adjunct monoclonal antibody therapy. 
Table 19 
Monoclonal Antibody Treatment Rate by Gender 
Gender Patients (n) Received Monoclonal Antibody 
Treatment (n (%)) 
Male 1083 460 (42.5%) 
Female 1158 470 (40.6%) 
Total 2241 930 (41.5%) 
 
Table 20 describes the Chi-Square statistic comparing monoclonal antibody 
treatment rate to gender.  Gender is not associated with monoclonal antibody treatment 
(Pearson’s Chi-Square p-value = .365).  Therefore, gender will not be included in the 




Differences in Gender-Based on Monoclonal Antibody Treatment Rate 






Pearson Chi-Square .821a 1 .365   
Continuity Correctionb .745 1 .388   
Likelihood Ratio .821 1 .365   
Fisher's Exact Test    .368 .194 
Linear-by-Linear 
Association 
.821 1 .365   
N of Valid Cases 2241     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 449.44. 
b. Computed only for a 2x2 table 
 
Reporting Registry 
The second covariate to be analyzed for association with monoclonal antibody 
treatment is reporting registry.  Table 21 describes the frequency of adjunct monoclonal 
antibody receipt based on reporting registry within the cohort.  There are some registries 
with higher than average rates and some with lower than average rates.  For example, 
Utah, Hawaii, and Seattle have relatively high treatment rates (61.8%, 57.1% and 53.8% 
respectively) while Connecticut, California, and New Jersey have lower treatment rates 





Monoclonal Antibody Treatment Rate by Reporting Registry 
Reporting Registry Patients (n) Received Monoclonal Antibody 
Treatment (n (%)) 
Connecticut 121 40 (33.1%) 
Detroit 93 48 (51.6%) 
Hawaii 35 20 (57.1%) 
Iowa 170 70 (41.2%) 
New Mexico 49 23 (46.9%) 
Seattle 106 57 (53.8%) 
Utah 34 21 (61.8%) 
Kentucky 161 69 (42.9%) 
Louisiana 153 61 (39.9%) 
New Jersey 302 116 (38.4%) 
Georgia 248 115 (46.4%) 
California 769 290 (37.7%) 
Total 2241 930 (41.5%) 
 
Table 22 describes the Chi-Square statistic comparing monoclonal antibody 
treatment rate to reporting registry.  Reporting registry is associated with monoclonal 
antibody treatment (Pearson’s Chi-Square p-value = .001).  Therefore, reporting registry 
will be included in the logistic regression models to control for confounding. 
Table 22 
Differences in Reporting Registry Based on Monoclonal Antibody Treatment Rate 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 32.378a 11 .001 
Likelihood Ratio 32.138 11 .001 
Linear-by-Linear Association 2.470 1 .116 
N of Valid Cases 2241   




Medicare Entitlement Characteristics 
The third covariate to be analyzed for association with monoclonal antibody 
treatment is original Medicare entitlement characteristics (age or disability).  Table 23 
describes the frequency of adjunct monoclonal antibody receipt based on entitlement 
characteristics.  Within the cohort, there are slightly higher rates of monoclonal antibody 
receipt in patients entitled due to age compared to patients entitled due to disability. 
Table 23 
Monoclonal Antibody Treatment by Medicare Entitlement Characteristics 
Entitlement Characteristicsa Patients (n) Received Monoclonal Antibody 
Treatment (n (%)) 
Age 2030 854 (42.1%) 
Disability 211 76 (36.0%) 
Total 2141 930 (41.5%) 
aPatients entitled due to End Stage Renal Disease were excluded from both Cohort 
 
Table 24 describes the Chi-Square statistic comparing monoclonal antibody 
treatment rate to original Medicare entitlement characteristics.  Medicare Entitlement 
Characteristics are not associated with monoclonal antibody treatment (Pearson’s Chi-
Square p-value = .090).  Therefore, entitlement characteristics will not be included in the 





Differences in Medicare Entitlement Characteristics Based on Monoclonal Antibody 
Treatment Status 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 2.882a 1 .090 
Likelihood Ratio 2.921 1 .087 
Linear-by-Linear Association 2.880 1 .090 
N of Valid Cases 2241   
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 87.56. 
 
Age at Diagnosis 
The final covariate to be analyzed for association with monoclonal antibody 
treatment rate is age at diagnosis.  Table 25 describes the mean age of diagnosis for 
individuals in the cohort who received and did not receive adjunct monoclonal antibody 
treatment.  The mean age of diagnosis is higher for individuals who did not receive 
adjunct monoclonal antibody therapy. 
 
Table 25 
Monoclonal Antibody Treatment by Age at Diagnosis 
Monoclonal 
Antibody Treatment 
              N Mean Age at 
Diagnosis 
Std. Deviation Std. Error Mean 
Yes 930 73.03 6.002 .197 
No 1311 74.84 6.742 .186 
 
 Figure 3 graphically represents the distribution of age at diagnosis for those who 
received and did not receive monoclonal antibody therapy.  The percentage of individuals 




Figure 3.  Bar graph showing the distribution of monoclonal antibody treatment by age at 
diagnosis. 
Table 26 presents the results from an independent samples t-test comparing 
monoclonal antibody treatment to age at diagnosis for the cohort.  As shown, age at 
diagnosis is significantly associated with monoclonal antibody treatment (p-value = 
.000).  Therefore, age at diagnosis will be included in the logistic regression models to 













t-test for Equality of Means 
































As presented in the sections above, two of the covariates are significantly 
associated with monoclonal antibody receipt.  Therefore, to control for confounding, 
reporting registry and age at diagnosis will be included in the logistic regression models.  
Specifically, if a significant association is found between any of the independent 
variables (race, SES, neighborhood characteristics) and monoclonal antibody treatment, 
an additional model will be run to include these three covariates as potential confounders.  
Including the covariates will test for an independent association between the independent 
and dependent variables.  
Descriptive Statistics 
 The results for the three research questions presented in this paper are outlined 
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and presented here.  This section first uses descriptive statistics to present the distribution 
of adjunct monoclonal antibody therapy based on race, SES, and neighborhood 
characteristics.  Specifically, this section describes the overall rate of adjunct monoclonal 
antibody treatment and the relationship between monoclonal antibody treatment rate and 
the three independent variables.  These relationships were also stratified on diagnosis 
year to test for maturation issues. 
Overall Rate of Adjunct Monoclonal Antibody Treatment 
As presented in Table 27, the average adjunct monoclonal antibody treatment rate 
was 41.5%.  The monoclonal antibody treatment rate declines slightly from 2007 to 2011.  
As shown in Table 28, this decrease in treatment rate from 2007 to 2011 approaches 
significance (Pearson Chi-Square p-value = .067).  Given that the difference in 
monoclonal antibody treatment is nonsignificant over the study timeframe, concerns 






Monoclonal Antibody Receipt by Diagnosis Year 
 2007 2008 2009 2010 2011 Total 
Total in Study 
Cohort (n) 


















Differences in Diagnosis Year Based on Monoclonal Antibody Treatment Status 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 8.762a 4 .067 
Likelihood Ratio 8.806 4 .066 
Linear-by-Linear Association 6.510 1 .011 
N of Valid Cases 2241   
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 168.90. 
 
 
Monoclonal Antibody Treatment Rate by Race 
The first research question in this project addresses disparities in adjunct 
monoclonal antibody treatment by race.  Table 29 presents the monoclonal antibody 
treatment rates in the cohort by race.  The White (nonHispanic) group had the highest 
rates of monoclonal antibody treatment (43.1%).  The other three race groups (Black 
Americans, Asian or Pacific Islander, and White (Spanish origin or surname)) had 




Monoclonal Antibody Treatment Rate by Race 
Race Total in Study Cohort (n) Monoclonal Antibody 
Treatment Rate (n (%)) 
White (nonHispanic) 1613 695 (43.1%) 
Black 239 88 (36.8%) 
Asian or Pacific Islander 180 69 (38.3%) 
White (Spanish origin or surname) 195 70 (35.9%) 
 
Monoclonal Antibody Treatment Rate by SES 
The second research question in this project addresses disparities in adjunct 
monoclonal antibody treatment by SES.  Table 30 presents the monoclonal antibody 
treatment rates in the cohort by SES (using the census tract poverty indicator).  The rate 
of monoclonal antibody treatment is fairly consistent across SES groups. 
Table 30 
Monoclonal Antibody Treatment Rate by SES Group  




Rate (n (%)) 
     0% - <5% (highest SES) 478 199 (41.6%) 
     5% - <10% 540 218 (40.4%) 
     10% - <20%  643 273 (42.5%) 
     20% - 100% (lowest SES) 518 220 (42.5%) 
 
Monoclonal Antibody Treatment Rate by Neighborhood Characteristics 
The third research question in this project addresses disparities in adjunct 
monoclonal antibody treatment based on neighborhood characteristics (degree of 
urbanization).  Table 31 presents the monoclonal antibody treatment rates in the cohort 
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by Neighborhood (i.e. Big Metro, Metro, Urban, Less Urban or Rural).  The rate of 
monoclonal antibody is lowest in the rural neighborhood group (31.6%).   
Table 31 
Monoclonal Antibody Treatment Rate by Neighborhood Characteristics  
 Total in Study Cohort (n) Monoclonal Antibody Treatment 
Rate (n (%)) 
Big Metro 1181 484 (41.0%) 
Metro 632 261 (41.3%) 
Urban 141 67 (47.5%) 
Less Urban 229 99 (43.2%) 
Rural 57 18 (31.6%) 
 
Statistical Assumptions 
 Logistic regression will be used in the subsequent sections to test for associations 
between the independent and dependent variables.  There are two main assumptions that 
must be met in order use logistic regression.  First, the dependent variable must be 
dichotomous (Burns & Burns, 2008).  The dependent variable in this case (monoclonal 
antibody therapy; “yes” or “no”) is dichotomous, meeting this assumption.  Second, the 
categories must be mutually exclusive and exhaustive, meaning that a sample must only 
be in one group and every sample must be assigned to a group (Burns & Burns, 2008).  
This assumption is also met with this data set.  For all independent and dependent 
variables every sample falls within one (and only one) of the categories.  Burns and 
Burns (2008) also note that larger samples are often needed for logistic regression and 
recommend at least 50 cases per predictor.  When all independent variables and 
covariates are included, the maximum number of predictor variables will is six (three 
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significant covariates and three independent variables).  Therefore, for these analyses, 
Burns and Burns would recommend at least 300 cases.  The total sample size exceeds this 
number since the cohort has 2,241 patients.  Logistic regression does not assume linear 
relationships between dependent and independent variables, nor does it assume equal 
variance within groups or normal distribution (Burns & Burns, 2008).  Therefore, these 
conditions do not need to be tested prior to analysis. 
Statistical Analysis of Research Questions 
 In previous sections in this chapter, cohort demographics were presented, 
covariates were assessed and descriptive statistics comparing the independent and 
dependent variables were introduced.  This section uses logistic modeling to test for 
significant and independent associations between the independent and dependent 
variables.  Specifically, this section will answer the three research questions presented in 
the project and determine whether or not, in these two cohorts, there are disparities in 
adjunct monoclonal antibody therapy based on race, SES, or neighborhood 
characteristics. 
Monoclonal Antibody Disparities by Race 
Prior to analysis, individuals with race American Indian/Alaska Native, unknown, 
or other unspecified (there were 11 patients or less in the cohort in each of these groups) 
were excluded.  This eliminated a total of 14 patients.  Race was coded as a categorical 
variable for dummy coding and White (nonHispanic) was listed as the reference variable.  
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Black American was dummy coded as (1), Asian/Pacific Islander was dummy coded as 
(2) and White (Spanish origin or surname) was dummy coded as (3).   
A binary logistic regression model was then executed using SPSS to determine if 
race predicts monoclonal antibody treatment.  The syntax for this analysis can be found 
in Appendix G.  Table 32 shows the result of the logistic regression analysis including a 
model summary and statistics for the association between race and monoclonal antibody 
treatment.  The pseudo R Square values (0.003 for the Cox & Snell and 0.004 for 
Nagelkerke) signify a poor model fit for race and monoclonal antibody treatment.   
The odds ratios for race versus monoclonal antibody treatment can be found in the 
Exp(B) column in the Table 32.  The odds ratios are all compared back to the reference 
group, in this case White (nonHispanic).  The odds ratio for White (nonHispanic) vs. 
Black American is 1.299 (95% CI: 0.981, 1.720), the odds ratio for White (nonHispanic) 
vs. Asian/Pacific Islander vs. is 1.218 (95% CI: 0.888, 1.671), and the odds ratio for 
White (nonHispanic) vs. White (Spanish origin or surname) is 1.352 (95% CI: 0.993, 
1.841).  Given that the overall model significance was 0.070 and all confidence intervals 
overlap 1.0, race is not a significant predictor of monoclonal antibody treatment.  
However, Black Amerian and White (Spanish origin or surname) do approach 







Logistic Regression Analysis – Race and Monoclonal Antibody Treatment 
 
Model Summary 
-2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
3013.928a .003 .004 
Variables in the Equation 





  7.071 3 .070    
Black (1) .262 .143 3.337 1 .068 1.299 .981 1.720 
Asian/Pacific Islander (2) .197 .161 1.493 1 .222 1.218 .888 1.671 
White (Spanish origin or 
surname) (3) 
.302 .158 3.664 1 .056 1.352 .993 1.841 
Constant .278 .050 30.632 1 .000 1.321   
a. Estimation terminated at iteration number 3 because parameter estimates changed by less than 
.001. 
 
 The logistic regression model shows that race is not a significant predictor of 
adjunct monoclonal antibody treatment in this cohort.  Therefore, the null hypothesis 
should be accepted for the first research question relating race to monoclonal antibody 
treatment.  Additionally, given the lack of association between race and monoclonal 
antibody therapy, no covariates need to be added to the models to control for 
confounding.  
Monoclonal Antibody Disparities by SES 
Prior to analysis, individuals with a census tract poverty indicator value of 
“unknown” were excluded from the cohort (the census tract poverty indicator variable is 
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the measure of SES for this research project).  This eliminated a total of 44 patients.  SES 
was coded as a categorical variable for dummy coding and the 0% to <5% poverty group 
was listed as the reference variable.  The 5% to <10% poverty group was dummy coded 
as (1), the 10% to <20% poverty group was dummy coded as (2) and the 20% to 100% 
poverty group was dummy coded as (3).   
A binary logistic regression model was then executed using SPSS to determine if 
SES predicts monoclonal antibody treatment.  The syntax for this analysis can be found 
in Appendix H.  Table 33 shows the result of the logistic regression analysis including a 
model summary and statistics for the association between SES and monoclonal antibody 
treatment.  The pseudo R Square values (0.000 for the Cox & Snell and 0.000 for 
Nagelkerke) signify no model fit for SES and monoclonal antibody treatment.   
The odds ratios for SES level versus monoclonal antibody treatment can be found 
in the Exp(B) column in the Table 33.  The odds ratios are all compared back to the 
reference group, in this case 0% to <5% poverty.  Therefore, the odds ratio for 0% to 
<5% poverty vs. 5% to <10% poverty is 1.054 (95% CI: 0.820, 1.353), the odds ratio for 
0% to <5% poverty vs. 10% to <20% poverty is 0.967 (95% CI: 0.761, 1.229), and the 
odds ratio for 0% to <5% poverty vs. 20% to 100% poverty is 0.966 (95% CI: 0.751, 
1.243).  Given that the overall model significance was p = 0.881 and all confidence 
intervals overlap 1.0, SES (as measured using the census tract poverty indicator variable) 




Table 33  
Logistic Regression Analysis – SES and Monoclonal Antibody Treatment 
 
Model Summary 
-2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
2960.649a .000 .000 
Variables in the Equation 
SES (dummy code) B S.E. Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
Lower Upper 
0% to <5% poverty 
(reference) 
  .668 3 .881    
5% to <10% poverty (1) .052 .128 .167 1 .683 1.054 .820 1.353 
10% to <20% poverty (2) -.034 .122 .077 1 .782 0.967 .761 1.229 
20% to 100% poverty (3) -.034 .128 .072 1 .789 0.966 .751 1.243 
Constant .338 .093 13.262 1 .000 1.402   
a. Estimation terminated at iteration number 3 because parameter estimates changed by less than 
.001. 
 
 The logistic regression model shows that SES is not a significant predictor of 
adjunct monoclonal antibody treatment.  Therefore, the null hypothesis should be 
accepted for the second research question relating SES to monoclonal antibody treatment.  
Additionally, given the lack of association between SES and monoclonal antibody 
therapy, no covariates need to be added to the models to control for confounding. 
Monoclonal Antibody Disparities by Neighborhood Characteristics 
Prior to analysis, one individual with a missing Rural/Urban Continuum code was 
eliminated.  The 2003 Rural/Urban Continuum code groups were coded as categorical 
variables for dummy coding and the Big Metro group was listed as the reference variable.  
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Metro was dummy coded as (1), Urban was dummy coded as (2), Less Urban was 
dummy coded as (3) and Rural was dummy coded as (4).   
A binary logistic regression model was then executed using SPSS to determine if 
Neighborhood Characteristics (degree of urbanization) predicts monoclonal antibody 
treatment.  The syntax for this analysis can be found in Appendix I.  Table 34 shows the 
result of the logistic regression analysis including a model summary and statistics for the 
association between neighborhood characteristics and monoclonal antibody treatment.  
The pseudo R Square values (0.002 for the Cox & Snell and 0.003 for Nagelkerke) 
signify a poor model fit for neighborhood characteristics and monoclonal antibody 
treatment.   
The odds ratios for neighborhood characteristics versus monoclonal antibody 
treatment can be found in the Exp(B) column in the Table 34.  The odds ratios are all 
compared back to the reference group, in this case Big Metro.  Therefore, the odds ratio 
for Big Metro vs. Metro is 0.987 (95% CI: 0.811, 1.201), the odds ratio for Big Metro vs. 
Urban is 0.767 (95% CI: 0.540, 1.089), and the odds ratio for Big Metro vs. Less Urban 
is 0.912 (95% CI: 0.685, 1.214) and the odds ratio for Big Metro vs. Rural is 1.505 (95% 
CI: 0.851, 2.662).  Given that the overall model significance was p = 0.309 and all 
confidence intervals overlap 1.0, neighborhood characteristics are not a significant 






Table 34  




-2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
3034.950a .002 .003 




B S.E. Wald df Sig. Exp(B) 95% C.I.for 
EXP(B) 
Lower Upper 
Big Metro (reference)   4.792 4 .309    
Metro (1) -.013 .100 .017 1 .897 0.987 .811 1.201 
Urban (2) -.265 .179 2.204 1 .138 0.767 .540 1.089 
Less Urban (3) -.092 .146 .400 1 .527 0.912 .685 1.214 
Rural (4) .408 .291 1.970 1 .160 1.505 .851 2.662 
Constant .365 .059 37.993 1 .000 1.440   
a. Estimation terminated at iteration number 3 because parameter estimates changed by less than 
.001. 
 
 The logistic regression model shows that neighborhood characteristics are not a 
significant predictor of adjunct monoclonal antibody treatment.  Therefore, the null 
hypothesis should be accepted for the third research question relating neighborhood 
characteristics (degree of urbanization) to monoclonal antibody treatment.  Additionally, 
given the lack of association between neighborhood characteristics and monoclonal 




Final Logistic Regression Model 
The three independent variables tested (race, SES, neighborhood characteristics) 
did not significantly predict the dependent variable group (monoclonal antibody therapy; 
yes or no) in the logistic regression models above.  However, two of the covariates 
(diagnosis age and reporting registry) did significantly associate with monoclonal 
antibody receipt in the covariate analysis section of this chapter.  Therefore, as a final 
analysis, a logistic regression model has been generated using these two significant 
variables to determine how well these variables fit the model and if they are both 
independently associated with monoclonal antibody treatment.   
Prior to analysis, the categorical variables reporting registry was coded as a 
categorical variable for dummy coding.  Binary logistic regression models were executed 
using SPSS to determine if the model predicts monoclonal antibody treatment.  The 
Syntax for these queries can be found in Appendix J.  Table 35 shows the result of the 
logistic regression analysis including a model summary and statistics for the association 
between the two variables (age at diagnosis, reporting registry) and monoclonal antibody 
treatment.  The pseudo R Square values (0.032 for the Cox & Snell and 0.042 for 








Logistic Regression Analysis – Final Model With Diagnosis Age and Reporting Registry  
  
Model Summary 
-2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
2969.819a .032 .042 
Variables in the Equation 
Variable (dummy code) B S.E. Wald df Sig. Exp 
(B) 
95% CI for 
EXP(B) 
Lower Upper 
Reporting Registry = Connecticut   28.953 11 .002    
Reporting Registry = Detroit (1) -.721 .286 6.331 1 .012 .486 .277 .853 
Reporting Registry = Hawaii (2) -.870 .396 4.816 1 .028 .419 .193 .911 
Reporting Registry = Iowa (3) -.293 .251 1.368 1 .242 .746 .456 1.219 
Reporting Registry = New Mexico 
(4) 
-.497 .348 2.038 1 .153 .608 .307 1.204 
Reporting Registry = Seattle (5) -.807 .277 8.466 1 .004 .446 .259 .769 
Reporting Registry = Utah (6) -1.017 .406 6.279 1 .012 .362 .163 .801 
Reporting Registry = Kentucky (7) -.298 .253 1.389 1 .239 .742 .452 1.219 
Reporting Registry = Louisiana (8) -.160 .257 .387 1 .534 .852 .515 1.411 
Reporting Registry = New Jersey 
(9) 
-.186 .229 .662 1 .416 .830 .530 1.300 
Reporting Registry = Georgia (10) -.464 .234 3.932 1 .047 .629 .397 .995 
Reporting Registry = California 
(11) 
-.124 .209 .350 1 .554 .883 .586 1.332 
Age at Diagnosis .043 .007 38.437 1 .000 1.044 1.030 1.058 
Constant -2.549 .558 20.892 1 .000 .078   
a. Estimation terminated at iteration number 3 because parameter estimates changed by less than 
.001. 
 
 Although the pseudo R Square values indicate that this is a weak model, the 
model does significantly predict monoclonal antibody therapy (0.002 for reporting 
registry and 0.000 for age at diagnosis).  Additionally, given that both variables 
maintained significance in the model, reporting registry and age at diagnosis are 




 In this research project, I explored disparities in adjunct monoclonal antibody 
treatment of elderly metastatic colorectal cancer patients.  The three independent 
variables tested for association with monoclonal antibody treatment were race, SES, and 
neighborhood characteristics (degree of urbanization).  There were also four covariates 
assessed for association with monoclonal antibody treatment; gender, age at diagnosis, 
reporting registry and reason for Medicare entitlement.  Two of the covariates (age at 
diagnosis and reporting registry) were found to significantly associate with monoclonal 
antibody therapy.  Logistic regression modeling of the three independent variables (race, 
SES and neighborhood characteristics) showed that none of the variables significantly 
predicted who would receive monoclonal antibody therapy.  These data support accepting 
the null hypotheses for all three research questions (H01, H02 and H03 listed at the 
beginning of this chapter).  A final logistic regression model was then executed with all 
variables shown to associate with monoclonal antibody therapy (age at diagnosis and 
reporting registry).  These two variables independently associated with monoclonal 
antibody therapy in the logistic regression model. 
 In the next chapter I will interpret the finding presented in this chapter.  Namely, I 
will compare the results to what was previously found in the literature and to the 
theoretical framework this study was based on.  Additionally, limitations of the research, 




Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
Colorectal cancer survival disparities based on race, SES, and neighborhood 
characteristics (degree of urbanization) have been documented in the literature.  
Disparities in treatment regimen have been associated with these survival disparities.  
However, assessments of disparities in adjunct monoclonal antibody treatment (a newer 
treatment specifically for metastatic colorectal cancer) were not found in the literature.  
Therefore, in this study, my aim was to determine whether these historical colorectal 
cancer treatment disparities, observed with surgery, radiation, and chemotherapy, 
extended into the newest class of treatments, monoclonal antibody therapies.  The 
specific aim of this quantitative study was to assess racial, SES, or neighborhood 
characteristic (degree of urbanization) disparities in first-line adjunct monoclonal 
antibody treatment of elderly metastatic colorectal cancer patients.   
To answer these research questions, a retrospective cohort study was performed 
using secondary data from the NCI’s SEER-Medicare database.  From this database, 
2,241 patient records that met the inclusion and exclusion criteria were selected for the 
study.  The demographics of this cohort including any differences across diagnosis year 
were described in Chapter 4 (Tables 12-18).  Generally, the cohort was stable over 
diagnosis years 2007 to 2011 with a few exceptions including a linear increase in the 
number of Black American patients in the cohort from diagnosis year 2007 to diagnosis 
year 2011 (7.4% of the cohort to 13.8% of the cohort over the timeframe).  Adjunct 
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monoclonal antibody treatment rate did not significantly change over the 2007 to 2011 
timeframe although a steady decline was observed that almost reached significance (p = 
0.067).  The covariates age at diagnosis and reporting registry were significantly 
associated with adjunct monoclonal antibody therapy, while the covariates gender and 
reason for original Medicare entitlement (age or disability) were not.  Logistic regression 
was then used to model the independent variables as predictors of the dependent variable.  
None of the three independent variables (race, SES, and neighborhood characteristics) 
predicted monoclonal antibody therapy.  As a result, the null hypothesis was accepted for 
all three research questions.  However, of note, the race vs. monoclonal antibody model 
did approach significance (overall model p = 0.070), with black race (p = 0.068) and 
White, Spanish origin or surname (p = 0.056) being almost significantly different than the 
reference group, White American race.  As a final analysis, a model was generated with 
the two variables that did significantly associate with monoclonal antibody therapy (age 
at diagnosis and reporting registry).  This final model was significant and both variables 
were independently associated with adjunct monoclonal antibody therapy. 
Interpretation of the Findings 
The results of this study were outlined in length in Chapter 4 and summarized 
above.  In this section, I will interpret the findings as they relate to the literature review 
and the theoretical foundation of this study.   
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Results as They Relate to the Literature 
 Multiple studies outlined in the literature review found disparities in either the 
type of aggressiveness of colorectal cancer treatment based on race, SES, and 
neighborhood characteristics (degree of urbanization; Bakogeorgos et al., 2013; Obeidat 
et al., 2010; Serra-Rexach et al., 2012).  This study is unique in that I examined a 
population of newly diagnosed metastatic colorectal cancer patients for disparities in 
treatment with adjunct monoclonal antibody treatment (a newer therapy specifically for 
metastatic colorectal cancer).  Unlike the vast majority of the literature, in this research, I 
did not identify significant treatment disparities based on race, SES, or neighborhood 
characteristics.  Therefore, the historically observed treatment disparities may not be 
relevant to newer therapies (monoclonal antibodies) prescribed to patients with severe 
disease (metastatic colorectal cancer).  The difference could be related to improved 
access to care or a change in treatment paradigm due specifically to the severity of 
metastatic colorectal cancer.   
 Although the null hypothesis was accepted for all three research questions 
(monoclonal antibody therapy disparities based on race, SES, or neighborhood 
characteristics), a few literature reported findings were confirmed.  First, age at diagnosis 
was selected as a covariate due to previous literature documentation of an association 
between diagnosis age and adjunct monoclonal antibody therapy.  Specifically, Fu et al. 
(2013) and Kozloff et al. (2010) observed reduced adjunct bevacizumab treatment with 
increasing patient age.  These results were confirmed in this study.  Age at diagnosis was 
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independently and significantly associated with adjunct monoclonal antibody therapy (p 
= 0.000).  In addition, another covariate, reporting registry was significantly associated 
with monoclonal antibody treatment.  SEER reporting registries are geographically 
dispersed across regions of the United States.  Previous research has shown marked 
differences in colorectal cancer survival improvements across geographical regions of the 
United States.  Specifically, over the timeframe 1990 to 2007, the southern states showed 
little to no improvement, whereas the north-eastern states showed improvement often in 
excess of a 33% reduction in mortality (Naishadham et al., 2011).  It is possible that 
regional treatment disparities influence these mortality rates.  This was not addressed as a 
primary question in this study due to the incomplete coverage of U.S. regions by the 
SEER registry data, but could be explored in future studies. 
Theoretical Framing of the Results 
The overarching theory for this research project was the fundamental cause 
theory.  According to this theory, as new methods of treating diseases become available, 
these resources are not distributed equally (Phelan & Link, 2005).  Instead they are 
distributed based on “knowledge, money, power, prestige, and beneficial social 
connections” (Phelan & Link, 2005, p. 227).  Based on this theory and the literature 
review documenting disparities in older colorectal cancer therapies, disparities in 
monoclonal antibody treatment based on race, SES, or neighborhood characteristics 
(degree of urbanization) would have been expected.  However, disparities in race, SES, 
and neighborhood characteristics were not observed in this study.  Therefore, the findings 
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are seemly inconsistent with this theory.  However, most of the previous research into 
colorectal cancer treatment disparities was performed with the general colorectal cancer 
population.  This study is addressing disparities in patients with advanced disease, 
specifically colorectal cancer that had metastasized at diagnosis.  Therefore, it is possible, 
given the severity of the disease and the high mortality rate, that some of the social 
barriers to treatment were eliminated.  For example, maybe patients with metastatic 
colorectal cancer are more likely to see a specialist or have a doctor advocate on their 
behalf.  These are questions that could be explored in future studies. Alternatively, given 
that monoclonal antibodies were approved in 2004 and I assessed patients diagnosed 
between 2007 and 2011, it is possible that the fundamental cause theory (which would 
support disparities in new treatments) is no longer applicable.  For example, if by 2007, 
uptake of monoclonal antibodies was already at a maximum level, monoclonal antibodies 
would no longer be considered a new method of treatment and their use may not be 
subject to unequal distribution. 
Two additional theories were used to extend the fundamental cause theory for the 
purpose of this research project: the diffusion of innovations theory and the theory of 
health disparities and medical technology.  The diffusion of innovation theory states that 
widening disparities are influenced by the nature of the new technology and the 
uptake/diffusion of the technology (Rogers, 2010).  Individuals who were treated with 
monoclonal antibody shortly after approval would be expected to have innovator-like 
characteristics such as proactive inquiry into treatment regimens that might contribute to 
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treatment disparities based on social characteristics or demographics. Renouf et al. (2011) 
found that 5.9% of patients diagnosed with colorectal cancer in 2004 were given the 
VEGF monoclonal antibody bevacizumab compared to 30.6% of colorectal cancer 
patients diagnosed in 2006.  In the Renouf et al. study, according to the diffusion of 
innovations theory, higher disparities in treatment would have been expected in 2004 
compared to 2006 given that treatment was in an uptake phase.  However, monoclonal 
antibodies were newly approved in 2004, likely accounting for this sharp increase in 
treatment rate between 2004 and 2006.  In this study, the rate of monoclonal antibody 
treatment was 44.5%, 42.7%, 44.6%, 39.8%, and 36.5% in diagnosis years 2007, 2008, 
2009, 2010, and 2011 respectively.  Therefore, in the years examined in this study (2007-
2011), the overall rate of monoclonal antibody therapy had reached a plateau.  Given this, 
the diffusion of innovations theory, which is most useful in explaining a disparity during 
the uptake of a technology, is likely not valid for this research study. 
As additional support for the fundamental cause theory, the theory of health 
disparities and medical technology was used (Goldman & Lakdawalla, 2005).  This 
theory states that medical advances are linked to widening disparities because new 
medical technologies disproportionately benefit the heaviest health care users, richer 
patients (Goldman & Lakdawalla, 2005).  Given that richer more well-educated patients 
tend to be the heaviest health care users and use more complex treatment regimens, richer 
patients disproportionately use newer therapies (Goldman & Lakdawalla, 2005).  This 
theory was used to hypothesize that there might be higher monoclonal antibody use by 
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high SES or nonminority populations.  This study did not demonstrate a social inequality 
in receipt of monoclonal antibody as would be expected based on this theory.  However, 
it is possible, given the severity of the disease and the high mortality rate, that some of 
the social/economic barriers to treatment in poorer populations were eliminated.   
 In summary, the lack of disparity in treatment of metastatic colorectal cancer 
patients with monoclonal antibodies is seemly inconsistent with the three theories used to 
provide rationale for the research questions.  Possible reasons for this include the extreme 
severity of disease studied and plateau in the uptake of monoclonal antibody therapy 
during the study period.  
Limitations of the Study 
 This study has multiple limitations.  First, due to the nature of the data, this study 
used a very specific population of elderly individuals enrolled in Medicare Part B and D, 
but with no HMO (Medicare Part C; Medicare Advantage) plan.  This population does 
differ systematically from the general Medicare population and from the population of 
Medicare enrollees with an HMO plan.  For example, the population sampled for this 
study has a higher average income rate compared to the general Medicare population 
(America’s Health Insurance Plans, 2015).  Additionally, lower frequencies of racial 
populations including Black Americans, Asians, and individuals with Hispanic origin are 
observed in the population sampled for this study compared to the general Medicare 
population (America’s Health Insurance Plans, 2015).  Therefore, the sample used in this 
study may not be completely representative of the overall Medicare population.  
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However, given the potential for missing data with HMO plan enrollees, this limitation 
was unavoidable. 
 Second, all individuals selected for inclusion in the study had colorectal cancer 
that had metastasized at diagnosis.  This was necessary as the SEER registry data only 
identifies metastasis state at diagnosis.  There is no way using the SEER registry data to 
identify patients that progress to metastasis.  Likewise, the Medicare claims files cannot 
provide information about metastasis.  Claims data are generated for the purpose of 
payment (billed items) and not for the purpose of research.  Cancer stage and progression 
cannot be determined using claims data.  Therefore, the sample selected for this study is 
entire composed of individuals who were diagnosed with severe metastasized colorectal 
cancer tumors.  As such, it is unclear how well these results would extrapolate back to 
individuals diagnosed in an earlier stage that subsequently progress to metastasis. 
 Third, the study sample was limited to individuals with a cancer sequence number 
of 00 or 01 indicating that the colorectal cancer tumor was their first tumor.  Given the 
potential implications to treatment for individuals with a history of other cancers, this 
exclusion criterion was necessary.  However, it is unclear how the results of this study 
would extrapolate to individuals with a history of other primary tumors. 
 Fourth, given the nature of the data used (Medicare claims) in this study, I used 
only included Medicare enrolled individuals aged 65+ at diagnosis.  As such is it unclear 
if these results can be extrapolated to the population of metastatic colorectal cancer 
patients under the age of 65 and with different insurance coverages.   
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 The fifth limitation is the ability to assess survival.  In order to assess survival 
relative to monoclonal antibody therapy, it would have been necessary to assess and 
control for any comorbidities.  This comorbidity analysis would have required research 
into ICD-9 codes present in the claims files during the pre- and post-diagnosis period for 
each patient. This would have been a significant undertaking and was determined to be 
out of scope for this research study.  Therefore, death dates were not collected, and 
survival was not assessed in this study.   
 Sixth, the population sampled came from the 13 geographically dispersed SEER 
registries.  The ability to extrapolate the results to the larger U.S. wide population of 
metastatic colorectal cancer patients is limited by the representativeness of the SEER 
database.  This SEER database includes data from approximately 28% of the U.S. cancer 
population.  However, it is unclear whether the data within the SEER database are a true 
representation of the greater U.S. cancer population.   
 Seventh, I used archival data from the SEER-Medicare database to address the 
research questions.  Therefore, the study quality is limited by the validity, reliability, and 
completeness of the SEER-Medicare database.  Given that hospitals, clinicians, and 
pathologists are responsible for accurate reporting and coding of SEER data, there is the 
potential for missing or inaccurate data.  However, there are published studies that have 
documented good reliability, validity, and completeness of different subsets of the SEER-
Medicare data (Du et al., 2008; Mahnken et al., 2008). 
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 Finally, adjunct monoclonal antibody treatment in this study was defined as being 
given any approved monoclonal antibody (Avastin, Erbitux, and Vectibix) in 
combination with first line chemotherapy.  The different antibodies were not separated 
out during the analysis.  Of importance, Erbitux and Vectibix (both EGFR antibodies) are 
only indicated for adjunct therapy after testing for a specific KRAS genetic mutation.  
Thus, there is an additional variable influencing whether or not a person is prescribed an 
EGFR antibody.  In this study, of the individuals that received adjunct monoclonal 
antibody therapy, there were only 72 individuals that received an EGFR antibody; the 
remaining 858 individuals received Avastin, a VEGF antibody.  Given this, it is unclear 
how the study results would extrapolate to a study looking at only adjunct EGFR 
antibody therapy. 
In summary, as a result of the database used for this study and the necessary 
inclusion and exclusion criteria, concerns regarding extrapolation of the study results do 
exist.  These limitations will be taken into account in the recommendations and 
implications sections below. 
Recommendations 
 Multiple previous reports have documented colorectal cancer treatment disparities 
based on race, SES, and neighborhood.  Given that treatment disparities were not 
observed in this study, these historical treatment disparities may not be relevant to newer 
therapies (adjunct monoclonal antibodies) prescribed to patients with severe disease 
(metastatic colorectal cancer).  The difference could be related to improved access to care 
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or a change in treatment paradigm due specifically to the severity of metastatic colorectal 
cancer.  Future studies aimed at understanding the causes of this observed difference is 
warranted.  Understanding the root cause of the reduced treatment disparities observed in 
this study could potentially be used to reduce treatment disparities in other cancer 
populations.  For example, given the severity of metastatic colorectal cancer, is it possible 
that patients are more likely to see a specialist or have a doctor advocate on their behalf, 
thus reducing the disparities in treatment?  These are questions that could be explored in 
future research studies. 
 As commented previously, race did approach significance in predicting 
monoclonal antibody treatment (overall model p = 0.070), with Black American race (p = 
0.068) and White, Spanish origin or surname (p = 0.056) being almost significantly 
different than the reference group, White American race.  Therefore, future confirmatory 
studies to confirm (or reject) the lack of racial disparities in monoclonal antibody 
treatment of metastatic colorectal cancer patients are needed.   
 Reporting registry was a significant predictor of adjunct monoclonal antibody 
therapy.  Given the reported U.S. regional differences in colorectal cancer survival, future 
studies could follow-up on regional disparities in adjunct monoclonal antibody treatment 
and potentially the influence of treatment on survival.  A GIS study to overlay treatment 




 An additional variable that almost reached significance was reason for original 
Medicare entitlement (age or disability).  Rates of monoclonal antibody treatment were 
lower in individuals entitled to Medicare due to disability compared to those entitled due 
to age (p = 0.090).  Given the marginal association, future studies assessing disparities in 
monoclonal antibody treatment of metastatic colorectal cancer patients based on 
disability are warranted.   
 When assessing the demographics of the study cohort, the number of Black 
Americans in the cohort increased linearly and doubled from 2007 to 2011.  Given that 
the cohort selection criteria required first line chemotherapy, it is possible that this 
increase is due to increased first line chemotherapy treatment rates in elderly Black 
Americans with metastatic colorectal cancer.  Exploring this was out of scope for this 
study.  However, it is an interesting finding that could be addressed in future studies. 
 The overall adjunct monoclonal antibody treatment rate in the cohort declined by 
8% from diagnosis year 2007 to diagnosis year 2011.  This difference in monoclonal 
antibody treatment rate based on diagnosis year was almost significant (p = 0.067).  
Given the reported efficacy of adjunct monoclonal antibody treatment, this decline is 
unexpected.  One possible explanation for the low and declining treatment rate is the cost 
of monoclonal antibody therapies and the cost-effectiveness of adding monoclonal 
antibody treatment to first-line chemotherapy.  Although monoclonal antibodies have 
been shown to improve survival rates in individuals with metastatic colorectal cancer, a 
low perceived cost-effectiveness of adding monoclonal antibodies to chemotherapy could 
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be driving down their use (Lange et al., 2014).  Prospective studies designed to illicit the 
rationale for prescribing behavior or qualitative studies to assess provider/patient feelings 
about adjunct monoclonal antibody therapy and their benefit versus their high cost might 
be the next logical step.  
Implications 
 The results demonstrate a potential improvement in historically documented 
colorectal cancer treatment disparities.  Specifically, historical treatment disparities may 
not be relevant to newer therapies (adjunct monoclonal antibodies) prescribed to patients 
with severe disease (metastatic colorectal cancer).  The difference could be related to 
improved access to care or a change in treatment paradigm due specifically to the severity 
of metastatic colorectal cancer.  Future studies aimed at understanding the causes of this 
observed social change (i.e. reduced treatment disparities) are warranted.  Understanding 
the root cause of the reduced treatment disparities observed in this study could potentially 
be used to reduce treatment disparities in other cancer populations.   
 Although disparities in treatment based on race, SES, and neighborhood were not 
observed, I did demonstrate, in this study, differences in adjunct monoclonal antibody 
treatment rate based on reporting registry and age at diagnosis.  The age at diagnosis 
disparity replicates results found in two other studies and highlights the need for 
interventions (at the policy or practice level) to improve access to monoclonal antibody 
therapy for those of advanced age.  Additionally, the regional differences in monoclonal 
antibody treatment rate demonstrated by the reporting registry differences highlight the 
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need to understand treatment patterns at a regional level across the United States.  
Remediation in the form of policies to improve access could help increase monoclonal 
antibody treatment rates in low treatment rate regions.   
 Finally, the study uncovered an overall decline in the percent of elderly metastatic 
colorectal cancer patients given first line chemotherapy who received adjunct monoclonal 
antibody therapy (8% decline from 2007 to 2011).  Monoclonal antibodies are efficacious 
and safe. Therefore, this study highlights the need for additional research into adjunct 
monoclonal antibody treatment patterns and prescribing habits.  Understanding this 
unexpected decline in adjunct monoclonal antibody treatment rates could illicit social 
change by improving antibody treatment rates and, in turn, colorectal cancer survival. 
Conclusion 
Previous research highlighted social disparities in colorectal cancer treatment that, 
in part, explained disparities in colorectal cancer survival.  However, all previous 
research looked at conventional therapies (chemotherapy, radiation, surgery) in the 
general colorectal cancer population.  This research project was unique in that it explored 
disparities in adjunct monoclonal antibody treatment within a specific population of 
elderly metastatic colorectal cancer patients.  In this study, race, SES, and neighborhood 
characteristics were not associated with adjunct monoclonal antibody therapy.   The 
results demonstrate a potential improvement in historically documented colorectal cancer 
treatment disparities.  Specifically, historical treatment disparities may not be relevant to 
newer therapies prescribed to patients with severe disease.  The difference could be 
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related to improved access to care or a change in treatment paradigm due specifically to 
the severity of metastatic colorectal cancer.  Future studies aimed at understanding the 
causes of this social change (i.e. reduced treatment disparities) are warranted.  
Understanding the root cause of the reduced treatment disparities observed in this study 
could potentially be used to reduce treatment disparities in other cancer populations. 
I accepted the null hypothesis for all three research questions.  However, two 
covariates (reporting registry and age at diagnosis) did significantly predict adjunct 
monoclonal antibody treatment rate.  The age at diagnosis disparity in monoclonal 
antibody treatment of metastatic colorectal cancer patients supports previous findings by 
Fu et al. (2013) and Kozloff et al. (2010).  In addition, two other findings were 
uncovered.  First, the number of Black American individuals in the cohort doubled from 
2007 to 2011.  The most likely cause, assuming insurance enrollment is stable in the 
population, is an increase in first-line chemotherapy rate.  This is encouraging and should 
be explored further.  Additionally, over the years of this study (2007 - 2011) there was an 
8% decline in the overall rate of monoclonal antibody treatment.  Monoclonal antibodies 
have been shown to be safe and efficacious when added to chemotherapy.  Given that all 
the individuals in the cohort received chemotherapy (which has multiple side effects), the 
low treatment rate and specifically the decline in adjunct monoclonal antibody treatment 
(which has been shown to be safe and effective) was unexpected.  Further research into 
prescribing habits and who receives adjunct monoclonal antibody therapy is warranted.  
One potential topic for further research is the perceived cost-effectiveness of monoclonal 
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antibodies for metastatic colorectal cancer.  This could be explored from both provider 
and the patient angles.  If an explanation for the low and declining rate of monoclonal 
antibody treatment is found, policies or support systems could be put into place to 
increase adjunct monoclonal treatment rates and possibly increase survival rates for 
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Appendix C: Power Analyses  
Logistic regression – A priori: Compute required sample size – given α, power and effect 
size: SES Input/Output Table 
 
Input Parameters: 
Tail(s) = Two 
Odds ratio = 1.15 
Pr(Y=1 I X = 1) H0 = 0.306 
α err prob = 0.05 
Power (1-β err prob) = 0.50 
R2 other X = 0.09 
X distribution = Normal 
X parm υ = 0 
X parm σ = 1 
 
Output: 
Critical z = 1.96 
Total sample size = 1029 
Actual power = 0.500 
 
Logistic regression – A priori: Compute required sample size – given α, power and effect 




Tail(s) = Two 
Odds ratio = 0.85 
Pr(Y=1 I X = 1) H0 = 0.306 
α err prob = 0.05 
Power (1-β err prob) = 0.50 
R2 other X = 0.09 
X distribution = Normal 
X parm υ = 0 
X parm σ = 1 
 
Output: 
Critical z = 1.96 
Total sample size = 764 
Actual power = 0.500 
 
Logistic regression – A priori: Compute required sample size – given α, power and effect 
size: Rural/Urban Neighborhood  
Input Parameters: 
Tail(s) = Two 
Odds ratio = 0.84 
Pr(Y=1 I X = 1) H0 = 0.306 
α err prob = 0.05 
Power (1-β err prob) = 0.50 
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R2 other X = 0.09 
X distribution = Normal 
X parm υ = 0 
X parm σ = 1 
 
Output: 
Critical z = 1.96 
Total sample size = 666 





Appendix D:  Database Generation and Cohort Selection Code (Organized by File 
Generated) 
Steps used to compile the study cohort: 
1. Build the database (seer_create.sql; Appendix D):  Script that creates the database 
and tables for use on this project. 
2. Import the PEDSF data (seer_load_pedsf.py; Appendix D):  Python script that 
connects to the database ‘seer_db’ created above and then runs sql insert queries 
to load the data from the seer text files into the database. 
a. This script loaded the data from the pedsf.cancer.file01.txt and 
pedsf.cancer.file02.txt files into the PEDSF table. 
3. Import the Claims File data (seer_load_other.py; Appendix D): Python script that 
connects to the database ‘seer_db’ created above and then runs sql insert queries 
to load the data from the seer text files into the database. 
a. This script loaded the following datasets (each dataset has multiple files): 
i. Durable Medical Equipment files to the seer_db.DME table (files 
loaded: dme07.txt, dme08.txt, dme09.txt, dme10.txt, dme11.txt, 
dme12.txt) 
ii. Part D Event files to the seer_db.PDE table (files loaded: 




iii. Carrier Claims files to the seer_db.NCH table (files loaded: 
nch07.file001.txt, nch07.file002.txt,  nch07.file003.txt,  
nch07.file004.txt, nch07.file005.txt,  nch07.file006.txt,  
nch07.file007.txt, nch08.file001.txt, nch08.file002.txt, 
nch08.file003.txt, nch08.file004.txt, nch08.file005.txt, 
nch08.file006.txt, nch08.file007.txt, nch08.file008.txt, 
nch09.file001.txt, nch09.file002.txt,  nch09.file003.txt,  
nch09.file004.txt, nch09.file005.txt,  nch09.file006.txt,  
nch09.file007.txt, nch09.file008.txt, nch10.file001.txt, 
nch10.file002.txt,  nch10.file003.txt,  nch10.file004.txt, 
nch10.file005.txt,  nch10.file006.txt,  nch10.file007.txt, 
nch10.file010.txt, nch11.file001.txt, nch11.file002.txt,  
nch11.file003.txt,  nch11.file004.txt, nch11.file005.txt,  
nch11.file006.txt,  nch11.file007.txt, nch11.file008.txt, 
nch12.file001.txt, nch12.file002.txt,  nch12.file003.txt,  
nch12.file004.txt, nch12.file005.txt,  nch12.file006.txt) 
iv. Outpatient claims files to the seer_db.OUTPATIENT table (files 
loaded: outsaf07.file001.txt, outsaf07.file002.txt, 
outsaf07.file003.txt, outsaf07.file004.txt, outsaf07.file005.txt, 
outsaf08.file001.txt, outsaf08.file002.txt, outsaf08.file003.txt, 
outsaf08.file004.txt, outsaf08.file005.txt, outsaf08.file006.txt, 
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outsaf09.file001.txt, outsaf09.file002.txt, outsaf09.file003.txt, 
outsaf09.file004.txt, outsaf09.file005.txt, outsaf09.file006.txt, 
outsaf10.file001.txt, outsaf10.file002.txt, outsaf10.file003.txt, 
outsaf10.file004.txt, outsaf10.file005.txt, outsaf10.file006.txt, 
outsaf10.file007.txt, outsaf11.file001.txt, outsaf11.file002.txt, 
outsaf11.file003.txt, outsaf11.file004.txt,outsaf11.file005.txt, 
outsaf11.file006.txt, outsaf11.file007.txt, outsaf12.file001.txt, 
outsaf12.file002.txt, outsaf12.file003.txt, outsaf12.file004.txt, 
outsaf12.file005.txt, outsaf12.file006.txt) 
4. Execute SQL queries to select data based on inclusion and exclusion criteria 
(seer_queries.sql; Appendix D):  The selection process is described below. 
a. Filters claim data to only those matching Chemotherapy or Monoclonal 
antibody NDC or HCPCS codes needed for this research study. 
b. Filters claim data to first claim after diagnosis. 
c. Combines filtered claim data and pedsf data into one master table 
d. Adds a ‘diagnosis_date’ column which is the last day of the month in 
which the patient was diagnosed. This date is combination of 
smPEDSF.date_yr and smPEDSF.date_mo.  
5. Database export (export_master_view.sh; Appendix D): BASH script - runs a 
simple SELECT query to export the seer_db.master_view to master_table.txt 
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6. Pre-SPSS processing (update_master_table.py; Appendix D):  Python script – 
computes and adds five columns to the master_table.txt and saves it as 
master_table_updated.txt.  Columns added are below. 
a. days – The number days between first chemotherapy treatment and first 
monoclonal antibody treatment. 
b. first_chemo – The date of the first chemotherapy treatment for that patient  
c. chemo_type – The type (ex. hcpcs code) for the first chemotherapy 
treatment 
d. first_ma -  The date of the first monoclonal antibody treatment for that 
patient 
e. ma_type – The type (ex. hcpcs code) for first monoclonal antibody 
treatment 
Code used to generate the study cohort: 
seer_build.py 
# -*- coding: utf-8 -*- 
# seer_build.py 
# MySQL Workbench Python script 
# Written in MySQL Workbench 6.3.2 
# Author: Andrew Schroeder, May 2015 
# Description: Connects to MySQL server and execute s 'seer_create.sql' 
#   SQL script to create the seer_db 
 
import mysql .connector 




PATH_TO_FILE = "seer_create.sql"  
 
try: 
    cnx = mysql .connector .connect (user ='root' ,  
        password ='' , host ='localhost' ) 
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except mysql .connector .Error as err : 
    if err .errno == errorcode .ER_ACCESS_DENIED_ERROR: 
        print("Something is wrong with your user name or password " ) 
    elif err .errno == errorcode .ER_BAD_DB_ERROR: 
        print("Database does not exist" ) 
    else: 
        print(err ) 
    sys .exit (1) 
 
cursor = cnx .cursor () 
sql = ""  
for line in open (PATH_TO_FILE): 
    ln = line .rstrip () 
    if re .match ("^--.*" , ln ): 
        pass 
    elif re .match ("^\s*$" , ln ): 
        pass 
    else: 
        sql += " "  + ln 
 
for q in sql .split (";" ): 
    if q == "" : 
        pass 
    else: 
        print (q + ";" ) 
        cursor .execute (q + ";" ) 
cnx .close () 
 
seer_load_pedsf.py 
# -*- coding: utf-8 -*- 
# seer_load_pedsf.py 
# MySQL Workbench Python script 
# Written in MySQL Workbench 6.3.2 
# Author: Andrew Schroeder  May 2nd 2015 
 
import mysql .connector 





    patient_id = 0 
    registry = 1 
    race = 2 
 
PEDSF_1_FILE = "/samba/seer/data/pedsf.cancer.file01.txt"  
PEDSF_2_FILE = "/samba/seer/data/pedsf.cancer.file02.txt"  
pedsf_tbl_cols = ['patient_id' , 'reporting_id' , 'rac_recb' ,  
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    'census_pov_ind' , 'urbrur' , 'm_sex' , 'birthyr' , 'age_dx' , 
'date_yr' ,  
    'date_mo' , 'rsncd1' , 'seq_num' , 'ptbcnt_2007' , 'ptbcnt_2008' , 
    'ptbcnt_2009' , 'ptbcnt_2010' , 'ptbcnt_2011' , 'ptbcnt_2012' , 
    'hmocnt_2007' , 'hmocnt_2008' , 'hmocnt_2009' , 
    'hmocnt_2010' , 'hmocnt_2011' , 'hmocnt_2012' ,  
    'ptd_2007' , 'ptd_2008' , 'ptd_2009' , 'ptd_2010' , 'ptd_2011' , 
'ptd_2012' , 
    'cs_met_1' , 'cs_met_2' , 'cs_met_3' , 'cs_met_4' , 'cs_met_5' , 
    'cs_met_6' , 'cs_met_7' , 'cs_met_8' , 'cs_met_9' , 'cs_met_10' ] 
pedsf_txt_cols =  
    [ 
    [1,10],[1,2],[101,2],[146,1],[97,1],[41,1], 
    [37,4],[1881,3],[1888,4],[1886,2], 
    #rsncd1  
    [43,1],[1884,2], 
    #ptbcnt 2007-2012  
    [1252,2],[1296,2],[1340,2],[1384,2],[1428,2],[1472,2], 
    #hmocnt 2007-2013  
    [1254,2],[1298,2],[1342,2],[1386,2],[1430,2],[1474,2], 
    #ptd 2007 - 2012  
    [261,2],[301,2],[341,2],[381,2],[421,2],[461,2], 
    # cs_mets  
    [1953,2],[2253,2],[2553,2],[2853,2],[3153,2],[3453,2], 
    [3753,2],[4053,2],[4353,2],[4653,2] 
    ] 
             
def slice (string , start , length ): 
    s = start - 1 #adjust for zero based list  
    return string [s:s+length ].strip () 
 
def insert_table (cursor , table_name , line , table_cols , text_cols ): 
    col_data = [] 
        tbl_cols = [] 
        count = 0 
    for tcol in text_cols : 
        data =slice (line ,tcol [0],tcol [1]) 
            if data != "" : 
                tbl_cols .append (table_cols [count ]) 
                #print table_cols[count] +": " + data  
        col_data .append (data ) 
            count +=1 
 
        table_string = ("INSERT INTO "  +  
            table_name + " ("  + "," .join (tbl_cols ))   
        table_string += ") VALUES ("  + ("%s,"  * (len (tbl_cols )-1)) + 
"%s)"  
    cursor .execute ((table_string ), col_data ) 
 
 
def insert_pdesaf (cursor , line , year ): 
    cols = [] 
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    cols .append (slice (line ,0,10)) 
    cols .append (slice (line ,0,2)) 
    cols .append (slice (line ,101,2)) 
    cols .append (slice (line ,146,1)) 
    cols .append (slice (line ,97,1)) 
    cols .append (slice (line ,41,1)) 
    cols .append (slice (line ,37,4)) 
    cols .append (slice (line ,1881,3)) 
    cols .append (slice (line ,1888,4)) 
    cols .append (slice (line ,1886,2)) 
    #rsncd1  
    cols .append (slice (line ,43,1)) 
    cols .append (slice (line ,1884,2)) 
    #ptbcnt 2007-2013  
    cols .append (slice (line ,1252,2)) 
    cols .append (slice (line ,1296,2)) 
    cols .append (slice (line ,1340,2)) 
    cols .append (slice (line ,1384,2)) 
    cols .append (slice (line ,1428,2)) 
    cols .append (slice (line ,1472,2)) 
    #hmocnt 2007-2013  
    cols .append (slice (line ,1254,2)) 
    cols .append (slice (line ,1298,2)) 
    cols .append (slice (line ,1342,2)) 
    cols .append (slice (line ,1386,2)) 
    cols .append (slice (line ,1430,2)) 
    cols .append (slice (line ,1474,2)) 
    #ptd 2007 - 2013  
    cols .append (slice (line ,261,2)) 
    cols .append (slice (line ,301,2)) 
    cols .append (slice (line ,341,2)) 
    cols .append (slice (line ,381,2)) 
    cols .append (slice (line ,421,2)) 
    cols .append (slice (line ,461,2)) 
    # cs_mets  
    cols .append (slice (line ,1953,2)) 
    cols .append (slice (line ,2253,2)) 
    cols .append (slice (line ,2553,2)) 
    cols .append (slice (line ,2853,2)) 
    cols .append (slice (line ,3153,2)) 
    cols .append (slice (line ,3453,2)) 
    cols .append (slice (line ,3753,2)) 
    cols .append (slice (line ,4053,2)) 
    cols .append (slice (line ,4353,2)) 
    cols .append (slice (line ,4653,2)) 




    cnx = mysql .connector .connect ( 
        user ='root' , password ='' ,  
        host ='localhost' ,database ='seer_db' ) 
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except mysql .connector .Error as err : 
    if err .errno == errorcode .ER_ACCESS_DENIED_ERROR: 
        print("Something is wrong with your user name or password " ) 
    elif err .errno == errorcode .ER_BAD_DB_ERROR: 
        print("Database does not exist" ) 
    else: 
        print(err ) 
    sys .exit (1) 
 
cursor = cnx .cursor () 
cursor .execute ("truncate PEDSF;" ) 
 
count = 0 
with open (PEDSF_1_FILE) as infile : 
    for line in infile : 
        insert_table (cursor ,"PEDSF",line ,pedsf_tbl_cols ,pedsf_txt_cols ) 
    count +=1 
        if count % 500  == 0: 
             print count 
with open (PEDSF_2_FILE) as infile : 
    for line in infile : 
        insert_table (cursor ,"PEDSF",line ,pedsf_tbl_cols ,pedsf_txt_cols ) 
    count +=1 
        if count % 500  == 0: 
             print count 
cnx .commit () 
cursor .close () 




# -*- coding: utf-8 -*- 
# seer_load_other.py 
# MySQL Workbench Python script 
# Written in MySQL Workbench 6.3.2 
# Author: Andrew Schroeder  May 2nd 2015 
 
import mysql .connector 





# constants and data  
###########################################  
DATA_PATH = "/samba/seer/data"  
 
DME_FILES = [] 
for i in range (7,13): 
    DME_FILES .append ('dme{:02d}.txt' .format (i )) 
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dme_tbl_cols = ['patient_id' , 'hcpcs' , 'ndc_cd' , 'claim_from_date' ] 
dme_txt_cols = [[1,10],[93,5],[409,11],[32,8]] 
 
PDE_FILES = [] 
for i in range (7,13): 
    PDE_FILES .append ('pdesaf{:02d}.txt' .format (i )) 
pde_tbl_cols = ['patient_id' , 'brand' , 'prod_srvc_id' , 'service_date' ] 
pde_txt_cols = [[1,10],[90,30],[35,11],[27,8]] 
 
nch_file_rages = [0,1,2,3,4,5,7,8,9,9,9,9,7] 
NCH_FILES = [] 
for i in range (7,13): 
    for j in range (1,nch_file_rages [i ]): 
        NCH_FILES .append ('nch{:02d}.file{:03d}.txt' .format (i , j )) 
nch_tbl_cols = ['patient_id' , 'hcpcs' , 'claim_from_date' ] 
nch_txt_cols = [[1,10],[93,5],[32,8]] 
 
op_file_rages = [0,1,2,3,4,5,6,6,7,7,8,8,7] 
OP_FILES = [] 
for i in range (7,13): 
    for j in range (1,op_file_rages [i ]): 
        OP_FILES .append ('outsaf{:02d}.file{:03d}.txt' .format (i , j )) 
op_tbl_cols = ['patient_id' , 'hcpcs' , 'claim_from_date' ] 
op_txt_cols = [[1,10],[241,5],[32,8]] 
 
progress_text = "Row Count: {:}\t\tTable: {:%}\t\tTotal: {:%}\r"  
 
###########################################  
#   functions  
###########################################  
def calc_num_records (FILES ): 
    record_size = 0 
    records = 0 
    for file in FILES : 
        path = os .path .join (DATA_PATH,file ) 
        if record_size == 0: 
            with open (path ) as infile : 
                record_size = len (infile .readline ()) 
                 
        if not os .path .isfile (path ):  
            print "Error {0} does not exist!" .format (path ) 
            sys .exit (1) 
         
        if record_size != 0: 
            records += os .path .getsize (path ) / record_size 
    return records 
             
def slice (string , start , length ): 
    s = start - 1 #adjust for zero based list  
    return string [s:s+length ].strip () 
 
def insert_table (cursor , table_name , line , table_cols , text_cols ): 
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    col_data = [] 
    tbl_cols = [] 
    count = 0 
    for tcol in text_cols : 
        data =slice (line ,tcol [0],tcol [1]) 
        #convert from MMDDYYYY to YYYYMMDD  
        if table_cols [count ] == 'claim_from_date'  or 
            table_cols [count ] == 'service_date' : 
            date = data [4:] + "-"  + data [:2]  + "-"  + data [2:4] 
            data = date 
        if data != "" : 
            tbl_cols .append (table_cols [count ]) 
            col_data .append (data ) 
        count +=1 
 
    table_string = "INSERT INTO "  + table_name + " ("  + 
"," .join (tbl_cols )   
    table_string += ") VALUES ("  + ("%s,"  * (len (tbl_cols )-1)) + "%s)"  
    cursor .execute ((table_string ), col_data ) 
 
###########################################  
# main script body  
###########################################     
 
# Connect to database  
try: 
    cnx = mysql .connector .connect (user ='root' , password ='' ,  
        host ='localhost' ,database ='seer_db' ) 
except mysql .connector .Error as err : 
    if err .errno == errorcode .ER_ACCESS_DENIED_ERROR: 
        print("Something is wrong with your user name or password " ) 
    elif err .errno == errorcode .ER_BAD_DB_ERROR: 
        print("Database does not exist" ) 
    else: 
        print(err ) 
    sys .exit (1) 
 
# open data files and count the number of records  
#   (used for progress reporting)  
dme_records = calc_num_records (DME_FILES) 
print "DME Records: {0}" .format (dme_records ) 
pde_records = calc_num_records (PDE_FILES) 
print "PDE Records: {0}" .format (pde_records ) 
nch_records = calc_num_records (NCH_FILES) 
print "NCH Records: {0}" .format (nch_records ) 
op_records = calc_num_records (OP_FILES) 
print "OP Records: {0}" .format (op_records ) 
 
#import the DME data to the DME table  
cursor = cnx .cursor () 
cursor .execute ("truncate DME;" ) 
total_progress = 0 
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total_records = dme_records + pde_records + nch_records + op_records 
count = 0 
for file in DME_FILES: 
    with open (os.path .join (DATA_PATH, file )) as infile : 
        for line in infile : 
            insert_table (cursor ,"DME",line ,dme_tbl_cols ,dme_txt_cols ) 
            count +=1 
            if count % 5000  == 0: 
                sys .stdout .write ( 
                   progress_text .format ( 
                        count , float (count )/float (dme_records ), 
                        float (total_progress + count )  
                        / float (total_records ) )) 
                sys .stdout .flush () 
cnx .commit () 
print "DME table committed."  
 
#import the PDE data to the PDE table  
cursor .execute ("truncate PDE;" ) 
total_progress += count 
count = 0 
for file in PDE_FILES : 
    with open (os.path .join (DATA_PATH, file )) as infile : 
        for line in infile : 
            insert_table (cursor ,"PDE" ,line , pde_tbl_cols ,pde_txt_cols ) 
            count +=1 
            if count % 5000  == 0: 
                sys .stdout .write ( 
                    progress_text .format ( 
                        count , float (count )/float (dme_records ), 
                        float (total_progress + count )  
                        / float (total_records ) )) 
                sys .stdout .flush () 
cnx .commit () 
print "PDE table committed."  
 
#import the NCH data to the NCH table  
cursor .execute ("truncate NCH;" ) 
total_progress += count 
count = 0 
for file in NCH_FILES : 
    with open (os.path .join (DATA_PATH, file )) as infile : 
        for line in infile : 
            insert_table (cursor ,"NCH",line ,nch_tbl_cols ,nch_txt_cols ) 
            count +=1 
            if count % 5000  == 0: 
                 sys .stdout .write ( 
                    progress_text .format ( 
                        count , float (count )/float (dme_records ), 
                        float (total_progress + count )  
                        / float (total_records ) )) 
                 sys .stdout .flush () 
221 
 
cnx .commit () 
print "NCH table committed."  
 
#import the outpatient data into the OUTPATIENT dat abase  
cursor .execute ("truncate OUTPATIENT;" ) 
total_progress += count 
count = 0 
for file in OP_FILES : 
    with open (os.path .join (DATA_PATH, file )) as infile : 
        for line in infile : 
            
insert_table (cursor ,"OUTPATIENT",line ,op_tbl_cols ,op_txt_cols ) 
            count +=1 
            if count % 5000  == 0: 
                 sys .stdout .write ( 
                    progress_text .format ( 
                        count , float (count )/float (dme_records ), 
                        float (total_progress + count )  
                        / float (total_records ) )) 
                 sys .stdout .flush () 
cnx .commit () 
print "OUTPATIENT table committed."  
 
cursor .close () 
cnx .close () 
 
update_master_table.py 
# -*- coding: utf-8 -*- 
# update_master_table.py 




from datetime import datetime 
 
class COLS: 
    patient_id = 0 
    reporting_id = 1 
    rac_recb = 2 
    census_pov_ind = 3 
    urbrur = 4 
    m_sex = 5 
    date_yr = 6 
    date_mo = 7 
    birthyr = 8 
    age_dx = 9 
    rsncd1 = 10 
    cs_met_1 = 11 
    diagnosis_date = 12 
    ccDME_hcpcs = 13 
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    ccDME_claim_date = 14 
    ccDME_ndc_cd = 15 
    mmDME_hcpcs = 16 
    mmDME_claim_date = 17 
    mmDME_ndc_cd = 18 
    ccNCH_hcpcs = 19 
    ccNCH_claim_date = 20  
    mmNCH_hcpcs = 21 
    mmNCH_claim_date = 22 
    ccOP_hcpcs = 23 
    ccOP_claim_date = 24  
    mmOP_hcpcs = 25 
    mmOP_claim_date = 26 
    mmPDE_brand = 27 
    mmPDE_srvc_date = 28 
    mmPDE_prod_srvc_id = 29 
 
 
MASTER_FILE_IN = "master_table.txt"  
MASTER_FILE_OUT = "master_table_updated.txt"  
 
future_date = datetime .strptime ('2025-01-01' , "%Y-%m-%d") 
 
count = 0 
with open (MASTER_FILE_OUT, 'w' ) as outfile : 
    with open (MASTER_FILE_IN) as infile : 
        outfile .write (  
            next (infile ).rstrip () + "\t" .join ( 
            ["" ,"days" ,"first_chemo" ,"chemo_type" , "first_ma" , 
"ma_type" ]) 
            + "\n" ) 
        for line in infile : 
 
            cols = line .split () 
            print("{0}, {1}, {2}" .format ( 
                cols [COLS.ccDME_claim_date ], 
                cols [COLS.ccNCH_claim_date ], 
                cols [COLS.ccOP_claim_date ])) 
            # chemo data        
            if cols [COLS.ccDME_claim_date ] == 'NULL' : 
                date1 = future_date 
                data = "NULL"  
            else: 
                date1 = datetime .strptime ( 
                    cols [COLS.ccDME_claim_date ], "%Y-%m-%d") 
                 
            if cols [COLS.ccNCH_claim_date ] == 'NULL' : 
                date2 = future_date 
            else: 
                date2 = datetime .strptime ( 
                    cols [COLS.ccNCH_claim_date ], "%Y-%m-%d") 
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            if cols [COLS.ccOP_claim_date ] == 'NULL' : 
                date3 = future_date 
            else: 
                date3 = datetime .strptime ( 
                    cols [COLS.ccOP_claim_date ], "%Y-%m-%d") 
              
 
            if  not (date1 > date2 or date1 > date3 ): 
                date_out = date1 
                if cols [COLS.ccDME_ndc_cd ] != "NULL" : 
                    data_out = cols [COLS.ccDME_ndc_cd ] 
                else: 
                    data_out = cols [COLS.ccDME_hcpcs ] 
            elif not (date2 > date1 or date2 > date3 ): 
                date_out = date2 
                data_out = cols [COLS.ccNCH_hcpcs ] 
                 
            elif not (date3 > date2 or date3 > date1 ): 
                date_out = date3 
                data_out = cols [COLS.ccOP_hcpcs ] 
                 
            # ma data  
            if cols [COLS.mmDME_claim_date ] == 'NULL' : 
                ma_date1 = future_date 
                ma_data = "NULL"  
            else: 
                ma_date1 = datetime .strptime ( 
                    cols [COLS.mmDME_claim_date ], "%Y-%m-%d") 
                 
            if cols [COLS.mmNCH_claim_date ] == 'NULL' : 
                ma_date2 = future_date 
            else: 
                ma_date2 = datetime .strptime ( 
                    cols [COLS.mmNCH_claim_date ], "%Y-%m-%d") 
                 
            if cols [COLS.mmOP_claim_date ] == 'NULL' : 
                ma_date3 = future_date 
            else: 
                ma_date3 = datetime .strptime ( 
                    cols [COLS.mmOP_claim_date ], "%Y-%m-%d") 
             
            if cols [COLS.mmPDE_srvc_date ] == 'NULL' : 
                ma_date4 = future_date 
            else: 
                ma_date4 = datetime .strptime ( 
                    cols [COLS.mmPDE_srvc_date ], "%Y-%m-%d")             
                 
              
 
            if  not (ma_date1 > ma_date2 or 
                    ma_date1 > ma_date3 or 
                    ma_date1 > ma_date4 ): 
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                ma_date_out = ma_date1 ; 
                if cols [COLS.mmDME_ndc_cd] != "NULL" : 
                    ma_data_out = cols [COLS.mmDME_ndc_cd] 
                else: 
                    ma_data_out = cols [COLS.mmDME_hcpcs] 
            elif not (ma_date2 > ma_date1 or 
                    ma_date2 > ma_date3 or 
                    ma_date2 > ma_date4 ): 
                ma_date_out = ma_date2 ; 
                ma_data_out = cols [COLS.mmNCH_hcpcs]                 
            elif not (ma_date3 > ma_date1 or 
                    ma_date3 > ma_date2 or 
                    ma_date3 > ma_date4 ): 
                ma_date_out = ma_date3 ; 
                ma_data_out = cols [COLS.mmOP_hcpcs] 
            elif not (ma_date4 > ma_date1 or 
                    ma_date4 > ma_date2 or 
                    ma_date4 > ma_date3 ): 
                ma_date_out = ma_date4 ; 
                if cols [COLS.mmPDE_brand] != "NULL" : 
                    ma_data_out = cols [COLS.mmPDE_brand] 
                else: 
                    ma_data_out = cols [COLS.mmPDE_prod_srvc_id ] 
            else: 
                print ('This should not happen' ) 
                sys .exit (1) 
             
             
            if date_out == future_date or 
                cols [COLS.diagnosis_date ] == "NULL" : 
                days_out = "NULL"  
                date_out = "NULL"  
            else: 
                diagnosis_date = datetime .strptime ( 
                    cols [COLS.diagnosis_date ], "%Y-%m-%d") 
                elapsed = date_out - diagnosis_date 
                days_out = elapsed .days 
                date_out = date_out .strftime ("%Y-%m-%d") 
 
             
            if ma_date_out == future_date or 
                    cols [COLS.diagnosis_date ] == "NULL" : 
                ma_days_out = "NULL"  
                ma_date_out = "NULL"  
            else: 
                diagnosis_date = datetime .strptime ( 
                    cols [COLS.diagnosis_date ], "%Y-%m-%d") 
                ma_elapsed = ma_date_out - diagnosis_date 
                ma_days_out = ma_elapsed .days 
                ma_date_out = ma_date_out .strftime ("%Y-%m-%d") 
             
            newline = line .rstrip () + "\t" .join ( 
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                                            ['' ,str (days_out ), 
                                            date_ou t ,data_out , 
                                            ma_date _out , 
                                            ma_data _out ]) 
            print(newline ) 
             
            outfile .write (newline + "\n" ) 
            count +=1 
 
seer_create.sql 
-- MySQL Script generated by MySQL Workbench 
-- seer_create.sql 
-- 05/01/15 17:33:43 
-- MySQL Workbench Forward Engineering 
 
SET @OLD_UNIQUE_CHECKS=@@UNIQUE_CHECKS, UNIQUE_CHECKS=0; 




-- ------------------------------------------------ ----- 
-- Schema seer_db 
-- ------------------------------------------------ ----- 
DROP SCHEMA IF EXISTS `seer_db` ; 
 
-- ------------------------------------------------ ----- 
-- Schema seer_db 
-- ------------------------------------------------ ----- 
CREATE SCHEMA IF NOT EXISTS `seer_db`  
DEFAULT CHARACTER SET utf8 COLLATE utf8_general_ci ; 
USE `seer_db` ; 
 
-- ------------------------------------------------ ----- 
-- Table `seer_db`.`PEDSF` 
-- ------------------------------------------------ ----- 
DROP TABLE IF EXISTS `seer_db` .`PEDSF` ; 
 
CREATE TABLE IF NOT EXISTS `seer_db` .`PEDSF` ( 
  `idPEDSF` INT NOT NULL AUTO_INCREMENT, 
  `patient_id` VARCHAR(10) NULL, 
  `reporting_id` VARCHAR(2) NULL, 
  `rac_recb` TINYINT(2) UNSIGNED NULL, 
  `census_pov_ind` TINYINT(1) UNSIGNED NULL, 
  `urbrur` TINYINT(1) UNSIGNED NULL, 
  `m_sex` TINYINT(1) UNSIGNED NULL, 
  `birthyr` YEAR NULL, 
  `age_dx` TINYINT(3) UNSIGNED NULL, 
  `date_yr` YEAR NULL, 
  `date_mo` TINYINT(2) UNSIGNED NULL, 
  `rsncd1` TINYINT(1) UNSIGNED NULL, 
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  `seq_num` TINYINT(2) UNSIGNED NULL, 
  ` year` YEAR NULL, 
  `ptbcnt_2007` TINYINT(2) NULL, 
  `ptbcnt_2008` TINYINT(2) NULL, 
  `ptbcnt_2009` TINYINT(2) NULL, 
  `ptbcnt_2010` TINYINT(2) NULL, 
  `ptbcnt_2011` TINYINT(2) NULL, 
  `ptbcnt_2012` TINYINT(2) NULL, 
  `hmocnt_2007` TINYINT(2) NULL, 
  `hmocnt_2008` TINYINT(2) NULL, 
  `hmocnt_2009` TINYINT(2) NULL, 
  `hmocnt_2010` TINYINT(2) NULL, 
  `hmocnt_2011` TINYINT(2) NULL, 
  `hmocnt_2012` TINYINT(2) NULL, 
  `ptd_2007` TINYINT(2) NULL, 
  `ptd_2008` TINYINT(2) NULL, 
  `ptd_2009` TINYINT(2) NULL, 
  `ptd_2010` TINYINT(2) NULL, 
  `ptd_2011` TINYINT(2) NULL, 
  `ptd_2012` TINYINT(2) NULL, 
  `cs_met_1` TINYINT(2) NULL, 
  `cs_met_2` TINYINT(2) NULL, 
  `cs_met_3` TINYINT(2) NULL, 
  `cs_met_4` TINYINT(2) NULL, 
  `cs_met_5` TINYINT(2) NULL, 
  `cs_met_6` TINYINT(2) NULL, 
  `cs_met_7` TINYINT(2) NULL, 
  `cs_met_8` TINYINT(2) NULL, 
  `cs_met_9` TINYINT(2) NULL, 
  `cs_met_10` TINYINT(2) NULL, 
  PRIMARY KEY (`idPEDSF` )) 
ENGINE = InnoDB ; 
 
 
-- ------------------------------------------------ ----- 
-- Table `seer_db`.`NCH` 
-- ------------------------------------------------ ----- 
DROP TABLE IF EXISTS `seer_db` .`NCH` ; 
 
CREATE TABLE IF NOT EXISTS `seer_db` .`NCH` ( 
  `idNCH` INT NOT NULL AUTO_INCREMENT, 
  `patient_id` VARCHAR(10) NOT NULL, 
  `hcpcs` VARCHAR(5) NULL, 
  `claim_from_date` DATE NOT NULL, 
  PRIMARY KEY (`idNCH` )) 
ENGINE = InnoDB ; 
 
 
-- ------------------------------------------------ ----- 
-- Table `seer_db`.`OUTPATIENT` 
-- ------------------------------------------------ ----- 




CREATE TABLE IF NOT EXISTS `seer_db` .`OUTPATIENT` ( 
  `idOUTPATIENT` INT NOT NULL AUTO_INCREMENT, 
  `patient_id` VARCHAR(10) NOT NULL, 
  `hcpcs` VARCHAR(5) NULL, 
  `claim_from_date` DATE NOT NULL, 
  PRIMARY KEY (`idOUTPATIENT` )) 
ENGINE = InnoDB ; 
 
 
-- ------------------------------------------------ ----- 
-- Table `seer_db`.`DME` 
-- ------------------------------------------------ ----- 
DROP TABLE IF EXISTS `seer_db` .`DME` ; 
 
CREATE TABLE IF NOT EXISTS `seer_db` .`DME` ( 
  `idDME` INT NOT NULL AUTO_INCREMENT, 
  `patient_id` VARCHAR(10) NOT NULL, 
  `hcpcs` VARCHAR(5) NULL, 
  `ndc_cd` VARCHAR(11) NULL, 
  `claim_from_date` DATE NOT NULL, 
  PRIMARY KEY (`idDME` )) 
ENGINE = InnoDB ; 
 
 
-- ------------------------------------------------ ----- 
-- Table `seer_db`.`PDE` 
-- ------------------------------------------------ ----- 
DROP TABLE IF EXISTS `seer_db` .`PDE` ; 
 
CREATE TABLE IF NOT EXISTS `seer_db` .`PDE` ( 
  `idPDE` INT NOT NULL AUTO_INCREMENT, 
  `patient_id` VARCHAR(10) NOT NULL, 
  `brand` VARCHAR(30) NULL, 
  `prod_srvc_id` VARCHAR(11) NULL, 
  `service_date` DATE NULL, 
  PRIMARY KEY (`idPDE` )) 
ENGINE = InnoDB ; 
 
SET SQL_MODE = '' ; 
GRANT USAGE ON *.* TO krista ; 
 DROP USER krista ; 
SET SQL_MODE='TRADITIONAL,ALLOW_INVALID_DATES' ; 
CREATE USER 'krista'  IDENTIFIED BY 'M#4806d#5656' ; 
 
GRANT ALL ON `seer_db` .* TO 'krista' ; 
GRANT SELECT ON TABLE `seer_db` .* TO 'krista' ; 
GRANT SELECT, INSERT, TRIGGER ON TABLE `seer_db` .* TO 'krista' ; 
GRANT SELECT, INSERT, TRIGGER, UPDATE,  










-- author: Andrew Schroeder 
-- May 5th, 2015 
 
-- NCH, OUTPATIENT, PDE, DME tables are filtered fo r specific criteria 
-- m, c, mm, cc prefixes are used to distinguish fi ltered results from 
-- original table. New tables are generated for per formance 
enhancements 
-- on final "master_view" queries 
 
-- c prefix indicates subset with matching chemothe rapy code 
-- cc prefix indicates subset of c with only first claim record  
--    after diagnosis_date 
-- m prefix indicated subset with matching monoclon al antibody code 
-- mm prefix indicates subset of m with only first claim record 
--    after diagnosis_date 
 
-- create "c" and "m" tables 
DROP TABLE IF EXISTS `seer_db` .`cNCH` ; 
CREATE TABLE cNCH AS 
     SELECT NCH.idNCH, NCH.patient_id , NCH.hcpcs , NCH.claim_from_date 
     FROM NCH 
     WHERE NCH.hcpcs IN ('J9190' ,'J8520' ,'J8521' , 
                        'J0640' ,'J9200' ,'J9263' ,'J9206' ); 
DROP TABLE IF EXISTS `seer_db` .`mNCH`; 
CREATE TABLE mNCH AS 
     SELECT NCH.idNCH, NCH.patient_id , NCH.hcpcs , NCH.claim_from_date 
     FROM NCH 
     WHERE NCH.hcpcs IN ('J9035' ,'J9055' ,'J9303' ); 
      
DROP TABLE IF EXISTS `seer_db` .`cOP` ; 
CREATE TABLE cOP AS 
     SELECT OUTPATIENT.idOUTPATIENT, OUTPATIENT.patient_id ,  
        OUTPATIENT .hcpcs , OUTPATIENT.claim_from_date 
     FROM OUTPATIENT 
     WHERE OUTPATIENT.hcpcs IN ('J9190' ,'J8520' ,'J8521' ,'J0640' , 
                                'J9200' ,'J9263' ,'J9206' ); 
DROP TABLE IF EXISTS `seer_db` .`mOP`; 
CREATE TABLE mOP AS 
     SELECT OUTPATIENT.idOUTPATIENT, OUTPATIENT.patient_id ,  
            OUTPATIENT .hcpcs , OUTPATIENT.claim_from_date 
     FROM OUTPATIENT 
     WHERE OUTPATIENT.hcpcs IN ('J9035' ,'J9055' ,'J9303' ); 
 
DROP TABLE IF EXISTS `seer_db` .`mPDE`; 
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CREATE TABLE mPDE AS 
    SELECT PDE.idPDE, PDE.patient_id , PDE.brand , PDE.prod_srvc_id ,  
           PDE .service_date 
    FROM PDE  
    WHERE brand IN ('AVASTIN' ,'ERBITUX' ,'VECTIBIX' ) OR  
          prod_srvc_id IN('5024206001' ,'50242006101' ,'66733094823' , 
                          '66733095823' ,'55513095401' ,'55513095601' ); 
 
DROP TABLE IF EXISTS `seer_db` .`cDME` ; 
CREATE TABLE cDME AS 
    SELECT DME.idDME, DME.patient_id , DME.hcpcs , DME.ndc_cd ,  
           DME .claim_from_date 
    FROM DME 
    WHERE DME.ndc_cd IN('00703301513' , '00703301812' , '00703301912' , 
          '10139006301' , '10139006310' , '10139006311' , '10139006312' ,  
          '10139006320' , '10139006350' , '63323011710' , '63323011720' , 
          '63323011751' , '63323011761' , '66758004401' , '66758004403' , 
          '00004110020' , '54868414300' , '54868414301' , '54868414302' , 
          '00004110150' , '00004110175' , '54868526000' , '54868526001' ,  
          '54868526002' , '54868526003' , '54868526004' , '54868526005' , 
          '54868526006' , '54868526007' , '54868526008' , '54868526009' , 
          '00703279301' , '00703279701' , '00703514001' , '00703514501' ,  
          '00703514591' , '00904231560' , '25021081310' , '25021081430' ,  
          '25021081530' , '25021081567' , '25021081630' , '25021081667' ,  
          '55390000901' , '55390005110' , '55390005210' , '55390005301' , 
          '55390005401' , '55390081810' , '55390082401' , '55390082501' ,  
          '55390082601' , '62701090030' , '62701090099' , '62701090125' ,  
          '63323071050' , '63323071100' , '55390013501' , '63323014507' , 
          '00024059010' , '00024059120' , '00024059240' , '00069006701' ,  
          '00069007001' , '00069007401' , '00069101001' , '00703398501' ,  
          '00703398601' , '25021021120' , '25021021250' , '41616017640' , 
          '41616017840' , '47335017640' , '47335017840' , '61703036318' ,  
          '61703036322' , '63323017530' , '63323017650' , '63323065010' ,  
          '63323065017' , '63323065020' , '63323065027' , '00009111101' ,  
          '00009111102' , '00009752901' , '00009752902' , '00009752903' ,  
          '00009752904' , '00009752905' , '00143970101' , '00143970201' ,  
          '00703443211' , '00703443411' , '10019093401' , '10019093402' ,  
          '10019093417' , '10019093479' , '10518010310' , '18111000202' ,  
          '18111000203' , '23155017931' , '23155017932' , '25021020002' ,  
          '25021020005' , '25021021402' , '25021021405' , '55390029501' ,  
          '55390029601' , '59762752902' , '61703034909' , '61703034916' ,  
          '61703034936' , '63323019302' , '63323019305' , '66758004801' ,  
          '66758004802' )  
          OR DME.hcpcs IN ('J9190' ,'J8520' ,'J8521' ,'J0640' , 
                           'J9200' ,'J9263' ,'J9206' ); 
DROP TABLE IF EXISTS `seer_db` .`mDME ;̀ 
CREATE TABLE mDME AS 
    SELECT DME.idDME, DME.patient_id , DME.hcpcs , DME.ndc_cd , 
           DME .claim_from_date 
    FROM DME 
    WHERE DME.ndc_cd IN( '50242006001' , '50242006101' , '66733094823' , 
                         '66733095823' , '55513095401' , '55513095601' )  
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          OR DME.hcpcs IN ('J9035' ,'J9055' ,'J9303' ); 
           
           
-- create "cc" and "mm" tables 
 
-- create ccDME, uses cDME_temp for simpler SQL 
DROP TABLE IF EXISTS `seer_db` .`cDME_temp` ; 
CREATE TABLE cDME_temp AS 
SELECT cDME.* 
FROM cDME 
INNER JOIN ( 
    SELECT cDME.patient_id ,MIN(cDME.claim_from_date ) as min_date 
    FROM cDME 
    GROUP BY cDME.patient_id ) tmp 
    ON cDME.patient_id = tmp .patient_id  
        AND cDME.claim_from_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`ccDME` ; 
CREATE TABLE ccDME AS 
SELECT c .* 
FROM cDME_temp c 
INNER JOIN ( 
    SELECT c .patient_id , MIN(c.idDME) as min_id 
    FROM cDME_temp c 
    GROUP BY c .patient_id ) tmp 
    ON c .patient_id = tmp .patient_id AND c .idDME = tmp .min_id ; 
     
-- create mmDME, uses mDME_temp for simpler SQL 
DROP TABLE IF EXISTS `seer_db` .`mDME_temp`; 
CREATE TABLE mDME_temp AS 
SELECT mDME.* 
FROM mDME 
INNER JOIN ( 
    SELECT mDME.patient_id ,MIN(mDME.claim_from_date ) as min_date 
    FROM mDME 
    GROUP BY mDME.patient_id ) tmp 
    ON mDME.patient_id = tmp .patient_id  
       AND mDME.claim_from_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`mmDME;̀ 
CREATE TABLE mmDME AS 
SELECT m.* 
FROM mDME_temp m 
INNER JOIN ( 
    SELECT m.patient_id , MIN(m.idDME) as min_id 
    FROM mDME_temp m 
    GROUP BY m.patient_id ) tmp 
    ON m.patient_id = tmp .patient_id AND m.idDME = tmp .min_id ;     
 
 
-- create ccNCH, uses cNCH_temp for simpler SQL 
DROP TABLE IF EXISTS `seer_db` .`cNCH_temp` ; 





INNER JOIN ( 
    SELECT cNCH.patient_id ,MIN(cNCH.claim_from_date ) as min_date 
    FROM cNCH 
    GROUP BY cNCH.patient_id ) tmp 
    ON cNCH.patient_id = tmp .patient_id  
       AND cNCH.claim_from_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`ccNCH` ; 
CREATE TABLE ccNCH AS 
SELECT c .* 
FROM cNCH_temp c 
INNER JOIN ( 
    SELECT c .patient_id , MIN(c.idNCH) as min_id 
    FROM cNCH_temp c 
    GROUP BY c .patient_id ) tmp 
    ON c .patient_id = tmp .patient_id AND c .idNCH = tmp .min_id ; 
 
-- create mmNCH, uses mNCH_temp for simpler SQL     
DROP TABLE IF EXISTS `seer_db` .`mNCH_temp`; 
CREATE TABLE mNCH_temp AS 
SELECT mNCH.* 
FROM mNCH 
INNER JOIN ( 
    SELECT mNCH.patient_id ,MIN(mNCH.claim_from_date ) as min_date 
    FROM mNCH 
    GROUP BY mNCH.patient_id ) tmp 
    ON mNCH.patient_id = tmp .patient_id  
       AND mNCH.claim_from_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`mmNCH;̀ 
CREATE TABLE mmNCH AS 
SELECT m.* 
FROM mNCH_temp m 
INNER JOIN ( 
    SELECT m.patient_id , MIN(m.idNCH) as min_id 
    FROM mNCH_temp m 
    GROUP BY m.patient_id ) tmp 
    ON m.patient_id = tmp .patient_id AND m.idNCH = tmp .min_id ;     
 
-- create ccOP, uses cOP_temp for simpler SQL 
DROP TABLE IF EXISTS `seer_db` .`cOP_temp` ; 
CREATE TABLE cOP_temp AS 
SELECT cOP .* 
FROM cOP 
INNER JOIN ( 
    SELECT cOP .patient_id ,MIN(cOP.claim_from_date ) as min_date 
    FROM cOP 
    GROUP BY cOP .patient_id ) tmp 
    ON cOP .patient_id = tmp .patient_id  
       AND cOP .claim_from_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`ccOP` ; 
CREATE TABLE ccOP AS 
SELECT c .* 
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FROM cOP_temp c 
INNER JOIN ( 
    SELECT c .patient_id , MIN(c.idOUTPATIENT) as min_id 
    FROM cOP_temp c 
    GROUP BY c .patient_id ) tmp 
    ON c .patient_id = tmp .patient_id AND c .idOUTPATIENT = tmp .min_id ; 
 
-- create mmOP, uses mOP_temp for simpler SQL     
DROP TABLE IF EXISTS `seer_db` .`mOP_temp` ; 
CREATE TABLE mOP_temp AS 
SELECT mOP.* 
FROM mOP 
INNER JOIN ( 
    SELECT mOP.patient_id ,MIN(mOP.claim_from_date ) as min_date 
    FROM mOP 
    GROUP BY mOP.patient_id ) tmp 
    ON mOP.patient_id = tmp .patient_id  
       AND mOP.claim_from_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`mmOP ;̀ 
CREATE TABLE mmOP AS 
SELECT m.* 
FROM mOP_temp m 
INNER JOIN ( 
    SELECT m.patient_id , MIN(m.idOUTPATIENT) as min_id 
    FROM mOP_temp m 
    GROUP BY m.patient_id ) tmp 
    ON m.patient_id = tmp .patient_id AND m.idOUTPATIENT = tmp .min_id ;     
 
-- create mmPDE, uses mPDE_temp for simpler SQL     
DROP TABLE IF EXISTS `seer_db` .`mPDE_temp` ; 
CREATE TABLE mPDE_temp AS 
SELECT mPDE.* 
FROM mPDE 
INNER JOIN ( 
    SELECT mPDE.patient_id ,MIN(mPDE.service_date ) as min_date 
    FROM mPDE 
    GROUP BY mPDE.patient_id ) tmp 
    ON mPDE.patient_id = tmp .patient_id  
       AND mPDE.service_date = tmp .min_date ;  
DROP TABLE IF EXISTS `seer_db` .`mmPDE ;̀ 
CREATE TABLE mmPDE AS 
SELECT m.* 
FROM mPDE_temp m 
INNER JOIN ( 
    SELECT m.patient_id , MIN(m.idPDE) as min_id 
    FROM mPDE_temp m 
    GROUP BY m.patient_id ) tmp 
    ON m.patient_id = tmp .patient_id AND m.idPDE = tmp .min_id ; 
     
-- create the master_view 
 




    smPEDSF .patient_id , smPEDSF.reporting_id , smPEDSF.rac_recb ,  
    smPEDSF .census_pov_ind , smPEDSF.urbrur , smPEDSF.m_sex, 
    smPEDSF .date_yr , smPEDSF.date_mo , smPEDSF.birthyr , smPEDSF.age_dx ,  
    smPEDSF .rsncd1 , smPEDSF.cs_met_1 , 
    LAST_DAY(CONCAT_WS('-' ,smPEDSF.date_yr ,smPEDSF.date_mo ,'1' ))  
        as `diagnosis_date` , 
    ccDME .hcpcs as ccDME_hcpcs , 
    ccDME .claim_from_date as ccDME_claim_date , 
    ccDME .ndc_cd as ccDME_ndc_cd , 
    mmDME .hcpcs as mmDME_hcpcs,  
    mmDME .claim_from_date as mmDME_claim_date ,  
    mmDME .ndc_cd as mmDME_ndc_cd, 
    ccNCH .hcpcs as ccNCH_hcpcs , 
    ccNCH .claim_from_date as ccNCH_claim_date , 
    mmNCH .hcpcs as mmNCH_hcpcs, 
    mmNCH .claim_from_date as mmNCH_claim_date ,  
    ccOP .hcpcs as ccOP_hcpcs , 
    ccOP .claim_from_date as ccOP_claim_date ,  
    mmOP .hcpcs as mmOP_hcpcs, 
    mmOP .claim_from_date as mmOP_claim_date ,  
    mmPDE .brand as mmPDE_brand,  
    mmPDE .service_date as mmPDE_srvc_date , 
    mmPDE .prod_srvc_id as mmPDE_prod_srvc_id 
FROM smPEDSF 
LEFT OUTER JOIN ccDME 
    ON smPEDSF.patient_id = ccDME.patient_id 
LEFT OUTER JOIN mmDME 
    ON smPEDSF.patient_id = mmDME.patient_id 
LEFT OUTER JOIN ccNCH 
    ON smPEDSF.patient_id = ccNCH.patient_id 
LEFT OUTER JOIN mmNCH 
    ON smPEDSF.patient_id = mmNCH.patient_id 
LEFT OUTER JOIN ccOP 
    ON smPEDSF.patient_id = ccOP .patient_id 
LEFT OUTER JOIN mmOP 
    ON smPEDSF.patient_id = mmOP.patient_id 
LEFT OUTER JOIN mmPDE 











Appendix E:  Variables Transferred to SPSS for Analysis 
 
• Ten digit patient ID (column #1 in the PEDSF document; patient_id)  
• Registry reporting the data (The first 2 digits in the patient ID; PEDSF column #1) 
• Race (column #101 of the PEDSF document; rac_recb) 
• Census Tract Poverty Indicator, measure of SES (column #146 of the PEDSF 
document; census_pov_ind)  
• PEDSF re-code of the 2003 Rural/Urban Continuum Codes (column #97 of the 
PEDSF document; urbrur)  
• Gender (PEDSF column #41; m_sex)  
• Year of birth (PEDSF file column #37) 
• Age at diagnosis (PEDSF column #1881) 
• Year of diagnosis (PEDSF column #1888) 
• Month of diagnosis (PEDSF column #1886) 
• Reason for original Medicare entitlement (PEDSF column #43) 
• Cancer sequence number (PEDSF column #1884) 
• Medicare Part B coverage months 2007-2011 (PEDSF columns #548 and below) 
• Medicare Part D coverage months 2007-2011 (PEDSF columns #221 and below) 
• Medicare managed care plan (Medicare Part C) coverage months 2007-2011 (PEDSF 
columns #550 and below; HMO Months).   
• Metastasis at Diagnosis (PEDSF column #1953; CS Mets at Dx)  
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• First Chemotherapy Claim and Date:  These are two computed variables (first_chemo 
and chemo_type) as in 6b and 6c in Appendix D above.  The variable first_chemo is 
the date of the first post diagnosis chemotherapy claim. The variable chemo_type is 
the NDC or HCPCS code for the first post diagnosis appearance of any of the 
following codes in any of the Part B files (Carrier Claims, DME or Outpatient 
Claims): HCPCS codes: J9190, J8520, J8521, J0640, J9200, J9263, J9206;  NDC 
codes: 00703301513, 00703301812, 00703301912, 10139006301, 10139006310, 
10139006311, 10139006312, 10139006320, 10139006350, 63323011710, 
63323011720, 63323011751, 63323011761, 66758004401, 66758004403, 
00004110020, 54868414300, 54868414301, 54868414302, 00004110150, 
00004110175, 54868526000, 54868526001, 54868526002, 54868526003, 
54868526004, 54868526005, 54868526006, 54868526007, 54868526008, 
54868526009, 00703279301, 00703279701, 00703514001, 00703514501, 
00703514591, 00904231560, 25021081310, 25021081430, 25021081530, 
25021081567, 25021081630, 25021081667, 55390000901, 55390005110, 
55390005210, 55390005301, 55390005401, 55390081810, 55390082401, 
55390082501, 55390082601, 62701090030, 62701090099, 62701090125, 
63323071050, 63323071100, 55390013501, 63323014507, 00024059010, 
00024059120, 00024059240, 00069006701, 00069007001, 00069007401, 
00069101001, 00703398501, 00703398601, 25021021120, 25021021250, 
41616017640, 41616017840, 47335017640, 47335017840, 61703036318, 
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61703036322, 63323017530, 63323017650, 63323065010, 63323065017, 
63323065020, 63323065027, 00009111101, 00009111102, 00009752901, 
00009752902, 00009752903, 00009752904, 00009752905, 00143970101, 
00143970201, 00703443211, 00703443411, 10019093401, 10019093402, 
10019093417, 10019093479, 10518010310, 18111000202, 18111000203, 
23155017931, 23155017932, 25021020002, 25021020005, 25021021402, 
25021021405, 55390029501, 55390029601, 59762752902, 61703034909, 
61703034916, 61703034936, 63323019302, 63323019305, 66758004801, 
66758004802.  The locations for these codes and dates in each of the files are 
outlined below. 
o Carrier Claims: 
 HCPCS codes (column #93) 
 Date of treatment for the previous code (column #32) 
o Outpatient Claims: 
 HCPCS code (column #241)  
 Date of treatment for the previous code (column #32)   
o DME: 
 HCPCS code (column #93) 
 NDC code (column #409)   
 Date of treatment for the previous code (column #32) 
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• First Monoclonal Antibody Claim and Date:  These are two computed variables 
(first_ma and ma_type) as in 6d and 6e in Appendix D above.  The variable first_ma 
is the date of the first post diagnosis monoclonal antibody claim. The variable 
ma_type is the NDC, HCPCS code, or Brand Name code for the first post diagnosis 
appearance of any of the following codes in any of the Part B files (Carrier Claims, 
DME or Outpatient Claims):  (Carrier Claims, Outpatient Claims, or PDE):  HCPCS 
codes: J9035, J9055, J9303; NDC codes: 50242006001, 50242006101, 66733094823, 
66733095823, 55513095401, 55513095601; or Brand Name codes: Avastin, Erbitux, 
Vectibix.  The locations for these codes and dates in each of the files are outlined 
below. 
o Carrier Claims: 
 HCPCS code (column #93) 
 Date of treatment for the previous code (column #32)  
o Outpatient Claims: 
 HCPCS code (column #241)  
 Date of treatment for the previous code (column #32)  
o PDE: 
 Brand name code (column #90)   
 NDC code (column #35) 
 PDE drug dispense date (column #27)  
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Appendix G:  Logistic Regression Syntax; Monoclonal Antibody Disparities by Race 
 
Monoclonal Antibody Treatment and Race Logistic Regression Syntax 
 
DATASET ACTIVATE DataSet1. 
USE ALL. 
COMPUTE filter_$=(NOT rac_recb = 3 and NOT rac_recb = 9 and NOT rac_recb = 12). 
VARIABLE LABELS filter_$ 'NOT rac_recb = 3 and NOT rac_recb = 9 and NOT 
rac_recb = 12 (FILTER)'. 
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'. 
FORMATS filter_$ (f1.0). 
FILTER BY filter_$. 
EXECUTE. 
 
LOGISTIC REGRESSION VARIABLES MA_treatment 
  /METHOD=ENTER Race_new  
  /CONTRAST (Race_new)=Indicator(1) 
  /PRINT=CI(95) 




Appendix H:  Logistic Regression Syntax; Monoclonal Antibody Disparities by SES 
Monoclonal Antibody Treatment and SES Logistic Regression Syntax 
 
DATASET ACTIVATE DataSet1. 
USE ALL. 
COMPUTE filter_$=(NOT census_pov_ind = 9 ). 
VARIABLE LABELS filter_$ 'NOT census_pov_ind = 9  (FILTER)'. 
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'. 
FORMATS filter_$ (f1.0). 
FILTER BY filter_$. 
EXECUTE. 
 
LOGISTIC REGRESSION VARIABLES MA_treatment 
  /METHOD=ENTER census_pov_ind  
  /CONTRAST (census_pov_ind)=Indicator(1) 
  /PRINT=CI(95) 




Appendix I:  Logistic Regression Syntax; Monoclonal Antibody Disparities by 
Neighborhood Characteristics 
Monoclonal Antibody Treatment and Neighborhood Characteristics Logistic Regression 
Syntax 
 
DATASET ACTIVATE DataSet1. 
USE ALL. 
COMPUTE filter_$=(NOT urbrur = 9 ). 
VARIABLE LABELS filter_$ 'NOT urbrur = 9  (FILTER)'. 
VALUE LABELS filter_$ 0 'Not Selected' 1 'Selected'. 
FORMATS filter_$ (f1.0). 
FILTER BY filter_$. 
EXECUTE. 
 
LOGISTIC REGRESSION VARIABLES MA_treatment 
  /METHOD=ENTER urbrur  
  /CONTRAST (urbrur)=Indicator(1) 
  /PRINT=CI(95) 




Appendix J.  Logistic Regression Syntax; Model Including All Significant Independent 
Variables and Covariates 
Monoclonal Antibody Treatment and All Significant Variables Logistic Regression  
 





LOGISTIC REGRESSION VARIABLES MA_treatment 
  /METHOD=ENTER reporting_id age_dx   
    /CONTRAST (reporting_id)=Indicator(1) 
  /PRINT=CI(95) 
 /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
